<SEC-DOCUMENT>0001193125-21-341249.txt : 20211126
<SEC-HEADER>0001193125-21-341249.hdr.sgml : 20211126
<ACCEPTANCE-DATETIME>20211126160209
ACCESSION NUMBER:		0001193125-21-341249
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20211126
DATE AS OF CHANGE:		20211126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252793
		FILM NUMBER:		211451811

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d273774d424b3.htm
<DESCRIPTION>424(B)(3)
<TEXT>
<HTML><HEAD>
<TITLE>424(B)(3)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) <BR> Registration No. 333-252793 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities<BR>to be Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount to be<BR>Registered<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering
Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per Share<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering Price<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, par value US$0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">1,000,293</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">US$27.87</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">US$27,878,165.9</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">US$2,584.31</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The ordinary shares are represented by American depositary shares (&#147;ADSs&#148;). Each ten (10)&nbsp;ADSs
represent twenty-three (23)&nbsp;ordinary shares. The ADSs issuable on deposit of the ordinary shares registered hereby have been registered under the registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> (No. <FONT
STYLE="white-space:nowrap">333-235557).</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes up to 1,000,293 ordinary shares to be offered by the selling shareholders identified in this
prospectus supplement. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), this registration statement shall be deemed to cover any additional number of ordinary shares that may be issued from time
to time to prevent dilution as a result of a distribution, split, combination or similar transaction. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(a) under the Securities
Act. In accordance with Rule 457(c) of the Securities Act, the price shown based on the average of the high and low prices for the Registrant&#146;s ADSs on November&nbsp;24, 2021, as reported on The Nasdaq Global Market. Each ten (10)&nbsp;ADSs
represent twenty-three (23)&nbsp;ordinary shares. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus Dated February&nbsp;5, 2021) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to 434,910 American Depositary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273774g83j43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Representing up to 1,000,293 Ordinary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling shareholders identified in this prospectus supplement may offer, from time to time, up to 1,000,293 ordinary shares, including
ordinary shares represented by American depositary shares (&#147;ADSs&#148;) of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Each ten (10)&nbsp;ADSs represent twenty-three (23)&nbsp;of our ordinary shares, par value US$0.0001 per share. This
prospectus supplement is principally to satisfy certain registration rights of the selling shareholders identified in this prospectus supplement. We are not selling any ordinary shares or ADSs and will not receive any of the proceeds from the sale
of ordinary shares or ADSs by the selling shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ADSs are listed on the Nasdaq Global Market under the symbol
&#147;IMAB.&#148; On November&nbsp;24, 2021, the closing trading price for our ADSs, as reported on the Nasdaq Global Market, was US$64.91 per ADS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling shareholders may offer and sell some, all or none of its ordinary shares or ADSs covered by this prospectus supplement in a number
of different potential ways and at varying prices. See &#147;Plan of Distribution&#148; elsewhere in this prospectus supplement for a more complete description. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in the ADSs involves risks. See &#147;<A HREF="#supprom273774_5">Risk Factors</A>&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-8</FONT> for factors you should consider before buying the ADSs. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal
offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus supplement is November&nbsp;26, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_2">SPECIAL NOTES REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_3">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_7">SELLING SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_11">WHERE YOU CAN FIND MORE INFORMATION ABOUT US</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom273774_12">INCORPORATION OF DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_2">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_3">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_6">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_7">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_8">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_9">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_10">SELLING SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_14">WHERE YOU CAN FIND MORE INFORMATION ABOUT US</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_15">INCORPORATION OF DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither we nor the selling shareholders have authorized anyone to provide any information other than that contained or incorporated by
reference in this prospectus supplement and the accompanying prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the selling shareholders take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. Neither we nor the selling shareholders are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume
that the information appearing in this prospectus supplement, the accompanying prospectus, any related free writing prospectus and the documents incorporated by reference herein or therein is accurate only as of their respective dates. Our business,
financial condition, results of operations and prospects may have changed since those dates. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is a supplement to the accompanying prospectus, which is also a part of this document. This prospectus supplement
and the accompanying prospectus are part of a registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-252793)</FONT> that we filed with the Securities and Exchange Commission, or SEC,
using a &#147;shelf&#148; registration process. In this prospectus supplement, we provide you with specific information about the terms of the offering of our securities by the selling shareholders. This prospectus supplement may add, update or
change information contained in the accompanying prospectus. To the extent that any statement made in this prospectus supplement is inconsistent with a statement made in the accompanying prospectus or any previously filed documents incorporated by
reference, the statements made in the accompanying prospectus or any previously filed documents incorporated by reference are deemed modified or superseded by the statements made in this prospectus supplement. You should read both this prospectus
supplement and the accompanying prospectus together with the additional information described under &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus supplement, unless otherwise indicated or unless the context otherwise requires: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADRs&#148; refer to the American depositary receipts that evidence our ADSs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADSs&#148; refer to our American depositary shares, each ten (10)&nbsp;ADSs represent twenty-three
(23)&nbsp;ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China&#148; or &#147;the PRC&#148; refers to the People&#146;s Republic of China, excluding, for the
purposes of this prospectus only, Hong Kong, Macau and Taiwan, and &#147;Greater China&#148; does not exclude Hong Kong, Macau and Taiwan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China Portfolio&#148; refers to our investigational drugs of which we
<FONT STYLE="white-space:nowrap">in-license</FONT> Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater
China with an aim for near-term product launch; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Global Portfolio&#148; refers to our own proprietary novel or differentiated drug candidates that we are
advancing towards clinical validation in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;I-Mab,&#148;</FONT> &#147;we,&#148; &#147;us,&#148; &#147;our
company&#148; and &#147;our&#148; refer to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> a Cayman Islands exempted company, and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;RMB&#148; refers to the legal currency of China; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;shares&#148; or &#147;ordinary shares&#148; refer to our ordinary shares, par value US$0.0001 per share;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;US$,&#148; &#147;U.S. dollars,&#148; &#147;$,&#148; and &#147;dollars&#148; refer to the legal currency of
the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reporting currency is RMB. This prospectus supplement also contains translations of certain
foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations from RMB to U.S. dollars were made at a rate of RMB6.4566 to US$1.00, the exchange rate in effect as of June&nbsp;30, 2021 as set
forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. We make no representation that any RMB or U.S. dollar amounts referred to in this prospectus supplement could have been or could be converted into U.S.
dollars or RMB, as the case may be, at any particular rate, or at all. On November&nbsp;19, 2021, the noon buying rate for RMB was RMB6.3863 to US$1.00. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_2"></A>SPECIAL NOTES REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein may contain
forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts are forward-looking statements. These statements are made under the &#147;safe harbor&#148; provisions of the U.S. Private
Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as &#147;may,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;aim,&#148; &#147;estimate,&#148;
&#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;likely to,&#148; &#147;potential,&#148; &#147;continue&#148; or other similar expressions. We have based these forward-looking statements largely on our current expectations and
projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements
about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of initiation and completion, and the progress of our drug discovery and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval, pricing and reimbursement of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market opportunities and competitive landscape of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment, receipt and timing of any milestone payments in relation to the licensing agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain senior management and key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future business development, financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future developments, trends, conditions and competitive landscape in the industry and markets in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans,
objectives and goals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue to maintain our market position in China&#146;s biopharmaceutical and biotechnology
industries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and integrate suitable acquisition targets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to regulatory and operating conditions in our industry and markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus supplement, the accompanying prospectus and the information incorporated by
reference herein and therein involve various risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results
could be materially different from our expectations. Other sections of this prospectus supplement include additional factors that could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New
risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should read thoroughly this prospectus supplement and the documents that we refer to with the understanding that our
actual future results may be materially different from, or worse than, what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement contains certain data and information that we obtained from
various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. Furthermore, if any one or more of the assumptions underlying the market data are later found to be
incorrect, actual results may differ from the projections based on these assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We would like to caution you not to place undue
reliance on the forward-looking statements and you should read these statements in conjunction with the risk factors disclosed in the documents incorporated by reference herein for a more complete discussion of the risks of an investment in our
securities and other risks outlined in our other filings with the SEC. The forward-looking statements included in this prospectus supplement or incorporated by reference into this prospectus supplement are made only as of the date of this prospectus
supplement or the date of the incorporated document, and we do not undertake any obligation to update the forward-looking statements except as required under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_3"></A>OUR COMPANY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and
growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further
enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative
pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global
pharmaceutical and biotech companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our business, financial condition, results of operations and other important
information regarding us, see our filings with the Securities and Exchange Commission (&#147;SEC&#148;) incorporated by reference in the accompanying prospectus. For instructions on how to find copies of these and our other filings incorporated by
reference in the accompanying prospectus, see &#147;Available Information&#148; in the accompanying prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People&#146;s
Republic of China. Our telephone number at this address is +86 <FONT STYLE="white-space:nowrap">21-6057-8000.</FONT> Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802
West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors should submit any inquiries to the address or through the telephone number of our principal executive offices. Our main website is <FONT
STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> The information contained on our website is not a part of this prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in the
ADSs involves significant risks. You should carefully consider all of the information in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference before making an investment in the ADSs. Below please find a
summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled &#147;Risk factors&#148; and in our most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT>
and in Exhibit 99.3 to our current report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> furnished with the SEC on November&nbsp;12, 2021, each of which is incorporated herein by reference, as updated by our subsequent filings under the
Exchange Act and, if applicable, in any accompanying prospectus supplement subsequently filed relating to a specific offering or sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks
Related to Our Financial Position and Need for Additional Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risks and uncertainties related to our financial position and
need for additional capital include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history, which may make it difficult to evaluate our current business and predict our
future performance; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We recorded net cash outflow from operating activities since inception, and we may need to obtain additional
financing to fund our operations, otherwise we may be unable to complete the development and commercialization of our major drug candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Clinical Development, Obtaining Regulatory Approval and Commercialization of Our Drug Candidates and Our Reliance on Third Parties
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risks and uncertainties related to clinical development, obtaining regulatory approval and commercialization of our drug
candidates include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier
studies and trials may not be predictive of future trial results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend substantially on the success of our drug candidates, all of which are in
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development, and our ability to identify additional drug candidates. If we are unable to identify new drug candidates, complete clinical development, obtain regulatory approval and
commercialize our drug candidates, or experience significant delays in doing so, our business will be materially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to identify, discover or <FONT STYLE="white-space:nowrap">in-license</FONT> new drug
candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of
success; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are
time-consuming and may evolve over time, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party
payors and others in the medical community necessary for commercial success; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face intense competition and rapid technological change and the possibility that our competitors may develop
therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug
candidates and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Our Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risks and uncertainties related to our intellectual property include, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent and other intellectual property protection for our drug
candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, adversely
affecting our ability to successfully commercialize any product or technology; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our
intellectual property rights throughout the world, including in the PRC. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Doing Business in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to risks and uncertainties related to doing business in China in general, including, but not limited to, the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The PRC government&#146;s significant authority in regulating our operations and its oversight or control over
offshore offerings and foreign investment in China-based issuers could significantly limit or completely hinder our ability to offer or continue to offer securities to investors. The PRC government may intervene or influence our operations at any
time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material adverse change in our operations and/or the value of our ADSs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in China&#146;s economic, political or social conditions or government policies could have a material
adverse effect on our business and operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risks and uncertainties arising from the legal system in China. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any failure to comply with the various applicable laws and regulations related to data security, cybersecurity
and personal information and privacy protection could affect our offshore listing and lead to liabilities, penalties or other regulatory actions, which could have a material and adverse effect on our business, financial condition and results of
operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our auditor is currently not subject to inspections by the PCAOB. Our ADSs may be delisted under the Holding
Foreign Companies Accountable Act if the PCAOB is unable to inspect auditors who are located in China. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are subject to PRC laws and regulations restricting capital flows which may affect our liquidity.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Risks Related to Our ADSs and this Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the risks described above, we are subject to general risks related to the ADSs and this offering, including, but not limited to,
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The trading price of our ADSs may be volatile; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our
ADSs for return on your investment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able
to exercise the same rights as our shareholders. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Ordinary shares offered by the selling shareholders </B></P></TD>
<TD>Up to 1,000,293 ordinary shares, including ordinary shares represented by ADSs. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to maintain the effectiveness of the registration statement until such time as all of the ordinary shares or ADSs covered here have been publicly sold by the selling shareholders. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>The ADSs </B></P></TD>
<TD>Each ten (10)&nbsp;ADSs represent twenty-three (23)&nbsp;ordinary shares, par value US$0.0001 per share. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>The depositary or its nominee will hold ordinary shares underlying your ADSs. You will have rights as provided in the deposit agreement among us, the depositary and all holders and beneficial owners of ADSs issued thereunder. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We do not expect to pay dividends in the foreseeable future. If, however, we declare dividends on our ordinary shares, the depositary will pay you the cash dividends and other distributions it receives on our ordinary shares after deducting its
fees and expenses in accordance with the terms set forth in the deposit agreement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>You may surrender your ADSs to the depositary in exchange for ordinary shares. The depositary will charge you fees for any such exchange. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We may amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>To better understand the terms of the ADSs, you should carefully read the &#147;Description of American Depositary Shares&#148; section of this prospectus. You should also read the deposit agreement, which is filed as an exhibit to the
registration statement that includes this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B></P></TD>
<TD>We will not receive any of the proceeds from the sale of our ordinary shares or ADSs by the selling shareholders. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P></TD>
<TD>Our ADSs are listed on the Nasdaq Global Market under the symbol &#147;IMAB.&#148; Our ADSs and shares are not listed on any other stock exchange or traded on any automated quotation system. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Depositary </B></P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risk. Before you decide to buy our securities, you should carefully consider all of the information in
this prospectus supplement and the risks described in our most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> and in Exhibit 99.3 to our current report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> furnished with the
SEC on November&nbsp;12, 2021, each of which is incorporated herein by reference, as updated by our subsequent filings under the Exchange Act and, if applicable, in any accompanying prospectus supplement subsequently filed relating to a specific
offering or sale. If any of these risks actually occurs, our business, financial condition and results of operations could suffer, and you may lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All ordinary shares or ADSs being offered by this prospectus supplement will be sold by the selling shareholders. We will not receive any
proceeds from the sale of ordinary shares or ADSs covered by this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_7"></A>SELLING SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as specifically noted, the following table sets forth information with respect to the beneficial ownership of our ordinary shares as of
the date of this prospectus supplement by each selling shareholder. We have agreed to file for the selling shareholders the registration statement of which this prospectus supplement and accompanying prospectus are a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares registered under this prospectus include (i) 540,293 ordinary shares (represented by 234,910 ADSs) that a selling
shareholder identified in this prospectus supplement purchased from Tasly Biopharm Limited, one of our existing shareholders; and (ii) 460,000 ordinary shares (represented by 200,000 ADSs) that a selling shareholder identified in this prospectus
supplement purchased from our existing shareholders CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited and IBC Investment Seven Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares held by the selling shareholders reflected in the table below may be sold by the selling shareholders from time to time in
one or more offerings described in this prospectus supplement and any applicable prospectus supplement. The selling shareholders may sell all, some or none of these ordinary shares (or the ADSs representing these ordinary shares) beneficially owned
by them, and therefore we cannot estimate either the number or the percentage of ordinary shares (or the ADSs representing these ordinary shares) that will be beneficially owned by the selling shareholders following any offering or sale hereunder.
We cannot advise you as to whether the selling shareholders will in fact sell any or all of the ordinary shares (or the ADSs representing these ordinary shares) that they own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling shareholders listed in the table below may have sold or transferred, or pledged as collateral, in transactions pursuant to this
prospectus or exempt from the registration requirements of the Securities Act, some or all of its ordinary shares (or the ADSs representing its ordinary shares) since the date as of which the information is presented in the table below. Information
concerning the selling shareholders may change from time to time, and any changed information will, if required, be set forth in prospectus supplements to the registration statement of which this prospectus is a part, as may be appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculations in the table below are based on 179,509,777 ordinary shares outstanding as of September&nbsp;30, 2021 (excluding 411,575
ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially
owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or other right or the conversion of any other
security. These shares, however, are not included in the computation of the percentage ownership of any other person. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B><br><B>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B><br><B>Being&nbsp;Registered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selling Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Huatai Capital Investment Limited<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,336,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">540,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sage Partners Master Fund<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">460,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">460,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 345,989 ADSs (representing 795,775 ordinary shares) and 540,293 ordinary shares directly held by
Huatai Capital Investment Limited., or Huatai, a Hong Kong limited liability company. Huatai is ultimately controlled by Huatai Securities Co., Ltd, a public company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange. The
registered address of Huatai is at Room 4201, 42/F, The Centre, 99 Queen&#146;s Road Central, Hong Kong. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 460,000 ordinary shares directly held by Sage Partners Master Fund, or Sage Partners, an exempted
company incorporated in the Cayman Islands with limited liability. Sage Partners is a long-term investment partnership whose beneficial owners include institutional and other sophisticated investors. The registered address of Sage Partners Master
Fund is at PO Box 309, Ugland House, Grand Cayman Cayman Islands, <FONT STYLE="white-space:nowrap">KY1-1104.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling shareholders identified in this prospectus supplement may offer, from time to time, up to 1,000,293 ordinary shares, including
ordinary shares represented by ADSs. Each ten (10)&nbsp;ADSs represent twenty-three (23)&nbsp;of our ordinary shares, par value US$0.0001 per share. Registration of such ordinary shares covered by this prospectus does not mean, however, that such
ordinary shares or the ADSs representing such ordinary shares necessarily will be offered or sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling shareholders and their
successors, including their transferees, may sell all or a portion of our ordinary shares or ADSs directly to purchasers or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or
commissions from the selling shareholders or the purchasers of our ordinary shares or ADSs. These discounts, concessions or commissions as to any particular underwriter, broker-dealer or agent may be in excess of those customary in the types of
transactions involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares or ADSs may be sold in one or more transactions on any national securities exchange or
quotation service on which our ordinary shares or ADSs may be listed or quoted at the time of sale, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or in transactions otherwise than on
these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying
prices determined at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. Additionally, the selling shareholders may enter into derivative transactions with third
parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. The selling shareholders may use any one or more of the following methods when selling our ordinary shares or ADSs: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or quotation service on which our ordinary shares or ADSs may be listed or
quoted at the time of sale, including Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions otherwise than on these exchanges or services or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether the options are listed on an
options exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell our ordinary shares or ADSs as agent but may
position and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debt-for-equity</FONT></FONT> exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus forms a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling shareholders to sell a specified number of such ordinary shares or ADSs
at a stipulated price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling shareholders may offer our ordinary shares or ADSs to the public through underwriting syndicates represented by managing
underwriters or through underwriters without an underwriting syndicate. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underwriters are used for the sale of our ordinary shares or ADSs, the securities will be acquired by the underwriters for their own account. The underwriters may resell our ordinary shares or
ADSs in one or more transactions, including in negotiated transactions at a fixed public offering price or at varying prices determined at the time of sale. In connection with any such underwritten sale of our ordinary shares or ADSs, underwriters
may receive compensation from the selling shareholders, for whom it may act as agents, in the form of discounts, concessions or commissions. Underwriters may sell our ordinary shares or ADSs to or through dealers, and the dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act as agents. Such compensation may be in excess of customary discounts, concessions or commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used for the sale of our ordinary shares or ADSs, to the extent required by law, the names of the underwriters will be set
forth in the prospectus or prospectus supplement used by the underwriters to sell those securities. The selling shareholders may use underwriters with whom we or the selling shareholders have a material relationship. We will describe the nature of
such relationship in any applicable prospectus supplement naming the underwriter or underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used for the sale
of our ordinary shares or ADSs, unless otherwise indicated in the prospectus or prospectus supplement relating to a particular offering of our ordinary shares or ADSs, the obligations of any underwriters to purchase the securities will be subject to
customary conditions precedent, and the underwriters will be obligated to purchase all of the securities offered if any of the securities are purchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used for the sale of our ordinary shares or ADSs, in connection with such offering, the underwriters may advise us that
they may engage in stabilizing transactions, which involves making bids for, purchasing and selling our ADSs in the open market for the purpose of preventing or retarding a decline in the market price of our ADSs while this offering is in progress.
These stabilizing transactions may include making short sales of our ADSs, which involves the sale by the underwriters of a greater number of ADSs than they are required to purchase in this offering, and purchasing ADSs on the open market to cover
positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional ADSs referred to above, or may be &#147;naked&#148; shorts,
which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional ADSs, in whole or in part, or by purchasing our ADSs in the open market. In making
this determination, the underwriters will consider, among other things, the price of our ADSs available for purchase in the open market compared to the price at which the underwriters may purchase our ADSs through the option to purchase additional
ADSs. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our ADSs in the open market that could adversely affect investors who purchase in this offering. To the
extent that the underwriters create a naked short position, they will purchase our ADSs in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of our ADSs pursuant to this prospectus and any applicable prospectus supplement and to the activities of the selling shareholders. In addition, we will make copies of
this prospectus and any applicable prospectus supplement available to the selling shareholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. To the extent applicable, Regulation M may also restrict the
ability of any person engaged in the distribution of our ADSs to engage in market-making activities with respect to the common stock. All of the foregoing may affect the marketability of our ADSs and the ability of any person or entity to engage in
market-making activities with respect to our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any securities that qualify for sale pursuant to Rule 144 or Regulation S
under the Securities Act or under Section&nbsp;4(1) under the Securities Act may be sold under such rules rather than pursuant to this prospectus or a prospectus supplement. The selling shareholders may enter into hedging transactions with
broker-dealers, which may in turn engage in short sales of our ordinary shares or ADSs in the course of hedging the positions they assume. The selling shareholders may also sell short our ordinary shares or ADSs and deliver our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ordinary shares or ADSs to close out short positions, or loan or pledge our ordinary shares or ADSs to broker-dealers that in turn may sell these ordinary shares or ADSs. The selling shareholders
may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities that require the delivery to such broker-dealer or other financial institution of our ordinary
shares or ADSs offered by this prospectus and any applicable prospectus supplement, which our ordinary shares or ADSs such broker-dealer or other financial institution may resell pursuant to this prospectus and any applicable prospectus supplement.
The selling shareholders also may transfer and donate our ordinary shares or ADSs in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus and any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling shareholders from the sale of our ordinary
shares or ADSs will be the purchase price of our ordinary shares or ADSs less discounts and commissions, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In offering our ordinary
shares or ADSs covered by this prospectus and any applicable prospectus supplement, the selling shareholders and any broker-dealers who execute sales for the selling shareholders may be deemed to be &#147;underwriters&#148; within the meaning of
Section&nbsp;2(a)(11) of the Securities Act in connection with such sales. Any profits realized by the selling shareholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. Selling shareholders
who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory and regulatory liabilities,
including liabilities imposed pursuant to Sections 11, 12 and 17 of the Securities Act and Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, our ordinary shares or ADSs must be sold in such jurisdictions
only through registered or licensed brokers or dealers. In addition, in certain states our ordinary shares or ADSs may not be sold unless the ordinary shares or ADSs are registered or qualified for sale in the applicable state or an exemption from
the registration or qualification requirement is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the selling shareholders
will sell any or all of our ordinary shares or ADSs registered pursuant to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time a particular offering of our ordinary shares or ADSs is made, a prospectus supplement, if required, will be distributed, which
will set forth the names of the selling shareholders, the aggregate amount of our ordinary shares or ADSs being offered by the selling shareholders and the terms of the offering, including, to the extent required, (1)&nbsp;the name or names of any
underwriters, broker-dealers or agents, (2)&nbsp;any discounts, commissions and other terms constituting compensation from the selling shareholders and (3)&nbsp;any discounts, commissions or concessions allowed or reallowed to be paid to
broker-dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents and underwriters and their respective affiliates may engage in transactions with, or perform services for us in
the ordinary course of business for which they may receive customary fees and reimbursement of expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses
payable by the selling shareholders, in addition to any underwriting discounts and commissions that will be paid by the selling shareholders, will be described in any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are being represented by Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP with respect to certain legal matters as to United States
federal securities and New York State law. The validity of the ordinary shares represented by the ADSs to be sold in this offering have been passed upon for us by Conyers Dill&nbsp;&amp; Pearman. Certain legal matters as to PRC law have been passed
upon for us by JunHe LLP. Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP may rely upon Conyers Dill&nbsp;&amp; Pearman with respect to matters governed by Cayman Islands law and JunHe LLP with respect to matters governed by PRC law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference to the annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2020 have been so incorporated in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The office of PricewaterhouseCoopers Zhong Tian LLP is located at 11th
Floor, PricewaterhouseCoopers Center, Link Square 2, 202 Hu Bin Road, Shanghai, the People&#146;s Republic of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_11"></A>WHERE YOU CAN FIND MORE INFORMATION ABOUT US </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and, in accordance with
the Exchange Act, we file annual reports and other information with the SEC. Information we file with the SEC can be obtained over the internet at the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement that we filed with the SEC, using a &#147;shelf&#148; registration process
under the Securities Act of 1933, as amended, or the Securities Act, relating to the securities to be offered. This prospectus supplement does not contain all of the information set forth in the registration statement, certain parts of which are
omitted in accordance with the rules and regulations of the SEC. For further information with respect to <FONT STYLE="white-space:nowrap">I-Mab</FONT> and the securities, reference is hereby made to the registration statement and the prospectus
contained therein. The registration statement, including the exhibits thereto, may be inspected on the SEC&#146;s website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom273774_12"></A>INCORPORATION OF DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with or submit to the SEC, which means that we can disclose
important information to you by referring you to those documents that are considered part of the accompanying prospectus. Information that we file with or submit to the SEC in the future and incorporate by reference will automatically update and
supersede the previously filed information. See &#147;Incorporation of Certain Documents by Reference&#148; in the accompanying prospectus for more information. All of the documents incorporated by reference are available at www.sec.gov under <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> CIK number 0001778016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our annual report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001778016/000119312521135440/d10811d20f.htm">Form
 <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the fiscal year ended December&nbsp;31, 2020 filed with the SEC on April&nbsp;
28, 2021 and our current reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> furnished with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1778016/000119312521177879/d174879d6k.htm">June&nbsp;
1, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1778016/000119312521316072/d249077d6k.htm">November&nbsp;2, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1778016/000119312521328042/d37906d6k.htm">November&nbsp;12,
2021</A>, respectively, are incorporated by reference into the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As you read the documents incorporated by
reference, you may find inconsistencies in information from one document to another. If you find inconsistencies, you should rely on the statements made in the most recent document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide a copy of any or all of the information that has been incorporated by reference into the accompanying prospectus, upon written
or oral request, to any person, including any beneficial owner of the securities, to whom a copy of this prospectus supplement is delivered, at no cost to such person. You may make such a request by writing or telephoning us at the following mailing
address or telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">I-Mab</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shanghai, 201210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">People&#146;s
Republic of China </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tel: +86 <FONT STYLE="white-space:nowrap">21-6057-8000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273774g83j43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time in one or more offerings offer and sell our ordinary shares, including ordinary shares represented by American
depositary shares, or ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, from time to time, the selling shareholders (if any) to be named in a prospectus supplement may
offer and sell our ordinary shares held by them. The selling shareholders may sell shares of our ordinary shares through public or private transactions at prevailing market prices or at privately negotiated prices. We will not receive any proceeds
from the sale of shares of our ordinary shares by the selling shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide specific terms of any offering in a
supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents
incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities,
their compensation and any over-allotment options held by them will be described in the applicable prospectus supplement. For a more complete description of the plan of distribution of these securities, see the section entitled &#147;Plan of
Distribution&#148; beginning on page 50 of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs are listed on the Nasdaq Global Market under the symbol
&#147;IMAB.&#148; On February 4, 2021, the last reported sale price of the ADSs on the Nasdaq Global Market was US$62.8 per ADS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should carefully consider the &#147;<A HREF="#rom273774_4">Risk
Factors</A>&#148; which may be included in any prospectus supplement or are incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus may not be used to offer or sell any securities unless accompanied by a prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
and sell these securities to or through one or more agents, underwriters, dealers or other third parties or directly to one or more purchasers on a continuous or delayed basis. The names of any underwriters will be stated in the applicable
prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this
prospectus is February&nbsp;5, 2021<I>.</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_2">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_3">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_6">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_7">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_8">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_9">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_10">SELLING SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_14">WHERE YOU CAN FIND MORE INFORMATION ABOUT US</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom273774_15">INCORPORATION OF DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or incorporated by reference into this prospectus, in the applicable
prospectus supplement or in any free writing prospectus filed by us with the SEC. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not
rely on it. You should not assume that the information contained or incorporated by reference into this prospectus and any prospectus supplement or in any free writing prospectus is accurate as of any date other than the respective dates thereof.
Our business, financial condition, results of operations and prospects may have changed since those dates. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act.
This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148; registration process. Under this shelf registration process, we may offer and sell the
securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities we may offer. Each time we use this prospectus to offer securities, we will provide one or more prospectus
supplements that will contain specific information about the offering and the terms of those securities. We may also add, update or change other information contained in this prospectus by means of a prospectus supplement or by incorporating by
reference information we file with the SEC. The registration statement on file with the SEC includes exhibits that provide more detail on the matters discussed in this prospectus. If there is any inconsistency between the information in this
prospectus and any related prospectus supplement, you should rely on the information in the applicable prospectus supplement. Before you invest in any securities offered by this prospectus, you should read this prospectus, any applicable prospectus
supplements and the related exhibits to the registration statement filed with the SEC, together with the additional information described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents
by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, unless otherwise indicated or unless the context otherwise requires: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADRs&#148; refer to the American depositary receipts that evidence our ADSs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADSs&#148; refer to our American depositary shares, each ten (10)&nbsp;ADSs represent twenty-three
(23)&nbsp;ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China&#148; or &#147;the PRC&#148; refers to the People&#146;s Republic of China, excluding, for the
purposes of this prospectus only, Hong Kong, Macau and Taiwan, and &#147;Greater China&#148; does not exclude Hong Kong, Macau and Taiwan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China Portfolio&#148; refers to our investigational drugs of which we
<FONT STYLE="white-space:nowrap">in-license</FONT> Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater
China with an aim for near-term product launch; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Global Portfolio&#148; refers to our own proprietary novel or differentiated drug candidates that we are
advancing towards clinical validation in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;I-Mab,&#148;</FONT> &#147;we,&#148; &#147;us,&#148; &#147;our
company&#148; and &#147;our&#148; refer to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> a Cayman Islands exempted company, and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;RMB&#148; refers to the legal currency of China; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;shares&#148; or &#147;ordinary shares&#148; refer to our ordinary shares, par value US$0.0001 per share;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;US$,&#148; &#147;U.S. dollars,&#148; &#147;$,&#148; and &#147;dollars&#148; refer to the legal currency of
the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References in any prospectus supplement to &#147;the accompanying prospectus&#148; are to this
prospectus and to &#147;the prospectus&#148; are to this prospectus and the applicable prospectus supplement taken together. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not
making an offer to sell the securities in any jurisdiction where the offer or sale is not permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reporting currency is RMB.
Unless otherwise noted, all translations from RMB to U.S. dollars in this prospectus are made at a rate of RMB6.7896 to US$1.00, the exchange rate in effect as of September&nbsp;30, 2020 as set forth in the H.10 statistical release of The Board of
Governors of the Federal Reserve System. We make no representation that any RMB amounts could have been, or could be, converted into U.S. dollars at any particular rate, or at all. On January 29, 2021, the exchange rate was RMB6.4282 to US$1.00.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_2"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference contain forward-looking statements that reflect our current expectations and views
of future events. These statements are made under the &#147;safe harbor&#148; provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as &#147;may,&#148;
&#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;aim,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;is/are likely to,&#148; &#147;future,&#148; &#147;potential,&#148;
&#147;continue&#148; or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements include statements relating to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of initiation and completion, and the progress of our drug discovery and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval, pricing and reimbursement of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market opportunities and competitive landscape of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment, receipt and timing of any milestone payments in relation to the licensing agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain senior management and key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future business development, financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future developments, trends, conditions and competitive landscape in the industry and markets in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans,
objectives and goals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue to maintain our market position in China&#146;s biopharmaceutical and biotechnology
industries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and integrate suitable acquisition targets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to regulatory and operating conditions in our industry and markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement
are subject to risks, uncertainties and assumptions about our company. Our actual results of operations may differ materially from the forward-looking statements as a result of the risk factors disclosed in this prospectus, in the documents
incorporated by reference herein or in any accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We would like to caution you not to place undue reliance
on these forward-looking statements, and you should read these statements in conjunction with the risk factors disclosed herein, in the documents incorporated by reference herein or in any accompanying prospectus supplement for a more complete
discussion of the risks of an investment in our securities. We operate in a rapidly evolving environment. New risks emerge from time to time and it is impossible for our management to predict all risk factors, nor can we assess the impact of all
factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. We do not undertake any obligation to update or revise the
forward-looking statements except as required under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_3"></A>OUR COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and
growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further
enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative
pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global
pharmaceutical and biotech companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Opportunities in China and Our Unique Position </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in
China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet
available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a
continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best
demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering&nbsp;&amp; Biotechnology News
(GEN) as a top 10 immuno-oncology <FONT STYLE="white-space:nowrap">start-up</FONT> in the world. To date, our research and development capabilities encompass discovery, translational medicine, biologics CMC development, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully
integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Unique Business Model </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve
our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars: a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy and a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> (proof of concept) global strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China
Strategy </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy
focuses on seeking opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights of investigational drugs from global biopharmaceutical companies for Greater China. We only select investigational
drugs that have the potential to become novel or highly differentiated medicines. Through our substantial <FONT STYLE="white-space:nowrap">in-house</FONT> research and development efforts, we build additional data packages to meet the requirements
of the National Medical Products Administration (the &#147;NMPA&#148;) to ensure programs are ready for late-stage or registrational clinical development. Our internal development capabilities combined with our deep insight into China&#146;s
regulatory framework and our clinical network enable us to efficiently navigate through the drug development process to registration. To date, we have built an innovative China Portfolio consisting of five investigational drugs with an aim for
near-term product launch. All of these investigational drugs have met the related <FONT STYLE="white-space:nowrap">pre-set</FONT> safety and preliminary efficacy endpoints in Phase 1 or Phase 2 clinical trials in Europe, the United States or
elsewhere and are either in or ready for Phase 2 or Phase 3 clinical trials in China. Set forth below is a summary of the latest development status of the anchor assets in our China Portfolio: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For felzartamab (TJ202), a differentiated anti-CD38, we are conducting two parallel registrational trials as a
third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track, and we expect to submit an NDA to the NMPA in
2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For eftansomatropin (TJ101), a differentiated long-acting growth hormone, in September 2020, the NMPA approved
our IND application for a registrational Phase 3 trial in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For enoblituzumab, a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> in the first
quarter of 2021, MacroGenics expects to initiate a Phase 2 study of enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational PD-1 antibody) in front-line patients with SCCHN who are PD-L1 positive or with
tebotelimab (an investigational PD-1 x LAG-3 bispecific DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are PD-L1 negative. We expect to participate in a subsequent Phase 3 global study if and when
initiated, as we deem appropriate. In addition, considering the dynamic regulatory environment and evolving clinical practice, we have been continually refining the development of enoblituzumab in our territory. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For efineptakin (TJ107), a long-acting interleukin 7, we obtained regulatory clearance from the NMPA in April
2020 to initiate a Phase 2 clinical trial in glioblastoma multiforme (GBM) patients with lymphopenia. We had the first patient in on December 31, 2020 and the first patient dosed on February 4, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the investigational drugs in our China Portfolio are positioned for a series of new drug applications (NDAs) in China with the
submission of the first NDA expected in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global
Strategy </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy focuses
on advancing our own novel or differentiated biologics towards clinical validation in the United States. First, we seek PoC of these drug candidates in the United States by conducting early phase clinical trials with a set of safety and efficacy
endpoints and leveraging the FDA&#146;s streamlined regulatory system for innovative drug development, including a predictable timeline towards IND approval. Second, we will use the data generated to advance clinical development in China, which we
believe confers several advantages, including access to China&#146;s large patient pool, extensive clinical trial resources through collaborations with leading hospitals in China, and a regulatory pathway for fast-track approval of drugs supported
by solid overseas clinical data. Building on this approach, we may <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of these investigational drugs following clinical validation in the United States,
while </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
retaining the Greater China rights for further development and commercialization. We believe this approach will allow Chinese patients to benefit from our most advanced treatments concurrently or
soon after their market approvals elsewhere. To date, we have created a Global Portfolio that consists of two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, which are internally
generated. They are highly innovative molecules compared to global competitor assets in the same or related classes of drug candidates. Set forth below is a summary of the latest development status of the anchor assets in our Global Portfolio: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For lemzoparlimab (TJC4), a differentiated anti-CD47, the topline results of the recently completed Phase 1a dose
escalation monotherapy trial in the United States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i) lemzoparlimab was well tolerated up to 30
mg/kg on a weekly basis without priming dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii) lemzoparlimab PK appears to be linear at mid to high dose levels
following a single dose with no significant &#147;sink effect&#148; and (iii) one confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three patients
achieved Stable Disease (SD). In September 2020, we received the NMPA approval for a Phase 1 clinical trial of lemzoparlimab in relapsed or refractory advanced lymphoma in China as part of the ongoing international multi-center trial. In addition,
lemzoparlimab is being evaluated in a Phase 1/2a clinical trial in China in patients with relapsed or refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS), and we anticipate reporting
<FONT STYLE="white-space:nowrap">top-line</FONT> results in early 2021. We have also entered into a clinical trial collaboration and supply agreement with Merck Sharp &amp; Dohme Corp, or MSD, through a subsidiary, under which we will sponsor a
Phase 1 clinical trial in the United States evaluating lemzoparlimab in combination with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s anti-PD-1 therapy, in patients with multiple types of solid
tumors. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to
develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For uliledlimab (TJD5), a differentiated anti-CD73, we have completed the initial assessment of the clinical
trial in the United States as a single agent and in combination with atezolizumab (TECENTRIQR), a PD-L1 antibody marketed by Roche, in patients with advanced solid tumors. Topline results from a clinical study under contract with TRACON show that
uliledlimab is safe and well tolerated at the dose range evaluated and demonstrate clinical activity in patients with advanced solid tumors. We are scheduled to submit an abstract to ASCO for the 2021 annual meeting. In China, we are conducting a
Phase 1/2 clinical trial to evaluate uliledlimab in patients with advanced solid tumors. The first patient in the single agent study was dosed in May 2020. The first patient in the combination study was dosed on February 3, 2021. This Phase 1/2
study is a multicenter, open-label, dose escalation and cohort expansion study, which will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of uliledlimab, and determine a recommended dose for further planned clinical
studies of its efficacy and safety as a single agent and in combination with standard dose of toripalimab (TUOYIR) in patients with advanced or metastatic cancers who are refractory to or intolerant of all available therapies. We have been able to
accelerate the Phase 1/2 trial in China by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the United States, which is a testament to our global clinical development capabilities and well-executed pipeline strategies.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For plonmarlimab (TJM2), an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF,</FONT></FONT> we have completed a single-dose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy volunteers
in the United States. It is the first antibody of its class entering clinical development in China. We dosed the first patient in a Phase 1b study of plonmarlimab in August 2020 in patients with rheumatoid arthritis (RA). We may expand plonmarlimab
to other autoimmune and inflammatory indications with high unmet medical need, where <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to
provide an effective </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
treatment option as a disease-modifying anti-rheumatic drug (&#147;DMARD&#148;) therapy. In addition, since the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we have sprung into
action to prioritize plonmarlimab in response to the urgent medical needs. In May 2020, we announced preliminary results from part 1 of a clinical study in the United States of plonmarlimab in patients with cytokine release syndrome (CRS) associated
with severe <FONT STYLE="white-space:nowrap">COVID-19,</FONT> in which plonmarlimab was found to be well tolerated. We are currently conducting part 2 of this clinical trial to evaluate the efficacy, safety and cytokine levels following a single
dose of 6 mg/kg plonmarlimab or placebo (standard care) in patients with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to finalize the plan for plonmarlimab in relation to clinical development
and potential registration in the United States.<B><I> </I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These two strategies and the resulting two portfolios
complement each other. This enables us to achieve a balance among our ambition to develop novel or highly differentiated drugs, our goal to efficiently advance our pipeline assets towards commercialization and the inherent development risks. With
this goal in mind, we are also aware that the intended novelty and key differentiation of our investigational drugs or drug candidates are subject to pivotal clinical validation and approval by the relevant regulatory authorities. There is no
assurance that any such investigational drug or drug candidate will receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Capabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Innovative Discovery Expertise </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Built by an elite group of seasoned immunologists with extensive academic research and drug development experience, our discovery engine has
generated a panel of internally developed innovative drug molecules in a short span of five years. Among them, 12 innovative drug molecules have met our standard of novelty or high differentiation and have advanced toward further development. This
achievement is a testament to our discovery team&#146;s acumen and technical prowess in translating target biology into points of innovation or differentiation.<B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discovery of lemzoparlimab showcases our innovative research capabilities. Not settling on performing routine or traditional antibody
screening, we set a specific goal to identify and select a unique CD47 antibody that is free from binding to red blood cells (RBC) from all CD47 antibody leads. As a result, we selected by design, our proprietary CD47 antibody (TJC4) with a rare
epitope that spares binding to RBCs as a differentiation point from other CD47 antibodies that typically cause inherent hematologic side effects. The topline results of the recently completed Phase 1a dose escalation monotherapy trial in the United
States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i) lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming
dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii) lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no significant
&#147;sink effect&#148; and (iii) one confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three patients achieved Stable Disease (SD). Therefore, we
believe that lemzoparlimab, if approved, will be a potentially highly differentiated anti-tumor CD47 antibody with the advantage of minimizing hematologic side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another example of our R&amp;D capability relates to our novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel that
represents a new wave of oncology drug candidates. We created novel biological properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are capable of enriching immune cells in tumors through dual targeting of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and immune cells for a synergistic anti-tumor effect. These <FONT STYLE="white-space:nowrap">bi-specific</FONT> drug candidates have been shown to exhibit unique properties that render tumors more responsive
to treatment. Our discovery expertise, when combined with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;fit-for-purpose&#148;</FONT></FONT> antibody engineering technology platforms, becomes a powerful engine of
innovation to create novel molecules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fit-for-Purpose</FONT></FONT>
Technology Platforms </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary antibody engineering platforms enable us to accurately capture the biological properties of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies and retain good manufacturability and druggability of the molecules. To date, we have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eight novel <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage <FONT STYLE="white-space:nowrap">bi-specific</FONT> drug molecules. In addition to our own
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody platform, we partnered with ABL Bio and WuXi Biologics to access their antibody engineering platforms in order to increase the probability of success, as different molecular configurations
require different technologies. Furthermore, our proprietary antibody-cytokine technology has enabled another form of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies such as <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> and <FONT
STYLE="white-space:nowrap">TJ-C4GM</FONT> that link a tumor-engaging antibody with an immune-modulatory cytokine. Superior to monoclonal antibodies or cytokines alone, this class of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies has
demonstrated unique properties of concentrating the drug molecules in tumors for a desired target effect with reduced systemic toxicity of cytokines or creating biologic synergy that can potentially translate into better treatment outcome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Biomarker-Enabled Translational Medicine Capabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we focus on developing innovative drug molecules, the ability to apply relevant biomarkers that link a drug response to treatment effects
is critical for early-stage clinical trials of our investigational drugs. This translational medicine capability requires cross-functional knowledge and unique skills to link the target biology of an investigational drug to clinical responses. We
have been developing tailor-made biomarkers for each of our investigational drugs, which are used to select potential responders, predict and measure target engagement, support dose determination and enable timely informed decisions on advancing our
assets to the next phase of clinical development. For example, for the development of uliledlimab, we intend to use CD73 in tumor tissue in combination with other tumor biomarkers to stratify potential target patient populations in our clinical
trial. To that end, we have developed assays to measure CD73 expression and activity in tumor tissues. Furthermore, we have developed specialized assays to measure uliledlimab drug concentrations in tumor tissues. By linking drug concentration with
its activity in the same tumor location, these data help us determine appropriate dose selection for further clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical
Development Capabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development is led by a global team of clinical scientists, industry physicians and experts
in portfolio management, quantitative science, clinical operations, drug safety and quality control. Our clinical team accounts for approximately 80% of our entire R&amp;D organization&#146;s headcount and 80% of our budget allocation. The skillset
of our clinical development team is highlighted by a combination of extensive global pharma, local drug development and operation experiences with clinical networks in China and the United States. The team is driven by high ethical standards, with
passion for improving the lives of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team has the ability to integrate internal core development functions to conduct global
and local clinical trials. We also effectively leverage external resources, including clinical contract research organizations, academic clinical centers and/or networks, and global pharmaceutical or biotech partnerships. Furthermore, we have
established and implemented a robust internal clinical governance system and processes to safeguard patient safety and data integrity. Our current clinical development functions and teams are strategically based in Shanghai, Beijing, and the United
States to cover Phase 1 through Phase 3 clinical trials in China and early-stage clinical trials in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical
development capabilities are best demonstrated by the rapid implementation of 11 clinical trials, including one completed trial in the United States and ten <FONT STYLE="white-space:nowrap">on-going</FONT> Phase 1/2 or registration trials in the
United States and China in the past three years. To ensure regulatory approval and subsequent product launch as currently planned, we strive to reach the following critical clinical milestones by early 2021: 11 active clinical programs consisting of
two Phase 3 or registrational trials in China, three Phase 2 trials and six Phase 1/2 trials in the United States and China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Global Strategic
Collaborations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established an excellent track record of <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> deals with our global and regional partners. These <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals enable us to acquire multiple innovative clinical stage assets with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
favorable clinical data packages. We have quickly built our China Portfolio through <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global biotech partners, including MorphoSys,
Genexine, MacroGenics and Ferring (as the sublicensee under our agreement with Ferring related to olamkicept). Over the past three years, we have established more than 10 global and regional partnerships with reputable pharma or biotech companies.
Our partners selected us among many China-based companies with the belief that we are an ideal partner in China given our strength in science and drug development capability, our outstanding track record of execution demonstrated by rapidly
progressing drug development programs in China and the United States, and our vision and network to tap into business opportunities and China&#146;s growing pharmaceutical market. For example, MorphoSys, MacroGenics and Genexine all stated that we
are an ideal or the best partner in China in their press releases or public announcements. The <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals enable us to streamline our pipeline, focus our resources on the most valuable assets in the
most desirable territories and build strategic alliances with leading global biopharmaceutical companies. In addition, we seek <FONT STYLE="white-space:nowrap">co-development</FONT> opportunities to share development costs, risks and territorial
commercial rights with our partners. In the past several years, we have <FONT STYLE="white-space:nowrap">out-licensed</FONT> four assets and initiated multiple <FONT STYLE="white-space:nowrap">co-development</FONT> programs with partners such as ABL
Bio, MSD, Roche and Junshi and WuXi Biologics. The revenue from <FONT STYLE="white-space:nowrap">out-licensing</FONT> and <FONT STYLE="white-space:nowrap">co-development</FONT> deals is expected to continue to grow as our pipeline progresses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Strategic Partnership with AbbVie </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of our company, entered into a broad global strategic collaboration with AbbVie Ireland Unlimited Company (&#147;AbbVie&#148;), a leading global,
research-based biopharmaceutical company. Pursuant to this collaboration, we grant AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab. We retain all rights to develop and commercialize
lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Hong Kong and Macau. AbbVie will conduct further global clinical trials (which we may elect to <FONT STYLE="white-space:nowrap">co-fund)</FONT> to evaluate
lemzoparlimab in multiple cancers. This deal also allows for potential collaboration on future CD47-related therapeutic agents, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and AbbVie&#146;s venetoclax
(Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of each other&#146;s related CD47-antibody programs in their
respective territories. In addition, we and AbbVie will share manufacturing responsibilities, with AbbVie being the primary manufacturer for supply outside of Mainland China, Hong Kong and Macau and us being the primary manufacturer for supply in
Mainland China, Hong Kong and Macau. We believe that this collaboration will accelerate the establishment of our commercial production operations in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to this collaboration, AbbVie has paid us an upfront payment of US$180&nbsp;million. Additionally, in connection with the recently
released clinical data from the Phase 1 trial of lemzoparlimab in the United States, we expect to be paid a first milestone payment of US$20&nbsp;million. We will also be eligible to receive up to US$1.74&nbsp;billion in further success-based
development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&nbsp;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of
lemzoparlimab, AbbVie will also pay tiered royalties from low double-digit percentages on global net sales outside of Mainland China, Hong Kong and Macau. In addition, AbbVie has a license and right of first negotiation to further develop and
commercialize two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by us and we cannot commercialize products containing these two additional lemzoparlimab-based bispecific antibodies outside of Mainland
China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to financial terms on such products. The potential value of each such license is minimum US$500&nbsp;million in upfront and milestone
payments, for a combined total of no less than US$1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This strategic collaboration with AbbVie reinforces our internal
research and development capabilities and our leading position in immuno-oncology and enables us to realize the full potential of our innovation. By </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
leveraging the combined development strength of our company and AbbVie, we aim to speed lemzoparlimab to market for patients in need around the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Pipeline </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The chart below
summarizes the development status of our drug pipeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g273774g46b24.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes:
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) for felzartamab (TJ202), we are conducting two parallel registrational trials with felzartamab as a
third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track, and we expect to submit an NDA to the NMPA in
2021. In addition, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for felzartamab in SLE; (ii)&nbsp;for eftansomatropin (TJ101), in September 2020, the NMPA approved our IND application for a registrational Phase 3
trial of eftansomatropin in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021; (iii) for enoblituzumab, we expect to submit an IND application in 2021 for a Phase 2 trial; (iv)&nbsp;for
efineptakin (TJ107), we have obtained regulatory clearance from the NMPA to initiate a phase 2 clinical trial in GBM patients with lymphopenia. We had the first patient in on December 31, 2020 and the first patient dosed on February 4, 2021; and
(v)&nbsp;for olamkicept (TJ301), we are conducting an ongoing Phase 2 clinical trial in patients with active ulcerative colitis. The enrollment of this trial is complete and topline data are expected to be released by early 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We were collaborating with Everest Medicines Limited (&#147;Everest&#148;) to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize felzartamab in Greater China for all indications in hematologic oncology. Everest was primarily responsible for sharing with us, by the proportion of 75% for Everest and 25% for
us, the development costs of felzartamab. On November&nbsp;4, 2019, we and Everest terminated the collaboration agreement (including all the supplements and amendments thereto) with respect to the
<FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of felzartamab in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize felzartamab or any economic interest
in its commercialization. All intellectual </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
property rights in respect of felzartamab arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum
flexibility to further develop, manufacture and commercialize felzartamab in Greater China. In consideration of the above arrangements, we issued a total value of US$37.0&nbsp;million of ordinary shares (the &#147;CPP Shares&#148;) to Everest,
representing Everest&#146;s historical contribution to our collaboration and the associated time cost. The CPP Shares were issued concurrently with the completion of our initial public offering in January 2020, at a per share price equal to the
initial public offering price adjusted to reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel consists of (i)&nbsp;six <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, including <FONT STYLE="white-space:nowrap">TJ-L1C4</FONT>
<FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; CD47), <FONT STYLE="white-space:nowrap">TJ-L1A3</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; LAG3), <FONT STYLE="white-space:nowrap">TJ-L1H3</FONT> <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> &times; <FONT STYLE="white-space:nowrap">B7-H3),</FONT> <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; <FONT STYLE="white-space:nowrap">4-1BB),</FONT> <FONT
STYLE="white-space:nowrap">TJ-L1T6</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; T1G1T) and <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-PD-L1</FONT></FONT>
&times; <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine), (ii) <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> (anti-CD47 &times; <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine), and
<FONT STYLE="white-space:nowrap">(iii)&nbsp;TJ-CLDN4B</FONT> (Claudin 18.2 &times; <FONT STYLE="white-space:nowrap">4-1BB).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Portfolio </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy is demonstrated by our China
Portfolio, which consists of novel or highly differentiated investigational drugs. Felzartamab, efineptakin, enoblituzumab and eftansomatropin are the four anchor assets in our China Portfolio. While we have been diligently pursuing our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy, we are aware that there is no assurance that we will always be successful in commercializing any of our product candidates in our China
Portfolio in an accelerated manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Felzartamab is a differentiated CD38 antibody originally developed by MorphoSys that meets the <FONT
STYLE="white-space:nowrap">pre-set</FONT> clinical safety and preliminary efficacy endpoints from a clinical trial conducted in the European Union (EU). <FONT STYLE="white-space:nowrap">In-licensed</FONT> from MorphoSys, felzartamab is being
developed to address the current unmet needs and commercial opportunities in China for multiple myeloma and potentially autoimmune diseases, such as SLE. We own an exclusive license to develop felzartamab in Greater China. We believe felzartamab, if
approved, is potentially highly differentiated compared with the currently marketed CD38 antibody. First, under a similar <FONT STYLE="white-space:nowrap">pre-medication</FONT> condition with dexamethasone, anti-pyretics and anti-histamines,
felzartamab has demonstrated a significantly shorter infusion time and lower infusion reaction rate. Second, unlike the currently marketed CD38 antibody, felzartamab does not down-regulate CD38 expression on the surface of bone marrow myeloma cells
in vitro, maintaining sensitivity of myeloma cells to felzartamab for repeated treatments. We are conducting two parallel registrational trials with felzartamab as a third-line monotherapy and as a second line combination therapy with lenalidomide,
both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track. We aim to submit an NDA for felzartamab as a third-line monotherapy in 2021, followed by another NDA submission for felzartamab
as a second-line combination therapy. Moreover, we believe felzartamab has great market potential in the treatment of pathogenic antibody-mediated autoimmune diseases, such as SLE, where there is a significant unmet need for more effective
therapies. We submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for felzartamab in SLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efineptakin is the
first long-acting recombinant human <FONT STYLE="white-space:nowrap">IL-7</FONT> known to boost cancer-fighting T lymphocytes by increasing their number and function and is being developed as a potential oncology investigational drug. The clinical
safety and effect of efineptakin on T cells have been investigated in multiple previous and ongoing clinical trials in South Korea and the United States. Efineptakin is being positioned to address a huge unmet medical need in oncology. First,
efineptakin can be an oncology-care agent to treat cancer treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received chemotherapy or radiation therapy, and there is no approved
treatment for this condition. This condition causes further damage to patients&#146; already compromised immune system and weakens its ability to fight cancers. Second, efineptakin has been shown to synergize with a
<FONT STYLE="white-space:nowrap">PD-1</FONT> antibody in a tumor animal model potentially through increased T lymphocyte activation and proliferation. In May 2020, we obtained regulatory clearance from the NMPA to initiate a phase 2 clinical trial
with efineptakin in GBM patients with lymphopenia. We had the first patient in on December 31, 2020 and the first patient dosed on February 4, 2021. We are coordinating our study globally with Genexine, which is conducting a Phase 2 clinical trial
in South Korea and parallel clinical trials in the United States towards clinical PoC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is a humanized antibody directed at
<FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell checkpoint regulators that is widely expressed across multiple tumor types and plays a key role in the regulation of immune response against cancers. Similar to other
inhibitors of the B7 family such as <FONT STYLE="white-space:nowrap">PD-L1,</FONT> targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> potentially provides a treatment option for a variety of cancers expressing
<FONT STYLE="white-space:nowrap">B7-H3.</FONT> Enoblituzumab was originally developed by MacroGenics, and we own the Greater China rights of this investigational drug. In multiple clinical trials conducted by MacroGenics, when combined with
pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), enoblituzumab has shown favorable clinical results
that warrant further investigation. In the first quarter of 2021, MacroGenics expects to initiate a Phase 2 study of enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational PD-1 antibody) in front-line
patients with SCCHN who are PD-L1 positive or with tebotelimab (an investigational PD-1 x LAG-3 bispecific DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are PD-L1 negative. We expect to participate in
a subsequent Phase 3 global study if and when initiated, as we deem appropriate. In addition, considering the dynamic regulatory environment and evolving clinical practice, we have been continually refining the development of enoblituzumab in our
territory. Further clinical development may be planned together with MacroGenics to extend to other cancer indications in China and/or globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eftansomatropin is a potentially highly differentiated long-acting human growth hormone that is being developed as a weekly treatment for
pediatric growth hormone deficiency as compared to currently available daily regimens of recombinant human growth hormone (&#147;rhGH&#148;). Eftansomatropin was originally developed by Genexine, and we own the Greater China rights of this product,
which has the potential to address an important clinical need and to cover a significant market gap in pediatric growth hormone deficiency. In a previous Phase 2 trial conducted by Genexine in South Korea and the EU, both weekly and <FONT
STYLE="white-space:nowrap">bi-weekly</FONT> administration of Eftansomatropin demonstrated similar therapeutic effects to daily injection of Genotropin, a short-acting rhGH. In September 2020, the NMPA approved our IND application for a
registrational Phase 3 trial of eftansomatropin in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Portfolio </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy is demonstrated by our Global
Portfolio, which mainly consists of our internally developed novel or differentiated biologics. Our Global Portfolio focuses on two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies.
While we have been diligently pursuing our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy, we are aware that there is no assurance that we will always be successful in achieving PoC or
pivotal development milestones for any of our product candidates in our Global Portfolio in an accelerated manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Monoclonal
antibodies</I>&#151;Among the five monoclonal antibody drug candidates, lemzoparlimab (TJC4), uliledlimab (TJD5) and plonmarlimab (TJM2) are in clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab is an internally discovered, fully human monoclonal antibody targeting CD47, which is one of the most promising immuno-oncology
targets after <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1.</FONT></FONT> Blocking CD47 activates tumor-engulfing macrophages, a component of the innate immune system as an important cancer-fighting mechanism. CD47
antibodies are being actively pursued in clinical trials by a few global companies. However, current development efforts on CD47 antibody drugs are hampered by hematologic side effects (such as anemia) due to binding to human RBCs. For example, at
least two clinical trials conducted by other companies have been suspended. Unlike competitor investigational drugs, lemzoparlimab is a rare antibody originally selected, by design, to purposefully avoid or minimize binding to RBCs while maintaining
a high antibody affinity and tumor killing properties. Lemzoparlimab&#146;s unique property of minimal RBC binding and no significant hematologic changes has been extensively validated in a whole series of robust in vitro assays and <FONT
STYLE="white-space:nowrap">non-human</FONT> primate studies. In a GLP toxicology study involving 40 monkeys, no hematologic side-effects were seen even with repeated injections of 100 mg/kg doses. This unique property may enable lemzoparlimab to be
used safely in a broader patient population to explore its treatment potential in cancers, differentiating it from other clinical stage lemzoparlimab investigational antibody drugs. Notably, the topline results of the recently completed Phase 1a
dose escalation monotherapy trial in the United States have demonstrated the differentiated profile of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i) lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming
dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii) lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no significant
&#147;sink effect&#148; and (iii) one confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three patients achieved Stable Disease (SD). Therefore, we
believe that lemzoparlimab, if approved, will be a potentially highly differentiated anti-tumor CD47 antibody with the advantage of minimizing hematologic side effects. In September 2020, we received the NMPA approval for a Phase 1 clinical trial of
lemzoparlimab in relapsed or refractory advanced lymphoma in China as part of the ongoing international multi-center trial. In addition, lemzoparlimab is being evaluated in a Phase 1/2a clinical trial in China in patients with relapsed or refractory
acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS), and we anticipate reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results in early 2021. We have also entered into a clinical trial collaboration and supply agreement
with Merck Sharp &amp; Dohme Corp, or MSD, through a subsidiary, under which we will sponsor a Phase 1 clinical trial in the United States evaluating lemzoparlimab in combination with
KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s anti-PD-1 therapy, in patients with multiple types of solid tumors. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong
Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Uliledlimab is an internally developed, humanized inhibitory antibody against human CD73. CD73 is a homodimeric enzyme expressed in tumors and
plays a critical role in suppressing immune cells in tumor micro-environment. Uliledlimab displays <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> binding affinity to CD73 and inhibits its nucleotidase activity. In vitro, uliledlimab
completely reversed the <FONT STYLE="white-space:nowrap">AMP-</FONT> or tumor cell-mediated suppression of T cells. In vivo, when combined with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, uliledlimab exhibited a superior or synergistic
inhibitory effect on tumor growth. The key differentiation of uliledlimab when compared to some of the other clinical stage antibodies of the same class, is related to its novel epitope, which works through a unique intra-dimer binding mode,
resulting in a complete inhibition of the enzymatic activity and avoiding the aberrant pharmacological property known as the &#147;hook effect.&#148; With this particular mode of action, uliledlimab, if approved, has the potential to become a highly
differentiated CD73 antibody. We have completed the initial assessment of the clinical trial in the United States as a single agent and in combination with atezolizumab (TECENTRIQR), a PD-L1 antibody marketed by Roche, in patients with advanced
solid tumors. Topline results from a clinical study under contract with TRACON show that uliledlimab is safe and well tolerated at the dose range evaluated and demonstrate clinical activity in patients with advanced solid tumors. We are scheduled to
submit an abstract to ASCO for the 2021 annual meeting. In China, we are conducting a Phase 1/2 clinical trial to evaluate uliledlimab in patients with advanced solid tumors. The first patient in the single agent study was dosed in May 2020. The
first patient in the combination study was dosed on February 3, 2021. This Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and
efficacy of uliledlimab, and determine a recommended dose for further planned clinical studies of its efficacy and safety as a single agent and in combination with standard dose of toripalimab (TUOYIR) in patients with advanced or metastatic cancers
who are refractory to or intolerant of all available therapies. We have been able to accelerate the Phase 1/2 trial in China by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the United States, which is a testament to our
global clinical development capabilities and well-executed pipeline strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plonmarlimab is an internally discovered neutralizing
antibody against human granulocyte-macrophage colony-stimulating factor <FONT STYLE="white-space:nowrap">(&#147;GM-CSF&#148;),</FONT> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases
such as rheumatoid arthritis (&#147;RA&#148;). Plonmarlimab is a humanized IgG1 that displays high affinity binding to <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and blocks its signaling and downstream effects. Plonmarlimab is being developed
for the treatment of autoimmune and inflammatory diseases, including RA and cytokine release syndrome (&#147;CRS&#148;). We have completed a single-dose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT>
study in healthy volunteers in the United States. In China, plonmarlimab is the first antibody of its class entering clinical development. We dosed the first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patient in a Phase 1b study of plonmarlimab in August 2020 in patients with rheumatoid arthritis (RA) in China. We may expand plonmarlimab to other autoimmune and inflammatory indications with
high unmet medical need, where <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to provide an effective treatment option as a
disease-modifying anti-rheumatic drug (&#147;DMARD&#148;) therapy. In addition, since the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we have sprung into action to prioritize plonmarlimab in response to the urgent medical needs. In
May 2020, we announced preliminary results from part 1 of a clinical study in the United States of plonmarlimab in patients with cytokine release syndrome (CRS) associated with severe <FONT STYLE="white-space:nowrap">COVID-19,</FONT> in which
plonmarlimab was found to be well tolerated. We are currently conducting part 2 of this clinical trial to evaluate the efficacy, safety and cytokine levels following a single dose of 6 mg/kg plonmarlimab or placebo (standard care) in patients with
severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to finalize the plan for plonmarlimab in relation to clinical development and potential registration in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">TJ210 is a novel monoclonal antibody directed at C5aR for cancers through a partnership with MorphoSys. In September 2020, the FDA has cleared
the IND application for TJ210 to initiate a Phase 1 clinical trial. The trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ210 and is expected to commence by early 2021. We plan to work jointly with
MorphoSys to develop this asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibody panel</I>&#151;This novel antibody class
represents an emerging and fast-moving area of new drug discovery. <FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibodies are typically constructed to have a dual specificity of two selected antibodies or combined properties of an antibody
linked with a cytokine, previously called an immune-cytokine. However, despite the recent success of checkpoint inhibitors, clinical efficacy of these drugs has been unsatisfactory. It is estimated that over 60% of cancer patients, including those
with melanoma, renal cell cancer, colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> monotherapies. In addition, some patients develop resistance after initial treatment with these therapies. As a result, the standard of care today leaves many cancer patients underserved. There is
consensus among cancer immunologists that tumors that do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment have poor immunologic features, such as an absence or paucity of
tumor-fighting immune cells or the presence of dysfunctional immune cells within the tumors, collectively known as &#147;cold tumors.&#148; We believe that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> <FONT
STYLE="white-space:nowrap">non-responders</FONT> can be better treated with novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. The unique and superior properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT>
antibodies over <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitors alone stem from a second targeting component attached to the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody moiety of the
<FONT STYLE="white-space:nowrap">bi-specific</FONT> molecules, thereby enabling them to elicit a sufficient immune response and converting a &#147;cold tumor&#148; to an immune-active &#147;hot tumor.&#148; Such unique properties of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies cannot be substituted by a combination of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody with a selected second component (either cytokine or antibody) in a free form. The
underlying mechanism is such that the second component must be structurally integrated with the tumor-engaging <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody in order to concentrate and function inside the tumor, which cannot be readily
achieved by the two free agents used in combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have successfully generated a panel of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies in which our proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody acts as the backbone (the first signal) and is linked with various second components (the second signal),
including, but not limited to, a <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonist antibody <FONT STYLE="white-space:nowrap">(TJ-L14B),</FONT> a <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody
<FONT STYLE="white-space:nowrap">(TJ-L1H3),</FONT> a CD47 antibody <FONT STYLE="white-space:nowrap">(TJ-L1C4)</FONT> and an <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine <FONT STYLE="white-space:nowrap">(TJ-L1I7),</FONT> which are shown to
work with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> backbone in various assays and cancer animal models. This unique panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is only made possible by our proprietary and
partnered antibody engineering technologies and the availability of our proprietary monoclonal antibodies. Furthermore, we have generated two other <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies
<FONT STYLE="white-space:nowrap">(TJ-C4GM</FONT> and <FONT STYLE="white-space:nowrap">TJ-CLDN4B)</FONT> that are tailor-made to function as novel fortified antibodies by linking lemzoparlimab with an engineered
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine for the treatment of solid tumors and by linking our Claudin 18.2 antibody with a <FONT STYLE="white-space:nowrap">4-1BB</FONT> antibody as a unique gastric cancer treatment agent that only
activates T cells conditionally upon tumor engagement. All <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies have been validated in a series of robust <I>in vitro</I> and <I>in vivo</I> studies for biology
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> providing a solid basis for clinical validation in cancer patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moving forward, we strive to become a fully integrated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company whose capabilities encompass drug discovery, GMP manufacturing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and
clinical development and commercialization. To achieve this goal, we intend to pursue the following strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rapidly advance our China Portfolio
towards commercialization </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to pursue the most efficient pathway to NDA approval for the investigational drugs in our
China Portfolio. In the next 12 months, we expect to make significant advances with our China Portfolio. Most of the clinical assets of our China Portfolio are expected to undergo Phase 2, Phase 3 or registrational clinical trials in 2021. We plan
to submit NDAs to the NMPA for our China Portfolio products in sequence from 2021 to 2024. With respect to commercialization capabilities, we plan to initially partner with a specialty pharmaceutical company that has existing commercial capabilities
and infrastructure in China to jointly market our leading products. Once we have acquired commercial experience and developed a distribution network, we plan to build a robust internal sales and marketing platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expand our research and development capabilities and footprint in the United States to advance our Global Portfolio </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of our global strategy, we plan to expand our research and development capabilities in the United States to include regulatory
affairs, translational medicine, drug formulation and clinical operations. These specific research and development functions in the United States are complementary to and an integral part of our overall research and development capabilities to
support clinical development of our Global Portfolio. Currently, three of our investigational antibody drugs (lemzoparlimab, uliledlimab and plonmarlimab) are in clinical trials in the United States. We aim to continue advancing the ongoing clinical
trials to Phase 2 for clinical validation and to initiate multiple new clinical programs by 2022 in the United States. In addition, we intend to expand our operational footprint in the United States to create an independent multi-functional business
entity covering global business development, investor relations and corporate communications and other operational capabilities. We are in the process of assembling an integrated management team with global experience and extensive track record
dedicated to overseeing our operations in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Build our manufacturing capabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe it is strategically important and advantageous that we own and control our GMP manufacturing process in order to ensure quality,
secure production slots and maximize cost-effectiveness for clinical trial materials and commercial supplies. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#147;Hangzhou Facility&#148;) as part of our
strategic plan to become a fully integrated biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an appropriate site, and negotiations with
external financing providers. The Hangzhou Facility targets to have a pilot capacity of 2 production lines (1 line configured with 2&nbsp;x&nbsp;2,000L and another line with 1 x 2,000L) by the end of 2021 and commercially progressive capacity up to
8 x 4,000L to begin operation by the end of 2023. Construction is expected to commence in April 2021 and ready for use by the end of 2023. <B><I></I></B>The project will be financed by a combination of internal and external sources. In September
2020, a group of domestic investors in China invested a total of US$120&nbsp;million (in RMB equivalent) in cash. Upon closing, I-Mab Hangzhou became an affiliate of us. We, through our wholly owned subsidiary and parties acting in concert, remain
the majority shareholder of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;), the entity holding the Hangzhou Facility, and retain a managing role and
take full control to build and operate the manufacturing facility. We plan to prioritize our therapeutic focus and resources on immuno-oncology in our global ambition to become a leading immuno-oncology company. This goal has been accelerated by our
recent global strategic collaboration with AbbVie and its commercialization plan for the initial oncology products. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou is positioned to provide manufacturing capabilities for us, as well as the
continued development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of selected biologics assets that are <FONT STYLE="white-space:nowrap">non-essential</FONT> to our immuno-oncology focus, i.e. olamkicept, plonmarlimab (excluding cytokine release syndrome
indications) and a few <FONT STYLE="white-space:nowrap">pre-clinical</FONT> <FONT STYLE="white-space:nowrap">CMC-stage</FONT> programs. We believe that this strategic alignment is necessary to maximize the pipeline value and balance the development
risk for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maximize the value of our pipeline </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to our successful <FONT STYLE="white-space:nowrap">in-licensing</FONT> efforts, we have established a good track record of <FONT
STYLE="white-space:nowrap">out-licensing</FONT> collaborations and <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships. For the years ended December&nbsp;31, 2017, 2018 and 2019, we recorded revenues of RMB11.6&nbsp;million,
RMB53.8&nbsp;million and RMB30.0&nbsp;million from upfront and milestone payments through three <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals, respectively. We have reached cost-sharing
<FONT STYLE="white-space:nowrap">co-development</FONT> deals for some of our drug candidates with multiple global and regional partners. In September 2020, we, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of our company, entered into a broad global strategic collaboration with AbbVie Ireland Unlimited Company (&#147;AbbVie&#148;), a leading global,
research-based biopharmaceutical company. Pursuant to this collaboration, we grant AbbVie an exclusive global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds
directed against CD47). We retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. Pursuant to this collaboration, AbbVie has paid us an upfront payment of US$180&nbsp;million. Additionally, in connection
with the recently released clinical data from the Phase 1 trial of lemzoparlimab in the United States, we expect to be paid a first milestone payment of US$20&nbsp;million. We will also be eligible to receive up to US$1.74&nbsp;billion in further
success-based development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&nbsp;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon
commercialization of lemzoparlimab, AbbVie will also pay tiered royalties consisting of low double-digit percentages on global net sales outside of Mainland China, Hong Kong and Macau. In addition, AbbVie has a license and a right of first
negotiation to further develop and commercialize two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by us, and we cannot commercialize products containing these two additional lemzoparlimab-based
bispecific antibodies outside of Mainland China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to financial terms on such products. The potential value of each such license is minimum
US$500&nbsp;million in upfront and milestone payments, for a combined total of no less than US$1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These achievements, in
particular our collaboration with AbbVie, have not only demonstrated our ability to optimize our pipeline but also provided a sustainable revenue stream. Going forward, we plan to enhance our <FONT STYLE="white-space:nowrap">out-licensing</FONT>
efforts. We expect that the revenue generated from <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities will continue to increase and will account for the majority of our net revenue before the commercialization of our marketed
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People&#146;s
Republic of China. Our telephone number at this address is <FONT STYLE="white-space:nowrap">+86&nbsp;21-6057&not;8000.</FONT> Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box&nbsp;31119 Grand Pavilion,
Hibiscus Way, 802 West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY
10168. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors should submit any inquiries to the address or through the telephone number of our principal executive offices. Our main
website is <FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> The information contained on our website is not a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risk. Before you decide to buy our securities, you should carefully consider the risks described in our
most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated herein by reference, as well as the risks that are described in the applicable prospectus supplement and in other documents incorporated by
reference into this prospectus. If any of these risks actually occurs, our business, financial condition and results of operations could suffer, and you may lose all or part of your investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents by Reference&#148; for information on
where you can find the documents we have filed with or furnished to the SEC and which are incorporated into this prospectus by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities we offer as set forth in the applicable prospectus supplement(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific allocations of the proceeds we receive from the sale of our securities will be described in the applicable prospectus
supplement(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_6"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Cayman Islands exempted company with limited liability and our affairs are governed by our memorandum and articles of association,
the Companies Act, Cap. 22 (Act 3 of 1961, as consolidated and revised), as amended, of the Cayman Islands, which is referred to as the Companies Act below, and the common law of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our authorized share capital is US$80,000 divided into 800,000,000 ordinary shares of a par value of
US$0.0001 each. As of the date of this prospectus, there are 165,477,620 ordinary shares issued and outstanding (excluding 4,036,868 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the
exercising or vesting of awards granted under our share incentive plans). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Sixth Amended and Restated Memorandum and Articles of Association
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material provisions of the sixth memorandum and articles of association of our company and of the
Companies Act (2020 Revision), insofar as they relate to the material terms of our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Objects of Our Company</I>. Under
our current memorandum and articles of association, the objects of our company are unrestricted and we have the full power and authority to carry out any object not prohibited by the Companies Act or any other law of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ordinary Shares</I>. Certificates representing the ordinary shares are issued in registered form and our ordinary shares are issued when
registered in our register of members. We may not issue shares to bearers. Our shareholders who are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the Cayman Islands may freely hold and vote their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Our directors may from time to time declare dividends (including interim dividends) and other distributions on our shares in
issue and authorize payment of the same out of the funds of our company lawfully available therefor. In addition, our company may declare dividends by ordinary resolution, but no dividend shall exceed the amount recommended by our directors. Our
current memorandum and articles of association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under the laws of the Cayman Islands, our company may pay a dividend out of either profit or
the credit standing in our share premium account; provided that in no circumstances may a dividend be paid out of the share premium account if this would result in our company being unable to pay its debts as they fall due in the ordinary course of
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be
demanded by the chairman of such meeting or any one shareholder or shareholders collectively holding not less than 5% of the votes attaching to the shares present in person or by proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching
to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes attaching to the ordinary shares cast at a meeting. A special
resolution will be required for important matters such as a change of name or making changes to our current memorandum and articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Alternation of Share Capital </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
may from time to time by ordinary resolution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increase our share capital by such sum, to be divided into shares of such classes and amount, as the resolution
shall prescribe; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consolidate and divide all or any of our share capital into shares of a larger amount than its existing shares;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide our shares, or any of them, into shares of an amount smaller than that fixed by the memorandum of
association, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cancel any shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken
by any person and diminish the amount of its share capital by the amount of the shares so cancelled. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may by special
resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital and any capital redemption reserve in any manner authorized by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>General Meetings of Shareholders</I>. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call
shareholders&#146; annual general meetings. Our current memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting
as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; general meetings may be convened by our directors (acting by a resolution of our board). Advance notice of at least 14
calendar days is required for any general shareholders&#146; meeting. A quorum required for any general meeting of shareholders consists of, at the time when the meeting proceeds to business, one or more of our shareholders holding shares which
carry in aggregate (or representing by proxy) not less than <FONT STYLE="white-space:nowrap">one-third</FONT> of all votes attaching to all of our shares in issue and entitled to vote at such general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Companies Act does not provide shareholders with any right to requisition a general meeting, nor any right to put any proposal before a
general meeting. However, these rights may be provided in a company&#146;s articles of association. Our current articles of association allow our shareholders holding in aggregate not less than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of
all votes attaching to all issued and outstanding shares of our company that as at the date of the deposit carry the right to vote at general meetings of the company to requisition an extraordinary general meeting of our shareholders, in which case
our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. However, our current memorandum and articles of association do not provide our shareholders with any right to put
any proposals before annual general meetings or extraordinary general meetings not called by such shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer of Ordinary
Shares</I>. Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or
on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it
relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is in respect of only one class of shares; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is properly stamped, if required; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be
transferred does not exceed four; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fee of such maximum sum as the Nasdaq Global Market may determine to be payable or such lesser sum as our
directors may from time to time require is paid to us in respect thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our directors refuse to register a
transfer, they shall, within three calendar months after the date on which the instrument of transfer was lodged with our company, send to each of the transferor and the transferee notice of such refusal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of transfers may, on ten calendar days&#146; notice being given by advertisement in such one or more newspapers, by
electronic means or by any other means in accordance with the rules of the Nasdaq Global Market be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine; provided, however,
that the registration of transfers shall not be suspended nor the register closed for more than 30 calendar days in any year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation</I>. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than
sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up,
subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay the whole of the share capital,
such assets will be distributed so that, as nearly as may be, the losses are borne by our shareholders in proportion to the par value of the shares held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Calls on Shares and Forfeiture of Shares</I>. Our board of directors may from time to time make calls upon shareholders in respect of any
moneys unpaid on their shares in a notice served to such shareholders at least 14 calendar days prior to the specified time or times of payment. The shares that have been called upon and remain unpaid are subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption, Repurchase and Surrender of Shares</I>. We may issue shares on terms that such shares are subject to redemption, at our option
or at the option of the holders of these shares, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by our shareholders by a special resolution. Our company may also repurchase any of
our shares on such terms and in such manner as have been approved by our board of directors or by an ordinary resolution of our shareholders or are otherwise authorized by the articles of association. Under Cayman Islands law, any redemption or
repurchase of shares by our company may be made out of profits of our company, out of our company&#146;s share premium account or out of the proceeds of a fresh issue of shares made for the purpose of the repurchase or, if so authorized by the
articles of association and subject to provisions of the Companies Act, out of capital. Any premium payable on a redemption or repurchase over the par value of the shares to be repurchased or redeemed must be provided for out of profits of our
company or from sums standing to the credit of the share premium account of our company or, if authorized by the articles of association and subject to the provisions of the Companies Act, out of capital. At no time may a company redeem or
repurchase its shares unless they are fully paid. A company may not redeem or repurchase any of its shares if, as a result of the redemption or repurchase, there would no longer be any issued shares of the company other than shares held as treasury
shares. In addition, our company may accept the surrender of any fully paid share for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Variations of Rights of
Shares</I>. Whenever the capital of our company is divided into different classes the rights attached to any such class may, subject to any rights or restrictions for the time being attached to any class, only be varied with the consent in writing
of the holders of all of the issued shares of that class or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued
with preferred or other rights shall not, subject to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights or restrictions for the time being attached to the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking <I>pari passu</I> with or
subsequent to them or the redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be varied by the creation or issue of shares with preferred or other rights including, without
limitation, the creation of shares with enhanced or weighted voting rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Issuance of Additional Shares</I>. Our current memorandum
and articles of association authorize our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current memorandum and articles of association also authorize our board of directors to issue from time to time one or more series of
preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of preferred shares to constitute such series; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rights, dividend rates, conversion rights, voting rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights and terms of redemption and liquidation preferences. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issuance of these shares may dilute the voting power of holders of ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Inspection of Books and Records</I>. The notice of registered office is a matter of public record. A list of the names of the current
directors and alternate directors (if applicable) are made available by the Registrar of Companies of the Cayman Islands for inspection by any person on payment of a fee. The register of mortgages is open to inspection by creditors and shareholders.
Shareholders have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we intend to provide our shareholders with annual audited financial statements. See &#147;Where
You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Anti-Takeover Provisions</I>. Some provisions of our current memorandum and articles of
association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preference shares in one or more series and
to designate the price, rights, preferences, privileges and restrictions of such preference shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, under Cayman Islands law,
our directors may only exercise the rights and powers granted to them under our current memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exempted Company. We are an exempted company with limited liability incorporated under the Companies Act. The Companies Act distinguishes
between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an
exempted company are essentially the same as for an ordinary company except that an exempted company: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not have to file an annual return of its shareholders with the Registrar of Companies;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is not required to open its register of members for inspection; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not have to hold an annual general meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may issue shares with no par value; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for
20 years in the first instance); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register as a limited duration company; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register as a segregated portfolio company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Limited liability&#148; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of
the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Act is modeled after that of England but does not follow recent English statutory enactments and differs from laws applicable to
U.S. corporations and their shareholders. Set forth below is a summary of the significant differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the United States and their
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mergers and Similar Arrangements</I>. The Companies Act permits mergers and consolidations between Cayman Islands
companies and between Cayman Islands companies and <FONT STYLE="white-space:nowrap">non-Cayman</FONT> Islands companies. For these purposes, (a) &#147;merger&#148; means the merging of two or more constituent companies and the vesting of their
undertaking, property and liabilities in one of such companies as the surviving company, and (b)&nbsp;a &#147;consolidation&#148; means the combination of two or more constituent companies into a consolidated company and the vesting of the
undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then
be authorized by (a)&nbsp;a special resolution of the shareholders of each constituent company, and (b)&nbsp;such other authorization, if any, as may be specified in such constituent company&#146;s articles of association. The plan of merger or
consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a statement of the assets and liabilities of each constituent company and an
undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court
approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A merger between
a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member
agrees otherwise. For this purpose a company is a &#147;parent&#148; of a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived
by a court in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Save in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from
the merger or consolidation is entitled to payment of the fair value of his or her shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, provided that the
dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled
by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Separate from the statutory provisions relating to mergers and consolidations, the Companies
Act also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors
with whom the arrangement is to be made, and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or
meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the
transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the statutory provisions as to the required majority vote have been met; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting
bona fide without coercion of the minority to promote interests adverse to those of the class; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the arrangement is such that may be reasonably approved by an intelligent and honest man or woman of that class
acting in respect of his interest; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies
Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a takeover offer is made and accepted by holders of 90% of the shares within four months, the offeror may,
within a <FONT STYLE="white-space:nowrap">two-month</FONT> period commencing on the expiration of such four-month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can
be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement and reconstruction is thus approved, or if a takeover offer is made and accepted, a dissenting shareholder would have no
rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholders&#146; Suits</I>. In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be
brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely
the rule in Foss v. Harbottle and the exceptions thereto) which may permit a minority shareholder to commence a class action against, or derivative actions in the name of, our company to challenge: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which is ultra vires or illegal and is therefore incapable of ratification by the shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which constitutes a fraud against the minority where the wrongdoers are themselves in control of the
company; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which requires a resolution with a qualified (or special) majority (i.e., more than a simple majority)
which has not been obtained. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Indemnification of Directors and Executive Officers and Limitation of Liability</I>.
Cayman Islands law does not limit the extent to which a company&#146;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts
to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
crime. Our current memorandum and articles of association permit indemnification of officers and directors for losses, damages, costs and expenses incurred in their capacities as such unless such
losses, damages, costs and expenses arise from dishonesty, willful default or fraud of such directors or officers. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have entered into indemnification agreements with our directors and executive officers that provide such persons with
additional indemnification beyond that provided in our current memorandum and articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Directors&#146; Fiduciary Duties</I>. Under Delaware corporate law, a
director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that
an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of
loyalty requires that a director acts in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by
a director and mandates that the best interests of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions
of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of
the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and
therefore it is considered that he or she owes the following duties to the company&#151;a duty to act in good faith in the best interests of the company, a duty not to make a personal profit based on his or her position as director (unless the
company permits him or her to do so), a duty not to put himself or herself in a position where the interests of the company conflict with his or her personal interest or his or her duty to a third party and a duty to exercise powers for the purpose
for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree
of skill than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are
likely to be followed in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholder Action by Written Consent</I>. Under the Delaware General Corporation Law, a
corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. Cayman Islands law and our current articles of association provide that shareholders may approve corporate matters by way
of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholder Proposals</I>. Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual
meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may
be precluded from calling special meetings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Act does not provide shareholders with any right to requisition a general
meeting, nor any right to put any proposal before a general meeting. However, these rights may be provided in a company&#146;s articles of association. Our current articles of association allow our shareholders holding in aggregate not less than <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board
is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders&#146; meeting, our current articles of association do not provide our
shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#146; annual general meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cumulative Voting</I>. Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the
corporation&#146;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the
votes to which the shareholder is entitled on a single director, which increases the shareholder&#146;s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman
Islands but our current articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors</I>. Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed
only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our current articles of association, subject to certain restrictions as contained therein,
directors may be removed with or without cause, by an ordinary resolution of our shareholders. A director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or until his or her
office is otherwise vacated. In addition, a director&#146;s office shall be vacated if the director (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&nbsp;is found to be or becomes of unsound mind or
dies; (iii)&nbsp;resigns his or her office by notice in writing to the company; (iv)&nbsp;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his or her
office be vacated; (v)&nbsp;is prohibited by law from being a director; or (vi)&nbsp;is removed from office pursuant to any other provisions of our current memorandum and articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transactions with Interested Shareholders</I>. The Delaware General Corporation Law contains a business combination statute applicable to
Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an
&#147;interested shareholder&#148; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#146;s
outstanding voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a <FONT STYLE="white-space:nowrap">two-tiered</FONT> bid for the target in which all shareholders would not be treated
equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the
person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware
business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the
company and not with the effect of constituting a fraud on the minority shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Dissolution; Winding up</I>. Under the Delaware
General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#146;s outstanding shares. Delaware law allows
a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its
members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court,
just and equitable to do so. Under the Companies Act and our current articles of association, our company may be dissolved, liquidated or wound up by a special resolution of our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Variation of Rights of Shares</I>. Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with
the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under our current articles of association, if our share capital is divided into more than one class of shares, we may
vary the rights attached to any class with the written consent of the holders of all of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment of Governing Documents</I>. Under the Delaware General Corporation Law, a corporation&#146;s governing documents may be amended
with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. As permitted by Cayman Islands law, our current memorandum and articles of association may only be amended with a
special resolution of our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>History of Securities Issuances </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of our securities issuances in the past three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;22, 2020, at the closing of our initial public offering, we issued and sold a total of 17,037,020 ordinary shares, represented by ADSs at a public offering price of US$14.00 per ADS. On February&nbsp;10, 2020, we issued and sold a total
of 1,767,205 ordinary shares, represented by ADSs at the initial public offering price pursuant to the partial exercise by the underwriters in our initial public offering of their option to purchase additional ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2020, we issued 6,078,571 ordinary shares to Everest Medicines Limited concurrently with the completion of our initial
public offering, at a per share price equal to the initial public offering price adjusted to reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio, at a total value of
US$37.0&nbsp;million, with respect to Everest&#146;s historical contribution to our <FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of felzartamab in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2020, we issued 4,036,868 ordinary shares to Citi (Nominees) Limited, the nominee of Citibank, N.A., the depositary of our
ADS program, for bulk issuance of ordinary shares reserved and issuable under our share incentive plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered
into definitive subscription agreements (collectively, the &#147;Subscription Agreements,&#148; and each, a &#147;Subscription Agreement&#148;) with a consortium of institutional investors (including Hillhouse Entities), pursuant to which we agree
to issue and sell to these investors (i)&nbsp;a total of 29,133,502 ordinary shares of our company for an aggregate purchase price of approximately US$418&nbsp;million (equivalent to a price of US$33 per ADS); and (ii)&nbsp;warrants (the
&#147;Investor Warrants&#148;) to subscribe for up to 5,341,267 ordinary shares of our company at an exercise price of US$45 per ADS, subject to the closing conditions set forth in the Subscription Agreements. Each ten ADSs of our company represents
twenty-three ordinary shares of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company. On September&nbsp;11, 2020 and December 17, 2020, we issued 20,421,378 ordinary shares and 8,712,124 ordinary shares, respectively, to these investors, pursuant to the Subscription
Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Subscription Agreement with the Hillhouse Entities contemplates two closings. The first closing occurred on
September&nbsp;11, 2020, and the second closing occurred on December 17, 2020. The closings of the Subscription Agreements with investors other than the Hillhouse Entities have occurred in September 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November 9, 2020, we issued 100,000 ordinary shares to Biomaster Holding Limited upon exercise of options granted to certain of our
employees for an aggregate exercise price of US$100,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November 19, 2020, we issued 200,000 ordinary shares to Biomaster Holding
Limited upon exercise of options granted to certain of our employees for an aggregate exercise price of US$200,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November 30, 2020,
we issued 582,076 ordinary shares to Biomaster Holding Limited upon exercise of options granted to certain of our employees for an aggregate exercise price of US$452,020 and RMB56,028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 17, 2020, we issued 900,000 ordinary shares to Genexine, Inc. as a result of its full conversion of interest-free convertible
promissory notes issued to it on February 5, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 31, 2020, we issued 115,000 ordinary shares to Biomaster Holding Limited
upon exercise of options granted to certain of our employees for an aggregate exercise price of US$115,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, we issued an aggregate of 16,723,646 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares to CBC
SPVII LIMITED and Genexine for an aggregate purchase price of US$30.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2017, we issued 14,089,714
Series B preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited for an aggregate purchase price of US$48.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2018, we issued 1,804,880 Series B preferred shares to <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten
Limited for an aggregate purchase price of US$6.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, we issued an aggregate of 2,535,201 Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited for an aggregate purchase price of
approximately US$13.7&nbsp;million as a result of the conversion by these two entities of the convertible promissory notes issued to them on September&nbsp;25, 2017 and February&nbsp;9, 2018, respectively. On the same date, we issued an aggregate of
2,253,512 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited for an aggregate
purchase price of approximately US$13.7&nbsp;million as a result of the exercise of the warrants granted to them on September&nbsp;25, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, we issued 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares, 5,938,640 Series B preferred
shares, and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares to Tasly Biopharma Limited in exchange for Tasly Biopharma Limited&#146;s equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, Tasly Biopharma Limited transferred to Rainbow Horizon Limited 947,218 Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares and the warrant in part to purchase 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for a total purchase price of US$6.0&nbsp;million. On the same date, we
issued 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to Rainbow Horizon Limited as a result of the exercise of the warrant by Rainbow Horizon for an aggregate purchase price of US$5.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, we issued to Qianhai Ark (Cayman) Investment Co. Limited (&#147;Qianhai Ark Cayman&#148;), (i) 1,455,549 Series B
preferred shares for a purchase price of approximately US$2.0&nbsp;million, (ii) 232,161 Series </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares for an aggregate purchase price of US$1.25&nbsp;million as a result of the conversion of a convertible promissory note issued to
Qianhai Ark Cayman on July&nbsp;6, 2018, and (iii) 206,366 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for an aggregate purchase price of US$1.25&nbsp;million as a result of the exercise of warrant granted to Qianhai Ark
Cayman on September&nbsp;25, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, we issued an aggregate of 31,046,360 Series C preferred shares to Fortune Eight
Jogging Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited, HH IMB Holdings Limited, Ally Bridge LB Precision Limited, Marvey Investment Company Limited, Mab Health Limited, Casiority H Limited, Southern Creation
Limited (formerly known as Ally Bridge <FONT STYLE="white-space:nowrap">LB-Sunshine</FONT> Limited), Tasly International Capital Limited, and Parkway Limited for an aggregate purchase price of US$200.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2019, we entered into a share purchase agreement with Caesar Pro Holdings Limited, WuXi Biologics HealthCare Venture, and
Hongkong Tigermed Co., Limited. Pursuant to the share purchase agreement, these investors will subscribe for an aggregate of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shares of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> for an aggregate purchase price of US$27.0&nbsp;million. On October&nbsp;17, 2019, we issued 1,428,571 Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shares to Wuxi Biologics HealthCare
Venture. On November&nbsp;6, 2019, we issued an aggregate of 2,428,572 Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shares to Hong Kong Tigermed Co., Limited and Caesar Pro Holdings Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the preferred shares outstanding were converted into ordinary shares immediately upon the closing of the initial public offering of our
company&#146;s ordinary shares in January 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we issued a US$12.1&nbsp;million convertible promissory note due September 2020 to CBC Investment <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Limited. On June&nbsp;29, 2018, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited converted this note to 2,247,321 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2018, we issued a US$9.0&nbsp;million convertible promissory note due February 2021 to Genexine. Genexine can at any time
prior to February&nbsp;5, 2021 convert this note into preferred shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> at US$10 per share, subject to certain price adjustments. On December 17, 2020, Genexine converted this note to 900,000 ordinary
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2018, we issued a US$1.6&nbsp;million convertible promissory note due September 2020 to <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited. On June&nbsp;29, 2018, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited converted this note into 287,880 Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, we issued a US$1.3&nbsp;million convertible
promissory note due July 2021 to Qianhai Ark Cayman. On July&nbsp;6, 2018, Qianhai Ark Cayman converted this note into 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Options and Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;6, 2017, we granted Shanghai Tasly an option to purchase up to 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares. On September&nbsp;25, 2017, we granted Shanghai Tasly an additional option to purchase up to
5,938,640 Series B preferred shares and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. On June&nbsp;29, 2018, Tasly Biopharma Limited, as Shanghai Tasly&#146;s permitted assign, exercised these options in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we granted (i)&nbsp;Qianhai Fund an option to purchase up to 1,455,549 Series B preferred shares and up to 232,161
Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, and (ii)&nbsp;CBC RMB Fund an option to purchase up to 1,804,880 Series B preferred shares and up to 287,880 additional Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred
Shares. The option granted to Qianhai Fund was exercised in full on July&nbsp;6, 2018. The option granted to CMC RMB Fund was terminated on February&nbsp;9, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we granted a warrant to each of CBC Investment <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Limited, Shanghai Tasly, Qianhai Fund and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited to purchase up to 4,994,046 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred
shares, up to 2,104,928 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, up to 515,914 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and up to 639,734 Series <FONT STYLE="white-space:nowrap">B-2</FONT>
preferred shares, respectively. On July&nbsp;6, 2018, these investors exercised their warrants in part and purchased 1,997,618 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 841,971 Series
<FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 206,366 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and 255,894 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, for an aggregate purchase
price of US$20.0&nbsp;million. These investors have waived and cancelled their rights under the rest of the warrants. On September&nbsp;25, 2017, we also granted a warrant to CBC RMB Fund to purchase up to 639,734 Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares, which was terminated on the same date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, Tasly Biopharm
Limited, as Shanghai Tasly&#146;s permitted assign, transferred to Rainbow Horizon Limited the warrant in part to purchase 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares. On the same date, Rainbow Horizon Limited
exercised this warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreements, we agree to issue and sell to the investors thereunder the Investor
Warrants, exercisable at the election of the applicable investors within 12 months after the initial or subsequent closing dates set forth in the applicable Subscription Agreements. On September&nbsp;11, 2020 and December&nbsp;17, 2020, we issued
and sold a portion of the Investor Warrants, allowing the applicable investors to purchase 3,744,032 ordinary shares and 1,597,235 ordinary shares, respectively. As of the date of this Prospectus, none of the Investor Warrants has been exercised.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted options to purchase our ordinary shares to certain of our directors, executive officers and&nbsp;employees. See
&#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into our fourth amended and restated shareholders agreement with our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shareholders agreement provides for certain special rights, including right of first refusal,
<FONT STYLE="white-space:nowrap">co-sale</FONT> rights, preemptive rights and contains provisions governing the board of directors and other corporate governance matters. Those special rights, as well as the corporate governance provisions,
automatically terminated upon the completion of our initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Deed of Undertaking </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2019, a deed of undertaking was made by our company and a few shareholders of our company, each as a warrantor, to the other
shareholders of our company (other than the shareholder warrantors), each as a warrantee, pursuant to which each warrantor represents and warrants to each warrantee that it has provided each warrantee with all information and documents in connection
with the initial public offering of our company that has the effect of establishing rights or otherwise benefiting any shareholder in a manner more favorable than the corresponding terms applicable to the relevant warrantee in relation to the
initial public offering of our company (collectively, the &#147;More Favorable Arrangements&#148;). Pursuant to the deed of undertaking, until the fifth anniversary of the completion of our initial public offering, we will not directly or indirectly
enter into any agreements or arrangements or modify, amend or waive any existing agreements or arrangements of any kind that would have the effect of establishing the More Favorable Arrangements; provided that it shall be allowed to adopt or modify
any employee incentive plans and grant options to the management or any employee of our company after our initial public offering pursuant to such plans and in accordance with the then effective memorandum and articles of association and the
applicable listing rules for the purpose of rewarding their bona fide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Registration Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our shareholders agreement, we have granted certain registration rights to our shareholders. Set forth below is a description of
the registration rights granted under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights</I>. At any time after the earlier of
(i)&nbsp;December&nbsp;31, 2020, or (ii)&nbsp;six months following the effectiveness of a registration statement for a firm underwritten public offering of our ordinary shares on The Stock Exchange of Hong Kong Limited, the New York Stock Exchange,
the Nasdaq Stock Market or other internationally recognized securities exchange, with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less
than US$1.0&nbsp;billion, the holders of a majority of the registrable securities then issued and outstanding may request in writing that we file a registration statement covering the registration of at least 20% of the registrable securities (or
any lesser percentage if the anticipated gross receipts from the offering are to exceed US$5.0 million). Upon such a request, we shall, within ten business days of the receipt of such written request, give written notice of such request to all
holders, and use our best efforts to effect, as soon as practicable, the registration of all registrable securities that the holders request to be registered and included in such registration by written notice given by such holders to us within 20
days after receipt of the request notice. We have the right to defer filing of a registration statement for a period of not more than 90 days after receipt of the request of the initiating holders if our board of directors determines in good faith
that filing of such registration statement at such time will be materially detrimental to us or our shareholders, but we cannot exercise the deferral right more than once during any twelve-month period and cannot register any other securities during
such twelve-month period. We are not obligated to effect any such registration if we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration. We are not obligated
to effect more than three demand registrations. This demand registration right is subject to the customary exclusion right of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Registration on Form <FONT STYLE="white-space:nowrap">F-3</FONT></I>. If we qualify for registration on Form
<FONT STYLE="white-space:nowrap">F-3,</FONT> any holder or holders of a majority of all registrable securities then issued and outstanding may request in writing that we effect a registration on <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT>
(or an equivalent registration in a jurisdiction outside of the U.S.). We shall promptly give written notice of the proposed registration and as soon as practicable, effect such registration within 20 days after we provide the aforesaid written
notice. The holders are entitled to an unlimited number of registrations on Form <FONT STYLE="white-space:nowrap">F-3</FONT> so long as such registration offerings are in excess of US$500,000. We are not obligated to effect any such registration if
we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration other than a registration from which registrable securities of the holders have been excluded, or if we
would be required to qualify to do business or to execute a general consent to service of process in effecting such registration in any particular jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights</I>. If we propose to register for a public offering of our securities (other than registration statements
relating to demand registration, Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration, any employee benefit plan or a corporate reorganization), we shall give written notice of such registration to all holders of registrable securities at
least 30 days prior to filing any registration statement and afford each such holder an opportunity to be included in such registration. If a holder decides not to include all of its registrable securities in any registration statement thereafter
filed by us, such holder shall nevertheless continue to have the right to include any registrable securities in any subsequent registration statement or registration statements as may be filed by us, subject to certain limitations. This piggyback
registration right is subject to the customary exclusion right of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expenses of Registration</I>. We will bear all
registration expenses. Each holder, however, should bear its proportionate share of all of the underwriting discounts and selling commissions applicable to the sale of registrable securities or other amounts payable to underwriter(s) or brokers in
connection with such offering by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Termination of Obligations</I>. Our obligations to effect any demand, <FONT
STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> or piggyback registration shall terminate upon the earlier of (i)&nbsp;the tenth anniversary of the initial public offering (ii)&nbsp;after the initial public offering, the date on which such
shareholder is eligible to sell all of the registrable securities held by it under Rule 144 within any <FONT STYLE="white-space:nowrap">90-day</FONT> period without volume limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Agreement with Hillhouse Entities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered into a Subscription Agreement with the Hillhouse Entities, as amended by an amendment to Subscription Agreement
entered into between Hillhouse Entities and our company in December 2020. The Subscription Agreement, as amended, provides for (i)&nbsp;certain investors&#146; rights, such as registration rights, board representation rights and anti-dilution rights
and <FONT STYLE="white-space:nowrap">(ii)&nbsp;lock-up</FONT> and other transfer restrictions. Set forth below is a description of certain rights and restrictions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration after Initial Closing (September 11, 2020)</I>. We agree to file with the SEC a registration statement to register
the resale of Hillhouse Entities&#146; registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT
STYLE="white-space:nowrap">F-1,</FONT> as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&nbsp;calendar days after September&nbsp;11, 2020, which period could be extended to one
hundred and twenty (120)&nbsp;calendar days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the registration statement pursuant to limitations under Rule 415 of
the Securities Act, the number of registrable securities to be registered for each selling shareholder named in the registration statement shall be reduced pro rata among all such selling shareholders. We shall maintain the continuous effectiveness
of the registration statement for a period of ninety (90)&nbsp;days after its effectiveness or such shorter period upon which the Hillhouse Entities have notified us that their registrable securities have actually been sold. We have fulfilled this
obligation. On December 14, 2020, the SEC declared effective a registration statement on Form F-1, under which the selling shareholders identified therein (including the Hillhouse Entities) may offer, from time to time, up to 25,123,751 ordinary
shares, including ordinary shares represented by ADSs of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration after Subsequent Closing</I> <I>(December
17, 2020)</I>. With respect to the registrable securities then held by the Hillhouse Entities which have not been previously registered pursuant to an effective registration statement, we agree to file a prospectus supplement or a registration
statement to register the resale of such registrable securities on a Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form F-3ASR registration statement (or, if Form F-3 or Form F-3ASR is not then available to us, on Form F-1 or such other form
of registration statement as is then available to effect a registration for resale of such registrable securities), and have such registration statement declared effective by the SEC no later than (a)&nbsp;the ten (10)&nbsp;business days after the
later of (i)&nbsp;the first date when we become eligible to use registration statement on <FONT STYLE="white-space:nowrap">F-3,</FONT> or (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period with respect to the
subsequent closing, or forty-five (45)&nbsp;calendar days after such <FONT STYLE="white-space:nowrap">lock-up</FONT> period expiration date if the SEC reviews and comments on the registration statement. We shall maintain the effectiveness of such
registration statement for a period ending on the date the registrable securities registered thereon have ceased to be registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights</I>. Upon written request from the Hillhouse Entities at any time after we have effected two registration
statements abovementioned, with respect to the registrable securities then held by the Hillhouse Entities, and in no event later than the forty-five (45)&nbsp;calendar days following the delivery of such request, we shall file a prospectus
supplement or a registration statement to register the resale of such registrable securities on a Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form F-3ASR registration statement (or, if Form F-3 or Form F-3ASR is not then available to us, on
Form F-1 or such other form of registration statement as is then available to effect a registration for resale of such registrable securities), have such registration statement declared effective, and maintain the effectiveness of such registration
statement for a period ending on the date the registrable securities registered thereon have ceased to be registrable securities. If the registrable securities are offered by means of an underwritten offering, and we or the underwriters determine
that marketing factors require a limitation of the number of securities to be underwritten, the number of registrable securities that may be included in the underwriting shall be reduced and allocated (i)&nbsp;first, to us and each holder in
accordance with the terms of the Shareholders Agreement; (ii)&nbsp;second, to investors in the private placements entered into in September 2020 (including the Hillhouse Entities) requesting inclusion of their registrable securities in such
registration statement on a pro rata basis based on the total number of registrable securities then held by each such investor; and (iii)&nbsp;third, to other holders of registrable securities, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Suspension of Registration</I>. We may suspend the use of any registration statement for
a period not exceeding thirty (30)&nbsp;consecutive trading days, if we (i)&nbsp;determine that we would be required to make disclosure of material information in the registration statement that we have a bona fide business purpose for preserving as
confidential; (ii)&nbsp;determine that we must amend or supplement the registration statement so that it shall not include an untrue statement of a material fact or omit to state a material fact; or (iii)&nbsp;have experienced or are experiencing
some other material <FONT STYLE="white-space:nowrap">non-public</FONT> event, the disclosure of which at such time would adversely affect us. However, we cannot exercise the suspension right more than once in any twelve (12)&nbsp;month period and
may not register any other securities during such suspension period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expenses</I>. We will bear all registration expenses, except any
(i)&nbsp;portions of fees and disbursements of counsel for the Hillhouse Entities exceeding US$30,000, (ii) underwriting discounts and selling commissions applicable to sale of registrable securities, and (iii)&nbsp;fees payable pursuant to the
deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ranking of Registration Rights</I>. Registration rights granted to the Hillhouse Entities shall not be senior to,
or on a parity with, those granted to holders under the Shareholders Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Board Representation Rights</I>. As long as the
Hillhouse Entities continue to jointly beneficially own at least five percent (5.0%) of our total issued and outstanding share capital, it is entitled to nominate and maintain one representative to our board of directors. We shall cause an
individual jointly designated by the Hillhouse Entities to be appointed as the investor director with immediate effect no later than the fifteenth (15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) business day after receiving written
notice from the Hillhouse Entities or such later date on which we receive necessary shareholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">Lock-up</FONT></I>. The Hillhouse Entities shall not dispose of any of the ordinary shares purchased by Hillhouse Entities on September 11, 2020 or December 17, 2020 within a 90-day period following September 11, 2020 or
December 17, 2020, as applicable, to any person other than affiliates of the Hillhouse Entities, who shall be bound by the Hillhouse Entities&#146; lock-up obligations for the balance of each applicable lock-up period. Each of the Hillhouse Entities
and their affiliates may directly or indirectly, place any charge, mortgage, lien, pledge, restrictions, security interest or other encumbrance in respect of the lock-up securities in connection with such Hillhouse Entity&#146;s (or any of its
affiliates&#146;) margin loans, collars, derivative transactions or other such downside protection transactions to be entered into on or after the date of the subscription agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Anti-dilution rights</I>. We agree not to issue, offer, sell, or grant any option or right to purchase any new securities, without the
prior written consent of the Hillhouse Entities, (i)&nbsp;during the <FONT STYLE="white-space:nowrap">90-day</FONT> period following each closing date; or (ii)&nbsp;at an effective purchase price per share lower than the purchase price under the
Subscription Agreement with Hillhouse Entities during the <FONT STYLE="white-space:nowrap">90-day</FONT> period commencing from the expiration of each <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Agreements with Other Investors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered into subscription agreements with various investors other than HillHouse Entities. The subscription agreements
are of the same form and provide for certain investors&#146; rights, such as registration rights and anti-dilution right. Set forth below is a description of certain rights and restrictions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration</I>. We agree to file with the SEC a registration statement to register the resale of such investors&#146;
registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-1,</FONT>
as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&nbsp;calendar days after the initial closing date, which period could be extended to one hundred and twenty (120)&nbsp;calendar
days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the registration statement pursuant to limitations under Rule 415 of the Securities Act, the number of
registrable securities to be registered for each selling shareholder named in the registration statement shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduced pro rata among all such selling shareholders. We shall maintain the continuous effectiveness of the registration statement for a period of ninety (90)&nbsp;days after its effectiveness or
such shorter period upon which such investors have notified us that their registrable securities have actually been sold. We have fulfilled this obligation. On December 14, 2020, the SEC declared effective a registration statement on Form F-1, under
which the selling shareholders identified therein (including these investors) may offer, from time to time, up to 25,123,751 ordinary shares, including ordinary shares represented by ADSs of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration</I>. We agree to notify such investors at least thirty (30)&nbsp;days prior to filing any registration statement for
purposes of effecting a public offering of ADSs (excluding registration statements relating to the mandatory registration described above). The Private Placement Investors has 20 days after receiving notice from us to notify us in writing of their
desire to include their registrable securities in the registration statement. However, if the registrable securities in such registration statement are offered by means of an underwritten offering, and we or the underwriters determine that marketing
factors require a limitation of the number of securities to be underwritten, the number of registrable securities that may be included in the underwriting shall be reduced and allocated (i)&nbsp;first, to us and each holder in accordance with the
terms of the Shareholders Agreement; (ii)&nbsp;second, to investors in the private placements entered into in September 2020 requesting inclusion of their registrable securities in such registration statement on a pro rata basis based on the total
number of registrable securities then held by each such investor; and (iii)&nbsp;third, to other holders of registrable securities, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Suspension of Registration</I>. We may suspend the use of any registration statement for a period not exceeding thirty
(30)&nbsp;consecutive trading days, if we (i)&nbsp;determine that we would be required to make disclosure of material information in the registration statement that we have a bona fide business purpose for preserving as confidential;
(ii)&nbsp;determine that we must amend or supplement the registration statement so that it shall not include an untrue statement of a material fact or omit to state a material fact; or (iii)&nbsp;have experienced or are experiencing some other
material <FONT STYLE="white-space:nowrap">non-public</FONT> event, the disclosure of which at such time would adversely affect us. However, we cannot exercise the suspension right more than once in any twelve (12)&nbsp;month period and may not
register any other securities during such suspension period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expenses</I>. We will bear all registration expenses, except any
(i)&nbsp;portions of fees and disbursements of counsel for such investors, and (ii)&nbsp;underwriting discounts and selling commissions applicable to sale of registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ranking of Registration Rights</I>. Registration rights granted to such investors shall not be senior to, or on a parity with, those
granted to holders under the Shareholders Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_7"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citibank, N.A. acts as the depositary for the American Depositary Shares. Citibank&#146;s depositary offices are located at 388 Greenwich
Street, New York, New York 10013. American Depositary Shares are frequently referred to as &#147;ADSs&#148; and represent ownership interests in securities that are on deposit with the depositary. ADSs may be<B> </B>represented by certificates that
are commonly known as &#147;American Depositary Receipts&#148; or &#147;ADRs.&#148; The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A.&#151;Hong Kong, located at 9/F,
Citi Tower, One Bay East, 83&nbsp;Hon Hai Road, Kwun Tong, Kowloon, Hong Kong. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have appointed Citibank as depositary pursuant to a
deposit agreement. A copy of the deposit agreement is on file with the SEC under cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public
Reference Room at 100 F Street, N.E., Washington, D.C. 20549 and from the SEC&#146;s website (<U>www.sec.gov</U>). Please refer to Registration Number <FONT STYLE="white-space:nowrap">333-234363</FONT> when retrieving such copy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please
remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge
you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ten (10)&nbsp;ADSs represent the right to receive, and to exercise the beneficial ownership interests in, twenty-three (23)&nbsp;ordinary
shares that are on deposit with the depositary and/or the custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary or the custodian on behalf of the owner of
the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary may agree to change the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the
depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their
nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the
deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to
exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on
behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of
any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the depositary to act on your
behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of the Cayman Islands, which may be different from
the laws in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain
regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements and obtaining such approvals. Neither the depositary, the custodian, us or any of their or our respective agents or affiliates shall be required to take any actions whatsoever on
your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an owner
of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you
will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit
agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manner in
which you own the ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary&#146;s services
are made available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary in your name reflecting the
registration of uncertificated ADSs directly on the books of the depositary (commonly referred to as the &#147;direct registration system&#148; or &#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry) registration
of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary to the holders of the ADSs. The direct registration system includes automated transfers
between the depositary and The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping
account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and
settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the
name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume
the reader owns ADSs and will own ADSs at the relevant time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of the ordinary shares in the name of the depositary or the
custodian shall, to the maximum extent permitted by applicable law, vest in the depositary or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at
all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on
behalf of the holders and beneficial owners of the ADSs representing the deposited property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Dividends and Distributions </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your
receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the
specified record date, after deduction of the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Distributions of Cash </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon
receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders,
subject to the laws and regulations of the Cayman Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars
are transferable to the United States. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the
deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the
distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Distributions of Shares </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever
we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will
<U>either</U> distribute to holders new ADSs representing the ordinary shares deposited <U>or</U> modify the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio, in which case each ADS you
hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash
distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of new ADSs or the modification of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the
terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law (<I>e.g.</I>, the U.S. securities laws) or if it is not operationally
practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution
of cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Distributions of Rights </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary and we will
assist the depositary in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to
exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the
transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary is not obligated to establish procedures to facilitate the distribution and
exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will <I>not</I>
distribute the rights to you if: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We fail to deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will sell the rights that are not exercised or not distributed if such sale
is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Elective Distributions </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever
we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available
to you. In such case, we will assist the depositary in determining whether such distribution is lawful and reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to
elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the election is not made
available to you, you will receive either cash or additional ADSs, depending on what a shareholder in the Cayman Islands would receive upon failing to make an election, as more fully described in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Other Distributions </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we
intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will notify the depositary in advance and will indicate whether we wish such distribution to be made to you. If so, we will
assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it is reasonably
practicable to distribute such property to you and if we provide to the depositary all of the documentation contemplated in the deposit agreement, the depositary will distribute the property to the holders in a manner it deems practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit
agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary will <I>not</I> distribute the property to you and will sell the property if: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not request that the property be distributed to you or if we request that the property not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Redemption </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we decide to
redeem any of the securities on deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the
redemption to the holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of
the applicable redemption price. The depositary will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the
net proceeds from the redemption upon surrender of their ADSs to the depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be
retired will be selected by lot or on a <I>pro rata</I> basis, as the depositary may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Changes Affecting Ordinary Shares </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT
STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive
the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT
STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary may not lawfully
distribute such property to you, the depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Issuance of ADSs upon Deposit of Ordinary Shares </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, the ordinary shares being offered pursuant to this prospectus will be deposited with the
custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary will issue ADSs to the underwriters named in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the closing of this offering, the depositary may create ADSs on your behalf if you or your broker deposit ordinary shares with the
custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary
shares and receive ADSs may be limited by U.S. and Cayman Islands legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of
ADSs may be delayed until the depositary or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in a
denomination of ten (10)&nbsp;ADSs or any whole multiple of ten (10) ADSs. No fractional ADSs will be issued and no fractional share will be accepted for deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary. As such, you will
be deemed to represent and warrant that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares are duly authorized, validly issued, fully paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or
exercised. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You are duly authorized to deposit the ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge,
mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary
may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Transfer, Combination and
Split Up of ADRs </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced
thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary and also must: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide such proof of identity and genuineness of signatures as the depositary deems appropriate;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to
the terms of the deposit agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must
surrender the ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a
combination or split up of ADRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of
underlying ordinary shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and Cayman Islands law considerations applicable at the time of withdrawal. In order to
withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of
all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold ADSs
registered in your name, the depositary may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares
represented by your ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary will only accept a number of ADSs for cancellation that
represent a whole number of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by your ADSs at any
time except for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed,
or (ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obligations to pay fees, taxes and similar charges. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your
ADSs except to comply with mandatory provisions of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Voting Rights </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in &#147;Description of Share Capital.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the depositary will distribute to you any notice of shareholders&#146; meeting received from us together with information
explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary may distribute to holders of ADSs instructions on how to retrieve such materials
upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in
person or by proxy) represented by the holder&#146;s ADSs as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In the event of voting by show of hands</I>, the depositary will vote (or cause the custodian to vote) all
ordinary shares held on deposit at that time in accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In the event of voting by poll</I>, the depositary will vote (or cause the Custodian to vote) the ordinary
shares held on deposit in accordance with the voting instructions received from the holders of ADSs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities for
which no voting instructions have been received will not be voted (except as otherwise contemplated in the deposit agreement).<B> </B>Please note that the ability of the depositary to carry out voting instructions may be limited by practical and
legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Fees and Charges </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS
holder, you will be required to pay the following fees under the terms of the deposit agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fees</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares,
upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited
property, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> shares ratio, or for any other reason)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS cancelled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Distribution of cash dividends or other cash distributions (e.g., upon a sale
of rights and other entitlements)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock
distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Distribution of securities other than ADSs or rights to purchase additional
ADSs (e.g., upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fees</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;ADS Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up&nbsp;to&nbsp;U.S.&nbsp;5&#162;&nbsp;per&nbsp;ADS&nbsp;held&nbsp;on&nbsp;the applicable record date(s) established by the depositary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Registration of ADS transfers (e.g., upon a registration of the transfer of
registered ownership of ADSs, upon a transfer of ADSs into DTC and <I>vice versa</I>, or for any other reason)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Conversion of ADSs of one series for ADSs of another series (e.g., upon
conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely transferable ADSs, and <I>vice versa</I>).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain charges such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxes (including applicable interest and penalties) and other governmental charges; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share
register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain cable, telex and facsimile transmission and delivery expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, expenses, spreads, taxes and other charges of the depositary and/or service providers (which may be a
division, branch or affiliate of the depositary) in the conversion of foreign currency; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reasonable and customary
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the depositary in connection with compliance with exchange control regulations and other regulatory requirements applicable to
ordinary shares, ADSs and ADRs; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, charges, costs and expenses incurred by the depositary, the custodian, or any nominee in connection
with the ADR program. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADS fees and charges for (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation of ADSs
are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC, the ADS issuance and
cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf
of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in
respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed.
In the case of (i)&nbsp;distributions other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions
made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with
the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers, the ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs
are transferred, and (ii)&nbsp;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit agreement, refuse the requested service
until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder. Certain depositary fees and charges (such as the ADS services fee) may become payable shortly after the closing of the ADS
offering.<B><I> </I></B>Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of such changes. The depositary may reimburse us for certain expenses
incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary agree from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Amendments and Termination </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
may agree with the depositary to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the
deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry
settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance
with applicable provisions of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs
after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its
own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request
the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a
<FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction
of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any termination of the deposit agreement, the depositary may make available
to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary. The ability to receive
unsponsored American depositary shares upon termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the payment of
applicable depositary fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Books of Depositary </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business
hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will maintain in New York facilities to record and process the issuance,
cancellation, combination, <FONT STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Limitations on Obligations and Liabilities </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement limits our obligations and the depositary&#146;s obligations to you. Please note the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without
negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which
a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action,
for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for
any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give
notice. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit
agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject
to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of
present or future provision of any provision of our current memorandum and articles of association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion
provided for in the deposit agreement or in our current memorandum and articles of association or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice
or information. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution,
offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary may rely without any liability upon any written notice, request or other document believed
to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the
terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary
relationship, among us, the depositary and you as ADS holder. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which
parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to
account for any payment received as part of those transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Taxes </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the
depositary and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any
deficiency if the sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may refuse to issue ADSs, to deliver, transfer, split
and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any
distributions on your behalf. However, you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary and the custodian may require to fulfill legal
obligations. You are required to indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Foreign Currency Conversion </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees
and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable
cost or within a reasonable period, the depositary may take the following actions in its discretion: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders
for whom the conversion and distribution is lawful and practical. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Distribute the foreign currency to holders for whom the distribution is lawful and practical.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hold the foreign currency (without liability for interest) for the applicable holders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Governing Law/Waiver of Jury Trial </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders
of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AS A PARTY TO THE
DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the
right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary
opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the
terms of the deposit agreement, to have waived our or the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_8"></A>ENFORCEABILITY OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Cayman Islands as an exempted company with limited liability. We are incorporated in the Cayman
Islands because of certain benefits associated with being a Cayman Islands exempted company, such as political and economic stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency
restrictions and the availability of professional and support services. However, the Cayman Islands has a less developed body of securities laws than the United&nbsp;States and provides less protection for investors. In addition, Cayman Islands
companies do not have standing to sue before the federal courts of the United&nbsp;States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our assets are located outside the
United&nbsp;States. In addition, most of our directors and officers are nationals or residents of jurisdictions other than the United&nbsp;States and all or a substantial portion of their assets are located outside the United&nbsp;States. As a
result, it may be difficult for investors to effect service of process within the United&nbsp;States upon us or these persons, or to enforce judgments obtained in U.S.&nbsp;courts against us or them, including judgments predicated upon the civil
liability provisions of the securities laws of the United&nbsp;States or any state in the United&nbsp;States. It may also be difficult for you to enforce judgments obtained in U.S.&nbsp;courts based on the civil liability provisions of the
U.S.&nbsp;federal securities laws against us and our officers and&nbsp;directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have appointed Cogency Global Inc. as our agent to
receive service of process with respect to any action brought against us in the U.S.&nbsp;District Court for the Southern District of New&nbsp;York in connection with this offering under the federal securities laws of the United&nbsp;States or the
securities laws of any state in the United&nbsp;States or any action brought against us in the Supreme Court of the State of New&nbsp;York in the County of New&nbsp;York in connection with this offering under the securities laws of the State of
New&nbsp;York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conyers Dill&nbsp;&amp; Pearman, our counsel as to Cayman Islands law, has advised us that there is uncertainty as to
whether the courts of the Cayman Islands would (1)&nbsp;recognize or enforce judgments of U.S.&nbsp;courts obtained against us or our directors or officers that are predicated upon the civil liability provisions of the federal securities laws of the
United&nbsp;States or the securities laws of any state in the United&nbsp;States, or (2)&nbsp;entertain original actions brought in the Cayman Islands against us or our directors or officers that are predicated upon the federal securities laws of
the United&nbsp;States or the securities laws of any state in the United&nbsp;States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conyers Dill&nbsp;&amp; Pearman has informed us
that the uncertainty with regard to Cayman Islands law relates to whether a judgment obtained from the U.S. courts under civil liability provisions of the securities law will be determined by the courts of the Cayman Islands as penal or punitive in
nature. The courts of the Cayman Islands may not recognize or enforce such judgments against a Cayman company, and because such a determination has not yet been made by a court of the Cayman Islands, it is uncertain whether such civil liability
judgments from U.S. courts would be enforceable in the Cayman Islands. Conyers Dill&nbsp;&amp; Pearman has further advised us that the courts of the Cayman Islands would recognize as a valid judgment, a final and conclusive judgment in personam
obtained in the federal or state courts of the United States under which a sum of money is payable (other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty)
or, in certain circumstances, an in personam judgment for <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, and would give a judgment based thereon provided that (a)&nbsp;such courts had proper jurisdiction over the parties subject to
such judgment; (b)&nbsp;such courts did not contravene the rules of natural justice of the Cayman Islands; (c)&nbsp;such judgment was not obtained by fraud; (d)&nbsp;the enforcement of the judgment would not be contrary to the public policy of the
Cayman Islands; (e)&nbsp;no new admissible evidence relevant to the action is submitted prior to the rendering of the judgment by the courts of the Cayman Islands; and (f)&nbsp;there is due compliance with the correct procedures under the laws of
the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">JunHe LLP, our counsel as to PRC law, has advised us that there is uncertainty as to whether the courts of China
would (1)&nbsp;recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States, or (2)&nbsp;entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United States or
any state in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">JunHe LLP has further advised us that the recognition and enforcement of foreign judgments are provided
for under the PRC Civil Procedures Law. The PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made
or on principles of reciprocity between jurisdictions. China does not have any treaties or other form of reciprocal arrangements with the United States or the Cayman Islands that provide for the reciprocal recognition and enforcement of foreign
judgments. In addition, according to the PRC Civil Procedures Law, courts in China will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC law or national
sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States or in the Cayman Islands. Under the PRC Civil Procedures Law, foreign
shareholders may initiate actions based on PRC law before a PRC court against a company for disputes, if the plaintiff can establish a sufficient contact with China for a PRC court to exercise jurisdiction and has a direct interest, cause of action
and a concrete claim. The action may be initiated by a shareholder through filing a complaint with the PRC court. The PRC court will determine whether to accept the complaint in accordance with the PRC Civil Procedures Law. The shareholder may
participate in the action by itself or entrust any other person or PRC legal counsel to participate on behalf of such shareholder. In addition, it will be difficult for U.S. shareholders to originate actions against us in China in accordance with
PRC laws because we are incorporated under the laws of the Cayman Islands and it will be difficult for U.S. shareholders, by virtue only of holding our ADSs or ordinary shares, to establish a connection to China for a PRC court to have jurisdiction
as required under the PRC Civil Procedures Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_9"></A>TAXATION </B><B><I></I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Material income tax consequences relating to the purchase, ownership and disposition of any of the securities offered by this prospectus will
be set forth in the applicable prospectus supplement(s) relating to the offering of those securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_10"></A>SELLING SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling shareholders (if any) to be named in a prospectus supplement may, from time to time, offer, sell and lend some or all of the ordinary
shares or ADSs held by them pursuant to this prospectus and the applicable prospectus supplement. Such selling shareholders (if any) may sell the ordinary shares or ADSs held by them to or through underwriters, dealers or agents or directly to
purchasers or as otherwise set forth in the applicable prospectus supplement. See &#147;Plan of Distribution.&#148; Such selling shareholders (if any) may also sell, transfer or otherwise dispose of some or all of the ordinary shares or ADSs held by
them in transactions exempt from the registration requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide you with a prospectus supplement,
which will set forth the name of each selling shareholder (if any), the number of ordinary shares beneficially owned by such selling shareholder and the number of the ordinary shares or ADSs they are offering. The prospectus supplement also will
disclose whether any of the selling shareholders (if any) have held any position or office with, have been employed by or otherwise have had a material relationship with us during the three years prior to the date of the prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any selling shareholders may sell the securities described in this prospectus from time to time in one or more of the following ways:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to one or more purchasers; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the offered securities will describe the terms of the offering, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proceeds from such sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any underwriting discounts or agency fees and other items constituting underwriters&#146; or agents&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchanges on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may distribute the securities from time to time in one or more of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices relating to prevailing market prices at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at varying prices determined at the time of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By Underwriters or Dealers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we use
underwriters for the sale of securities, they will acquire securities for their own account. The underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions, at a fixed public offering
price or at varying prices determined at the time of sale. Unless we otherwise state in the applicable prospectus supplement, various conditions will apply to the underwriters&#146; obligation to purchase securities, and the underwriters will be
obligated to purchase all of the securities contemplated in an offering if they purchase any of such securities. Any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to
time. The underwriter or underwriters of a particular underwritten offering of securities, or, if an underwriting syndicate is used, the managing underwriter or underwriters, will be set forth on the cover of the applicable prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we use dealers in the sale, unless we otherwise indicate in the applicable prospectus supplement, we will sell securities to the
dealers as principals. The dealers may then resell the securities to the public at varying prices that the dealers may determine at the time of resale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may designate agents who agree to use their reasonable efforts to solicit purchases for the period of their appointment or to sell
securities on a continuing basis. Any agent involved will be named, and any commissions payable by us to such agent will be set forth, in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Direct Sales </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell securities
directly without using agents, underwriters, or dealers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into agreements with underwriters, dealers and agents that entitle them to indemnification against certain civil liabilities,
including liabilities under the Securities Act, or to contribution with respect to payments which the underwriters, dealers or agents may be required to make. Underwriters, dealers and agents may be customers of, may engage in transactions with, or
perform services for, us or our subsidiaries in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents that participate in the
distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions received by them from us and any profit on the resale of the securities by them may be treated as underwriting discounts and
commissions under the Securities Act. Any underwriters, dealers or agents used in the offer or sale of securities will be identified and their compensation described in an applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are being represented by Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP with respect to certain legal matters as to United States
federal securities and New York State law. Certain legal matters of United States federal securities and New York state law in connection with this offering will be passed upon for the underwriters by a law firm or firms named in the applicable
prospectus supplement. The validity of the securities offered will be passed and legal matters as to Cayman Islands law will be passed upon for us by Conyers Dill&nbsp;&amp; Pearman. Certain legal matters as to PRC law will be passed upon for us by
JunHe LLP and for the underwriters by a law firm or firms named in the applicable prospectus supplement. Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP and Conyers Dill&nbsp;&amp; Pearman may rely upon JunHe LLP with respect to matters governed
by PRC law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference to the annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2019 have been so incorporated in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The office of PricewaterhouseCoopers Zhong Tian LLP is located at 11th
Floor, PricewaterhouseCoopers Center, Link Square 2, 202 Hu Bin Road, Shanghai, the People&#146;s Republic of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_14"></A>WHERE YOU CAN FIND MORE INFORMATION ABOUT US </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, and in accordance with the Exchange Act, we file annual reports and other
information with the SEC. Information we file with the SEC can be obtained over the internet at the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we have filed with the SEC. This prospectus omits some information contained in the
registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information on us and the securities we are offering. Statements in this prospectus
concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to
evaluate these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom273774_15"></A>INCORPORATION OF DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with them. This means that we can disclose important
information to you by referring you to those documents. Each document incorporated by reference is current only as of the date of such document, and the incorporation by reference of such documents shall not create any implication that there has
been no change in our affairs since the date thereof or that the information contained therein is current as of any time subsequent to its date. The information incorporated by reference is considered to be a part of this prospectus and should be
read with the same care. When we update the information contained in documents that have been incorporated by reference by making future filings with the SEC, the information incorporated by reference in this prospectus is considered to be
automatically updated and superseded. In other words, in the case of a conflict or inconsistency between information contained in this prospectus and information incorporated by reference into this prospectus, or between information incorporated by
reference into this prospectus from different documents, you should rely on the information contained in the document that was filed later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference the documents listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our annual report on <A HREF="http://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254d20f.htm">Form
 <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the fiscal year ended December&nbsp;31, 2019 filed on April&nbsp;29, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any future annual reports on Form <FONT STYLE="white-space:nowrap">20-F</FONT> filed with the SEC after the date
of this prospectus and prior to the termination of the offering of the securities offered by this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current report on <A HREF="http://www.sec.gov/Archives/edgar/data/1778016/000119312521030570/d123013d6k.htm">Form
 <FONT STYLE="white-space:nowrap">6-K</FONT></A> (<A HREF="http://www.sec.gov/Archives/edgar/data/1778016/000119312521030570/d123013dex991.htm">Exhibit 99.1</A> of which contains our unaudited consolidated financial statements and the notes thereto
as of and for the nine months ended September 30, 2020) furnished to the SEC on February&nbsp;5, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any future reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> that we furnish to the SEC after the date
of this prospectus that are identified in such reports as being incorporated by reference in this prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of
all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits are specially incorporated by reference in this prospectus, will be provided at no cost to each person, including any beneficial
owner, who receives a copy of this prospectus on the written or oral request of that person made to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">I-Mab</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shanghai, 201210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">People&#146;s
Republic of China </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tel: +86 <FONT STYLE="white-space:nowrap">21-6057-8000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g273774g46b24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273774g46b24.jpg
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MTB4F,3<Y57=XDY6TMC(*,SA!<G5YM[C3UE%A<2<T0H'!_\0 '0$!   ' 0$
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M8RX\-ELU7PNR<UUK(H@&PL^]Q8L/%4\I'&RVYDT\CI&\HWQ9F]@#<#)<)3%
MY:A'OQ5;K+#<1!0?)+,7OL2:S39@QF[K%++)28^"M$V)W)/CLNX^@-2/8?H?
M&*)*WW>V2R+SQ$M[LVFK:L0>EPNA#(&3U9S@2*KW%\A]1I]EKQW/JZO&#L<%
M?PO7)/H,4,(\1MI(8.6RMP1B&O!(QTU*N>2L.VA;==-'#)><ZQ5AFP3()F79
MY'.@=/RDDO+%T9<WL'"VR8,-1=,;%BS$]D-^R.5JMV7?0;7EL18Y@JW+%?:*
M2U7?CZT;([(KB..'M<#S7?4)Z1(>\>K8^[*T#[BO7^Y\VN%0K]?H%D1UQASU
M!<+78F2F= )E2[KL\"ULI%;B@D+\GM8V,J>? F1I?$^$VF.&V:93DFARV,Q%
M^K:GGNP33QW9JM>".03OY2*=IDCD=&Y[9-R(L$K=[>"5]H-DAG=JWW8H)\+E
M\YCKE2O7H68*\F/@NVK$D3H&&*>NX12Q-E9&Z,OE$AA=N[I5Z4CU(>A6IU"_
M6"MUA#0>H7?C[^KV$=10+Y+G:R77TG\^IABOES&*PRK*&D"[I%V0VW[,HBXG
M"ZVU2:OZX 4QD(*6Y@=L+-JG!/8FNX^IDX;$#I;M,?>*NT=ZTR3(QF%LER5^
M'=BFUN3+3$^M9$W?RELU92VCV'J5+]BM5KT,G=P]BK8;%0O'_K-W93'TGQ8N
M06#%1@9G!F7W.5#Q-%;JFOWD0-?T_P"Q?AY6SLT%^885DU-C>.ZW"W W+GO0
M;)T:YVBQ]CZ;8:VYM5]<XNP<]3L/+7-$7*@I:Q8;&OMJDW+T2O'G,^AFPAQ>
MV];%FE'RC;$=3#U:KZMZC!1J5H,7CX)X:]*+M1XLP9&&X^1XLP0OK2MY%T[&
M1T6QL9CL?6\RV^\1.J27L[<MLN4,A9R-RS9S&3L5IK5Z;MUAJSXN:A'$PU;-
MF.W$_EVUY))<B^YL^J/T DUVJT0VJK@^:#! 5)U7*W1KVEL;513_ %C] Z#6
MI^@M5KU7#T*HG\7LU.9DK&3(JUZ/J[8P]"53:6O3;4_<[MHV>Q<99D??<Y]F
M*>Q<IS01S6MEZ5&=M*.2&4TK+,K!:C;)&QM;D9H';LD8F"J>Z?8)U>I1DJQL
MQK61U)ZU:E?@L2PU-L,AD*QR$L<\0OU),-:IRNC?*^WR]>RP.AF-8G"EDZQ^
M'_BOW5$'S>G-;-8:'=%9UV24:^I%</1!/2N>-3K)RE2:Z&FJ%><^J0*M%%"O
M$T)$23ZR3LGKU;<')=;M7QNVO+U)GW[4=>"Y4D94FN4II#1=M&QUJODI&1.%
MJ>+9U\[6NAE+3-R31-//$R566SE=@NU[L#,;3ELV*-R*2]#2OP1-R+-EGMJ6
M<5$^=AJ5YMJ(Z[W,G@#A!RSC!6K320"[U7J4]*;7\-D'TPV"[W91?T];>6,)
M#"G>3+W76QK;T^U+%]@T&1%U)=3]8W54DJUW1'R=(:.9C*7T+<'FP*@JOTLN
M!VCCV\?M!!4JRTI9X8'SF:%KHL:ZMCZTCX=Z9MI]K[U9%FI,P4(X@VW1#[[Y
M&SUD6TFR\O8XCV9GNW8;\%>>S' V*<QSY9MO)VXH[ ; ^I'3TFJ=JWH)#DI9
MG24\AR>-9"ZMDS\&?_FB_%?_ .X!U+_VQ<?*#LI_E3L;_P#&>/\ YBHKGV'?
MR/V5O^ <I_*W%PF\W"M&KH;Q3M_*D7I@%Y4XZ1:N6L(>R7*U=MJM7K;4N;U0
M<ALU6YRDKW.Y+2GGAA7D4HNM7[(*FXR!UE;/?\7!,7-9%^POF$9;$9*;:!^1
MBHU\C&[%5*V)L6)XV#9[)U[-^:>\*\H+GMMML4M^2J'3R"EVK*T0/#EL##9K
M%P;,MQ<N1MXN09B[:S56K7E<[:?$6JN-@KXXVH2!&ZD^MD.3BN.CJQNR';D+
MC9C+5LIMVC\,Y1:M)2N3T"ZB&N*@N>&+N=]2K]0UHL]O]01+G:MHY;4NL:RZ
M)><NN'UIZ\DFTRTL2D]LCRQ:*I+JUL'-.W\E<AF2NU7,BM20LDO8^>T;C:N%
M;%R\PKR025);T.6L0PZ?>X)6Q3;D4HJ19&<SV-X;0+L30NM?/3CG>S'Y2O4[
M0=;V@=,:T!MQ6(KD..FP5>><D<K8AEE@Y2:(WIK'V[WZ" *PS8 \(YRSO#^D
MD."@6U(ON:_7^HB>F3A>BM96AQ;:%")4R_5 EZL<Q )D.!E0F;"YWCJ3F1<5
M6<S;9OL1L?F+T=2&X(FOCMTN6GQSL_F#))8<ZL\NLMV>EQK(WM#'B=H=H;,0
MD;1.SNPD=:22+!8Z6[8I.E>R:E?Y"OE&;,X(11UFMML:VH_:>#+/D8XR-,#]
MW45)C&Z^&G6?PL0S!I*WR%:Q2Q]HZD\.%LD71XVFU0(Z'U-GSB!8H7H=Y3J)
M+RYGS.HGJ&/5TKU0]3&-8*INRU*M;.DCQO9$>QPL9.2.4XG'PL=7- Q]M-HX
MZ.\Z25\P#+@R,>0M,E9CI898961.LB/=K,KI<KV+F2--;$,D@&:RD\C+(R E
M--V0RDF-;%#'!O/H'%RXRI)#)E8)XK$+Y6U3('6Y;%J7:?1=HF!B8QJZ"KZ!
MQRGU7IU;HG/.@16(*^3^IG@5^ZQFR3PVP.L7WG1E+J5Z9<SI6&.RY,"M2)#-
M$MBA7&S5EG%;5F5YCY2[)2REJS0GN7J1@?3& S-+&B &LZQ3NMM6:<=^WN<I
M*^2:5G*P&1HH*F9V-Y%C9.3H17\-3J9*O1Q]\667W;38#(94V2VVRM?Q[Z52
M]+C*7*\E#''! \0V&Q/.._6#V+TP6?EZSG?IT$U4CP]11WQPK7*7 5>E9YXE
M3:9;7">=I7*?K\NTN21F7 /#4:II+#-@Z.MIM",@PUNR^+VAKY"2]G7<HXXZ
M:G%))+$^<1\[6;=:*41SVN^CJRL:7&S9((W#8E+=\V_:[+[,VL;'C]GF<BUN
M3@O311Q3,KF7F2E3MS0NEKU.]EN02N:T5*@<#R@K0AVX.;GF>+72[\__ "@;
M_GG]'/\ W(.8?^Z[UYICL+?DO:G_ (MR'\O46^>SY^6=C_\ @C%_S5]<%E*P
METU6)POAY,;, E@GQ=_AQ?,GDQBP?$D]FWN1_%ET]_?W=O=U]N?9GV>SS<DL
MC8HY)7Z[D3'R.T&IW6-+G:#PG0'0+1,4;II8XF:;\LC(V:G0;SW!K=3X!J1J
M? MRNI?A\^IGF9QD 50CZJI72GA,K/R31Y:$:URKZ%<.5&H3XST:)Z(W_,"A
MV>M+89DFH]A. US6BG$)(TLN*X[;;9_(,87VCCI9 Q\=?)&*O+)%)2JY%DS"
MR::%T7:5RO8D(F+H&//;#8BUP&8Y38#:7&2/:RGSI%&7LDLXD3VH(IH\A<Q3
MZ\@?!!.R;G"A9K1AT(98>P=K/F:YI-JU#T1^I:UWQ-1)^7V2K2,[IS6D'6>S
M+#A:D@/ZL\%150]DX"'/U,6RS$2FE[H8G!8R]>S(R)M\B1II4V=K<!7IRW&Y
M"O8$=2_;97@D8ZS.S&PNFLLCB>YF[( T,9RQB:Z1\;0[OVZTM38K:2U?AHNQ
M=FJ9;N-I26;,4C:E>3*SL@J22S,;('QDN+WF 3/;''*[<^]O I]E]'7?T*=O
M:%M!L-RIE<J"BZ6>YU:M6[:MUQ8TJBZ[30-#7]=03;DIZRS@<LR5HS!+NHA-
M>*6[1""4TBGK[4X6:6*O)<@JVI[4M2O4L6*W+SR1V7U 8VPSS -EL1F*-LCH
MY1*60R1QS/;&?*QLCGH89;4="Q<IUZ<-VS<JUK9K5XI:L=TMDDL5ZY+X:TC9
MI71-DAY(/FBFE@8Z4>[1Z-/436K2QK47.;"^@%Z%<>:*K. D?I*]9['1#[ M
ML.R3[Y45%]$O%+JUB@S._1(YX#$K56<*&W6,%XJOM5@YZT=@WH(2ZE5OR5WR
MPS3UX+C(9(!+VG+9A+W-L0.W89I062Q2-<Z*1CW1M;'[05K4E48ZQ.&Y"YC(
MK,<%B&O9LT)+$=@P=O0U)Q&U]6R-ZQ! 0Z"6-[62Q21LQYUGB-VXL/S?-['B
M6->D4VP7&&N30L@[!5,5?L/4^)NJY;US->#NLLH-NY'9)"%\&QL0Z\A;@@F)
MCL<O!K<;EZF6=?[3<9(Z%J"J9P8W06>V,9CLM#/5?&]XD@?6R4 :]P82]LFZ
MTLW'OM^5PMW#-QW;S1%+D:=BXVL1*RQ5%7,97"35[D<L<9BLLMXBR71MWPV-
MT>\\2;\;*AZ9/_I)>GO_ +<.3_\ OU!Y)M!^0<W^R,E_)3+UV9_[Q[/_ +;Q
M7\_76_7XY_\ TIOJB_\ M<8__1[Y1YAG8@_V>;/_ /W7_P!:R*SSLX?[4=J/
MTX;_ /CV)7)7S92U0NCKC\+7U1! /2:Z+4.CG(Q&&,(.=L+"]?LK$BN/,*;9
MJ:N5F5A01+8*Z7U^DL"IMM=*ZS"/F@KCYVV%F6:X+%V1-GGOA;.ZU19,YAY:
M\R"&&.":KD+5>U)(RQ*T03MQEN-H_IXWL#IX8HG"1;$F[&&U#(YWUXZF1?"R
M3[QCY+%BQ)8@N8RG9IQPNK1/=8KOR]*1[B!7ECD+:T\\S71#5U3Z7/4,] KK
M53R&[&K+4,X,2L8E6^H$HR$ 5HUE.,DWT'38&6G GZZN9%^Y(AP) FL\1@VT
MN0R;18.%\\<F3J,DKNB9+&9._#IWNCB#&@$RETC'L^]!^ZYCP[0M=IC$6S&T
M$\=>6+$77Q6VS/@D$1Y,MKQMEE=(\D-A#8WLD'+&/?8]CF;P>W6V'O$>K559
M1'MMI#FHU_I<H4=,L5JBBKM?:ZL0D[4(B5RWE$7*A"$=@1V.(MN0 /O66ZVR
M:2;(S1F$GO#E\;9DNPUK<5J?'AYMP5B9YHS&^6-[1%&'/E<V:": MB#W"Q%)
M 1RS',%-/A<I5BHSVZ4U2ODBSM*Q: KUYA(R&5CC-,61Q,=!8@LA\SHVFM-%
M9UY"1DAA=FY-9>&=+L_*[>6B/L-4E61GG5EA*U0EZ-TJU^"0L8S" R%C2KFH
MF^)=A8<9WSOC7&VN-=]IL5DJ^7H5\C5;,R"R)"QEA@CF:8I9(7MD8'/#7!\;
MAIO'AI^A0S.)LX/)6L7;?!)8JF,2/K2&6!XEACG8Z*1S&%[3'*PZE@XZ^#B<
M8>7!6Q=O_P ;+^5/P[__ ,.;@?\ ZBS>:D[$W]'MO_QSF?\ #76ZNS1_2]CW
M_P"G.S_^*VN('FVUI5;]TG\./OG0JG4+;5&- <17*GF7 1 "X?36A;'+QWM'
M;*@C8J\UB.$E[T&L<%Z MK ]>->BC6 5:%:#*Z.S&,VPNWMWA:-FU5LLNQ&K
M9;6=,^*%M:0MRN*Q%J5DG;!<V&E8S-)]AT[(7.A<]]=L[HW,6=TNQWGLA4J6
MZCZ$PMTWVV5V33FS&'8?,YJG#)%VL Z;(5L#D(JS:[[#6V&1QVGUVRL><&:^
MDGU,;E,P-.(=$D/2W$6@-E\=>*D/76LXZ!6$M,"TQL5!"4Q*%!':R1:IY2RA
MH-&&9)XM=[P=IL &QO.7HADU5UV)YF:&25F,,CI&O/>ES8VN>8@>6#6N/)Z-
M.ED&RFTA=+&,)D3)#<;0FC%=YDCMOD;$R-\8&^UKI'-C;*6\B7N:T2:N -IO
MN"]DK%197Y]SBTKJ4H?$5IA:95VTB.!L*QF3S1X80;2CS X<CSIM' ^\J>9Q
M%NJA/D88^7\J8<SBK%J.E#?KR6Y86V&5P_29T3HQ*#N$!S7\DX2F)P$HB/*%
M@9WRI9\%F*U22_/CK4=*&PZM):,1,#9F2&%PY0:M,8F:81,TF$S PB0R=ZJY
MUST^V?C]2Y->F-HH5PJ?9DMA;U%Q1';!K##/47.E?M*5O"U2HBQV21QO@&4L
M&!C7F$ND^4CQIH*5M#Y8S-U\I9R52.O=JV<5+!%9BN0LC)%F(S5Y8C'+,US)
M8AOAKW,GC!'+0QES=?;+8&SB:F*O26J-RIF(;$U2:C-)*UKJDW:]J"9LL,#V
MRP3?>W.8V2O(0[D)Y0UQ;@?R\*QKN/ZM/^A&_"R_[2_4Y_\ FIT?S46S7^UK
MLB?J& _].HK=NU7^Q3L7_M/:?_U;)+ECZ8NMJ>$=ZYMUQZC(LJFCNB&IR 63
M6*9K#*I8K\!_$V)#SK%)N9I\?.A8TOP,2XAGCESIOC8NT&-ES&'OXV&9L$MN
M$1LF<-1&1(Q^]INOX@-.FK'#>TU:1J%J[9K+18/.XW+3P.LQ49S+) TZ&5IB
MDCW-=]A )>-[1[';NNZYIT(W;6?B.AV3EY/.>Q<Z#L:MB;T2(M%6D-2A0J*W
MOQGTW\EX@EJ)UO%M-A1S\U'X3N42U(-9GMI"4S%U-96(Y&=<2DV%?!?;>Q=Y
MT$D;*)9-8FLF:2<97.Y++RVF575H)A?=EPUL;61LC#98XA7C<-<UC[(C+.+=
MC<OCF68I'Y%KX*\%400UCAMG,3A(:<EMEJQ _&MP1<Z9TDDDI=#),ZS(URR)
M</Q O2P\8O)H_3N8[1EJ>-P[H&-;K]?875MR[KUQM\NUSN$5WMAV];<\YL*V
MC6"MN5%^@L9*=2P5DT+2O*<9H:NQ6T4+(1SXR*9LN4/+LGFFCJ19#&5:H[5J
MFI68+$5Z&2Y!/%+2,#9)&2-N<O+I<;FWVR\\D[AL\^>!\6'::\E:O!)=EQ>7
MN7'=N7!=M2&M/CK$=&Q6FAO-L/ABDB=1%>%8,>^KGCSWUC4WU XIQ*2D4U4J
MT@4(^45&5@]:I7+!PNDMM.MG2[<CLA0PY@B.&QD6\8H2-%6VZQ*NRB#3>7>'
M9K*0[+VL+VTV:W:EDUEFR-D,ABEB9$\5K5:A6FKM<YKI3 VLYKN6GBDF?RSY
M58I]K,1/MA3S_:;H*-..+2&OBJ9DGDAFDFC-NG:R-N"R]H>V%ME]MKF""M-'
M#'VNR%1.:>LGC%7L?J=LMDY"X89[-U>T=&KZDO%5OLS2I/TW6U^O%^B6Z\B3
M/X*ULWZ!6;4WN5<T)?MW-*%)+5;M,I'5>A?V6RMB#9^"#)QL&*QU:C/(TV:0
MCLP38V0Y6C6IN$+K BI3UHJM@MABBMN#9!&)89XXW;##UK&T]FQB)9#F<I:R
M->)_:M]TM2Q#EX^9<C;O,-AM8S9"K:FNU@ZQ--2:Y\)E,$U?53U+]E"[IU5A
M=4J,>KU:!+7*Y5*R,FKJ31&F2*1X9A]QJR$$O)(->2.'!3&?4ED>2SE(8%D$
M[[;8R/ 8I^'QK*DLQL6#-//9L&6>8S2S2N<'!UASWM:R$11-C&[&QL8:QH:
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M@V.M)+[.M+2F]114Q"IZ(<C/ZO/VXM+.[$&T&B63=*(S8OE0EHFNFT< 4>=
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M!:T&%K;C&6VMCW0++6S@"5H>+5):VQE%ALMG:61MQ[I+;9)LH\6I'TWX][[
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MXM:]1!0EK$X7TU0N)4"D1+YP%:[.0%P<H^XX(7^2C1Q0?Q?DTD&RTLS;$L.
MDL-?)(V>2/'/F;)*_?ED;*X%X?(_OY'!P<]_?.)/%216=KX8'589]I(JSXXX
MGUXI<I' ^*%G)11NA:X1NCBC)CC86EK&'<: W@NK7X8%8Z7/P?\ %X96ZO7F
M:PV[T57J;8^QJ7\CFSV!F)<2C)MBF8^QSIRP,)W()DS(2:63/M-+F267.VVN
M>R#8QXS'8SCJSTQ!5VLI#<@E@$5>"-U5K1NQNW(HHV-#6C1K&M;H- %M3L95
M<D[!=EN2W7O&Q;V+OGE+,-@S6;$K+CGG?E;OS32/<7..KGO<XDZDZKB;^574
M/Z-[[^I]A_9WFV.<L=U^EZ5![1:6YJRGBV_Z'8]FGY5=0_HWOOZGV']G>.<L
M=U^EZ5![1.:LIXMO^AV/9K?WE'JD[QRT/B"J'TY,G:KB?--^?KM9J20 ]>$2
M^I!SZAY'9MP@H\UL@#P0VUJ@]2D<'5P/4>6S""PMV!D<F%Y+9[#9!^7E.>CA
MDRV0%U^EQKX86C PX00MJFX*Q=I%VRZR(F3NWA7<XQ,:1GF*VFSV,9A(F[.R
M3187&G'Q[U%[)YR[:2?:%TS[C:1M-9O3=J-JF9]9@:;+6":1X.<.?^O#KBMU
MS]+;_3?T*/EB^T\_8=&0H5]E:_<ZREK?2(C%9;U=FH4(7C]$#Z6BF=8@<L!H
M!F7270NC-=")N:QM%W8_&217IJN>HG(R5[K*,TSZ\?:\EI^TTSH^V(Y9)HH)
MG[1-CL&)CBZ.A"XQR%P8R]T-N<O%/CX;6SF0&*BM8^3(UX([,O;45*/9&!LI
MK210P3V((]EWRU6S2-:V7)3,Y6-K"^33#UALK;W[O5EZ;4Z1Z@&2!HAH*<"7
MI]4*DM,&*G1*[5IPLY3#G#_2 R4\T*6<YBTL#!=K TM+5E93FQT^5[+LJX7#
M08^S<PD<T<]V5XQ]EHKN[9N3V0_[ZYCN5>V4&8,9'"R3>CKQLKLC8,-VNDN9
M[.V<G5HY^2"6"A#&<G4<;314H5JIC)@:]IA8Z$M@<^26Q)$&RVI9;+YI':P_
ME5U#^C>^_J?8?V=YD'.6.Z_2]*@]HL:YJRGBV_Z'8]FGY5=0_HWOOZGV']G>
M.<L=U^EZ5![1.:LIXMO^AV/9K]7 7K2[(N!KRT*"B#@U1_\ =%>&TIJ[,:M_
M\0>;ZG!G;?;;:?X@H^_NS;2P^V+'\7[,[8S@'N(=C[Q?>_M2YZZS+_I)=E3Q
MIC/[&H^S0WUI=E8@V%8;!1" +6_^Z;"-O35V-&E@^)/-]3(SKOKOK/\ $*GW
M]V':.+VR;?Q?LQK['N(=C[Q?>_M2YZZ?])+LJ>-,9_8U'V:Z+>A'K]F]2]H]
M06>MKZR[D.HJ(AG,$CA3RM=AR]QQXV&P$D6)88(E@6L<>FL6,9@QG;.V=M_>
MU#V6NQ_LULC5P$N%K6(7W\A-7L\M;GL!\3(XG-#1*X[AU<>^;H3K\06^^P1V
M4]L-O+VT\&T=NI8CQ>*KVJ8KT*]0LFDFF8YSS"T&0%K&Z-=J!T^%;S:*$49H
M;#1&JU-7U#6@ASX'V]\>GZ#R":(M,?%]WY34::2+&^VNQ'N[YS\;WO9G&K^:
M:/P3O.2>LMU\^9'X5GFH_54DH6U,2:MQIE2'6?F13$6O1BXQ-)5376D+=B-G
M3!$FT))L+ 9AO =C>3Y<P>>/36">';9S31X_>W<.!^^OX'370]][Q!_04Y[R
M0TUD8-1J/O,?$:D:CO>(U!'Z01X%YBJ=3@6AJ(:RGT6K[1FZ!"8@E^&/:,QQ
M0Y<Z9S/G?)/PX8M/=VWV@]FF/XKV^W.7--'X-WG)/63GS(_"L\U'ZJBG5JLL
MH+6*=75!(]X9B.+7%O!)C5TS (F*#+*]V;7.LD!$\TNF(,PZ9VWSC;3;&,8P
MYIH_!N\Y)ZR<^9'X5GFH_54T6G1G'6!D6C5SG6E##6+ 1N/OC=FA'A$@A6SX
MUEQIK!'"")IC:'6.7V0ZYS)G.=L[.::/P;O.2>LG/F1^%9YJ/U5++0ZODM0V
M5+44I542FT928'C4CZ2G'R<O8(-=HYY(]<C;E'B%13XW+'FVEBDVTECQC0,3
M1/1&X\=.$KSQ][\+I0YO)#ID8. /&&/H/0?P>@^!? :[6%D-2'!KR<:"BGGM
M*EII#O[J1@R(B,8$BYWFVSON01!%-)@C,VF,Z8]W777VXRYIH_!.\Y)ZR<^9
M'X5GFH_54MM6:=.LW3[5Y'(L86C[ZV$QIOF,JT8'VA^NZ9U(]_>? \^VO\7O
M\M[DF-OA>W.N?'--'X-WG)/63GS(_",X=/WF/A__ &KZY!IDH=S/>KJYHOO4
MRJ6ZFG;:#".9E9^DJC8XG<F*&+8=CM'B#$&\&-R-M(ML;YVQIES31^#=YU_K
M*(S>2)T$C2?>$+-??Z-WWN*J,B=%*:P8R(U6QK6H[4)@1F#;WRJCO!"+LBD]
MDN-<"Y@&ABSMIKJ1[(\?QWO>W.7--'X)WG)/64.?,C\*SS4?JKZ G1K#:JQ
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MLU&>6J+>4[&KEJ&1,4,:3G4K7;66$@B:77$&88_>DSC.F=<8QC&%F"E#J3R
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MFS]"E<E9-9[B>_=-O?R85G,TF"/CXQMGV:8TU_>\>X[M'XPPGG[_ /[<G_2
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M^#I6U9&F/O6'<:SB7 ;I$DLDK6!K=&LF#VLT'!K&[I! "G??A>)OOD@+W2<
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M'11>FK4(,A*F&,Y_F@EQV@E0)O,:(NV@UGBT+8*QCYC8B U+B!PT.Z[B2SE
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M5?QPEPQK,#1\3:U.0!&%7 JE@9NX;"<0D$WJ.!5P!7O69>58 86:_P!_74+
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MLSU\.^Z,JY-/.1\@UU$4&P$Q)(W -1(6'>U#A%((R7:-):"7-<W=#^]/'0Z
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M3#8A+C%*&L<6%S',<0U[7-.K7.'%ITUU&A *I+U&IDZDU&]"+%6P&MFA<Y[
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MD<=--YVI].)[',=EZ6CW-<\@L;O"-@9&W1LH:&L:.#6@ G0G4M;IFW25AN:
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M6M'@ $7[R>DDDDDDE6B;L<[$6)9)Y]G*$LTKB^223EW.<X^$DS>]H !H
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M= ?@CS[FYV&+Y)V8=P"$ JI3XAXX03<^T>(ZOE%T6F/!;6Y7 5HY.\A9 M2
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M6V@S9./D%DO?\XL,3CXNWRJX BNN)B<J;0@-8$6'SOQ3N-CSQ-8.?]?_ "_
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M'KE>X)KF=,UOX:G0ZM"X:%IZ200YP()>Z0D$'@=YSCJ/ =.C@H-NV&G4/'0
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M)FR(KHK74_5V)<ZI4V*-8W3&=JZXKL]KM'(>M)=<45=Z@)$E53HRZ@CL*$&
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MJRL30W!+M;M9>GJ;?2WE1GRPVC@MO.:&M+YK2V1F8(JGJ]:69-K[37R&R3F
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MNQY8O:)^4_1/T48_VA?\1XY_PW7X?))ZB=RNT/BNQY8O:)^4_1/T48_VA?\
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M&#OV[J,Y(MI^X)G$JOC6&3%5\./3[',C@Y'"ITJV-M-IOF@%8-T^)-)C[O\
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M9F=58<-2-UI%I_84WXB%Q:E6N)1T1%:WE#3*$CI?+I6(P)*W0OQ70Z1:F=-
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M=69\S4RQXE<X+3J<+76OK[01=,/"+33U'_SN2_U<A_O-EYLG8S\G6?UU_P#
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MM0M#BXUQ%CFH>LAMO%9BKW1&(.M=M;%$]%1@@3+: F@[CZF>9PVN]7*&XNU
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M@W>";J%Z6^7IGPC6=(;^4;I$P%IEP64M>NVY/M$ I668\K2LLWY/Q#6UD^3
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M@%K"JIR@34W<D9M@.N)A=/;$M71Q$5,63>F$HRA6576>;99/W]G@Y\[@YX%
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M'9T.F^,15=H#Z8UY5L7-*;S*,FD.A^B6H>7G2R;"FS.81-8;G+G2O21DV4V
MD/21V'L2XVCVTTG(QK'MC0BR/IU2@;FB+]+%#L8?4-;Z)!@)G[9JEN/(7JYQ
MMD+X>L61XI)/EM]]3O9K[N1??SC7)%"7]:YXTS4-0+) 1F^[,M*EC +73ZSL
MG(W$98B^*#I@;Y4B/>/;Y[Y7$F=?>B^)KG&V2*6B[/S.=<&WBM(^ZYA:?LL,
MGZ>XQK-9_AQR_2L:;+\2ZR?#ECV^8DCT#_A>SYCVXSC!%93)GZ;0W-]O#-'S
M_6R(F]96]!M<U$&FL'UA2X6F5*)NYU02-&\R9[5TQZ2?0@[10Q0J#A)19EP$
MT1%5K VX,R-MRRS+*8U,6)Y[E<AV]/B9^\J<U8&KEN&6Q*4B)E(RIA(%9,QC
M<LTFN;1HB(]ET6PFA%* 3>G?=>MHJZOT'1+<J+"6#5H*,) C=<_63O7 PDZO
M"*-7ND!+,L3$9*=%II 8Q9DP ZD,9]IR*4K!_IL7LJ1::BAY\I<VR$FG4=^E
MH8JEN6$EV&5SUX%D,@%/7*P?:*'&"1*&OQ#K'I!IM#'_  2*]).T<RB6D.)+
M4/JM%M6*3.5]/<9UCM&89",*<QX7YES)\&*3?YC6/8/V:^SYGWLXQDBFC^M\
M[5XN&3[+ /B@RK(;=G8%KO\ 1I7). UFDOPP=_F<E$[8BUR#\UB/.?>FS'I_
M"\(L;WK7D-W?S;.K>R#:5^B?=I@J^&:.."FQ?\(Y=2Y(1F8D]D;"/;(\,V2\
MZ;::X#]_7?R^8S/V\5 ^"O%6>R24S$S-E<X.+&,T!9+&-W1@/$$ZD\=- ,:S
M6R]#.V(K-N:W$^&$0-%=\+6%@>^35PD@E)=J\C4. T X:ZDV8OHW#&AU57 7
MBQ$&W9>8TJ\&,::9; +XRY3"(]Y:QI&/K#&"7MG0S<:7?X.<1Z;YVTQM<N[/
M)=7H^;L?659_<\PW6\GYVK]34B%5_3^Q"K; *_V"<.W/=JU79\1YTPS>:S0#
M[ 1Z25;22#?$Q4&GQB](!_;)C.)O=QMG5W9Y+J]'S=CZRGN>8;K>3\[5^IKX
M76?3\  \:%] L,(%:L/VJ[(S%MMJ!8/>GT^G;Z:57:6;?WAI\?&'TF%_@9_C
M_9MK[SNSR75Z/F['UE/<\PW6\GYVK]34\PI'"U95L"/O-B')HPP1EKBSKKOE
M0,Q^7^2EDVBK&^A.)_FH/9J%L3OI\3'Q-=/=V]UW9Y+J]'S=CZRGN>8;K>3\
M[5^IK[BC<,V-@7XO%BR834,7V&#W=/>WJ6P^Q>'&-OMCX>L>1]-I/EMM\'>S
M'N_*^_G&N7=GDNKT?-V/K*>YYANMY/SM7ZFH8%*X2TDJ$0%ZL)$E\PQVJ6NN
MNNGUC"J:2!AF+,M8TP-\M-%)IM\]D7W\Z^V+W]<XSEW9Y+J]'S=CZRGN>8;K
M>3\[5^IJ4@K/I^)7+F\'0+#(N:V;[.7DXBVUU)LON12?2]=-JKK+I)[DT6?C
MRQZ"?PO9\Q[<;8P[L\EU>CYNQ]93W/,-UO)^=J_4U$.JG EHUI+-OUA@&I38
M9'9Y<QYWPJ:ED3"CB2:QU;?8C:2<>:/$@>I$.N=/>WDUUSKMEW9Y+J]'S=CZ
MRGN>8;K>3\[5^IJ;,HW#%YUB6F7BQ0FU-(/8K#!G77?*U*5$)/ =OO'6-XY]
M)(CA-\1"[SD:XFQC:+7;63&KNSR75Z/F['UE/<\PW6\GYVK]32"C<,*-3+H+
MQ8I#;#6=KBG@QKIC)M;TA*GV::[[5C$<4>(@B=_ER-XB_P"*SC _O;:8V=V>
M2ZO1\W8^LI[GF&ZWD_.U?J:EP:AP1E%49@;Y89XKX:Q75+?&GN?6#%),0;""
M+$E7TV&R,3-%%MN=@:/?.WO1;[Z8VVP[L\EU>CYNQ]93W/,-UO)^=J_4U VK
M7I^T62.=N@6#"V*V8H^Y7PMO=UM61]RL*/AXJOQLR?+Q[R?,8CR%[-?=^9][
M.-<N[/)=7H^;L?64]SS#=;R?G:OU-3)].X,LUN&YU[L(^M!G5C6[.=,;_1IW
M)60ED<N(ZOODG)16/A:[ X*UCS_"FVCT_A>.[/)=7H^;L?64]SS#=;R?G:OU
M-1I:-PR YHMEO%BT-2U/-Y9P9QIG86J:PC$9;[;8K.8Y(\0EC[_+0[R&^R7&
M/EO>UWQJ[L\EU>CYNQ]93W/,-UO)^=J_4T HW#&9U76@WBQ$&W188YK,&-==
M-FJT"$R<LJ/>2L:1CZPQ %[YC,W'FWQ#G$<>^=X\;N[/)=7H^;L?64]SS#=;
MR?G:OU-2056X Q$K)X5_L,XEP=[URMS8CSIAFZCG@&W!CUDJVFX^^LQ,&GQ2
M]1Q\YDQMB7.N-LZN[/)=7H^;L?64]SS#=;R?G:OU->2JSZ?@E[EJ5T"P1+Z_
M8OM-P3F+;;4*P^V;'TW;32J[2R[^T>;^/@TE%_@?_/\ [^OM=V>2ZO1\W8^L
MI[GF&ZWD_.U?J:G6%(X4K(MHI]YL0Y%$@!(MD>VNN^4\+/:#0&27:*L;ZDX(
MV(AQC 6Q.VGOXS)C3&-LX=V>2ZO1\W8^LI[GF&ZWD_.U?J:]?8W#/G=%_P!\
M6+YS>H??ND'NZ>W-2R/DOZS[WVQ\/X7R^,R?+9WP=[,>[\K[_P#!\=V>2ZO1
M\W8^LI[GF&ZWD_.U?J:RW1[=R9&OI:"K/(=];QHP)K.^X3+YNR2+-Y(61D\^
MZ^'6.:+<>33/SFH>F-(]8Q(L0ZQZ8QV]?LY&PZS9?O/=P:T:B.-@Z(XVDG=:
M-??)))<XN<23EN,Q=/$5&4Z<>Y&WOGO=H99I" '2S/ &\]V@' !K0 QC6L:U
MHJP_:.9%KU34>U#R+W=DS459&%[C74NQXQ#G*S73==K+')["(?X^;2,7^'C^
M/_>V]E&K@O9W9.:K1;.:;:((!J8XA06:78!OMA6W(GG&A#DUC7[[D;;SC3QX
ME#U(@Q[F=MI<:[:[;$4X;U2@KC;*N-L4,!M/4"O;)!D)GOE8I-A$G%,DWC"W
MCGUEB.$WQ&)N1/KB;&-XM=M=\:D2'JM (.4K8;%#(<]JWWJI@P$SQL95_@E$
M?5M=]@L1QQ_!"*W^7GWB,_BLX^7][;3&Q%+@=>YRSCJ$H-F@(TOI3(*I;:@M
MM/K)2<K0-E%%B0#3(V129-(MMCL"Z;YV]Z+:33&=L$4#\Y^9?2_K/W4/],^[
M/L;YKZ>X]W[J^7^;^D?#^G_&^)\OGXGS/P_DO9_!^9]_^#X11SNO<Y6QW"4V
MS001T$I:%;ML@M=_HQ3<K<)=%+B,#?).22H]XM=@<%::9U]Z7:/3.-LD4Q-U
M6@#G-ELUBAT-15;[U:P9"9YR'5_@BD?5MM]0LQRQ_!,&W^7@WE,_C<8^7][7
M?&I%-C7*M6=3O(B:1L-&-:^X0MM!RX?CIRY"@QS<?,CPYUUD)&GBQ%)C2?7,
M>=MXM=-M=MB*Q?"*T(N?4* (I;#2*A"N.('+- BK2:,(PH/.^PA)0N@6(""!
M=I)-AYI8]Y(,[[YBVUSMM[;F[-9E\L<[\MDW3PLDCBF=?M.EBCE $L<<AE+V
M,D#6B1K2&O#1O Z!69FSFST<$M9F"PS*T\D4T]=F+HM@FEA+C#++$(!'))$7
M.,3WM<Z,N<6$:G69DI5-F-/92U*LRL6HTH31A(A5;FL@YXHX)A#RMA,SF#30
M110RP$221211QQ[Z9TTUQB1N6RK(H8&Y/(-@KO;+7A;=LB*"1CG/;)#&) R)
M[7N<YKV-:YKG.<""25ZNP>$?/8M/P^+=9MQ.@MV'8^HZ>U"]C6/AL3&$R31/
M8QC'1R.<QS&-:00T 1\52K:H]JSK6D&*WM_\5?PF781[?Y3@W^$IP-\AG_+-
M=2_WQ\_Y3C$__P [C&_DAR61-L9 W[IOCHNFU.;8^]F+A9Y3EA]Z)C_#_HR6
M?@\%.,1B10.+&+QPQAZ<<*584#]]$W&F(NUS]^ F_H_Z4"3\,:J'!3JB+LMW
M&JU<'W3#%!J-X$:R+94(=F3)HJW:,77((Q>9ILE0"YBB(S+)\77?W]O;,_*9
M.03B3(WWBU)'+9#[=APL2Q;HBDG#I")I(@Q@C?)O.9NMW2-T:2LPN&B-9T6)
MQD;J44L%,LH56&I#/O\ +PUBV(&"*;??RL<6XR3??O@[QU]K*E54H):Q/6:^
MI6G[9V.7K$RX $W;:/$6VQ8@HT0Y.V8M=8\YFCWSF/7&F<^[C&/);&2R-J:.
MQ:R%VS8A&D,]BU/--$-2[2.621SXQO$N[UPXDGI4U7#XFC!-5I8O'4ZM@DSU
MJM&M7@G):&$S0Q1,CE)8 TE[7$M ;T#17!Y1*XK\B:3$^SI1J-(NA)V: 8'E
M<:!R*8I\EQ8BD:1L(IP)%VDGN[&Z'03![#8EU)BDASOIGZ96=T5K!>V9S!!+
MOMKF1MAS>3=O-@,+F2B8C41&)S9 \M+'-=H1\<*0>;E01NKLD-F 1NMB)U5K
MS*W<=9;8:^!U<.T,PF8^(QAPD:YF\#N?ZAUB%/RRNIU\O/W+M(SIX%L>U"'A
M:\H6S359M(^0$J:'R"MWX:!<Z'9KXB[!T9R,VU4:,F"G=@0/]'UIL?-:LYV[
M9F9EZU:S!D9<?5R+MJI8Y*+;]=M2VR?+;17<0]\U9\$SHZ>&K25S8,,,XA8\
MV=Q;?P4:NS%"G _!W+M.SB8,I=Q4>Q->2+).QEIUZA)5PFR>/SL;*]N.S79+
M>VAN1VA5%B>J9Y(Q4VE_!]_G_P!F_J?6O[Z-\P7[HG\D[-_M&[_+1+9?W)GY
M=VP_9.-_G)EUW7>H_CC*T]$J.EH/7F<H8_1K_8+#3;S5N=('GRM>-S7\]8LM
M:4\O:6+ 5J0&;5]-;V+G45AJ1L#B$<O>#E)=Q*=OGJ!XYSBH6>ZV/H-8V55/
MEMC[0>$G<K7=@/YG541MC;6U!7UI1#9^HU4KR9Q#%0I(QNVNL0\V^^^N,NE%
M0&WJEX>I>H4.;J*WELBP%NL:5H<FSU_Y [HB#EF2#7R&-@K7Q+KG8UP#R<TF
M ="-H>Q<3!!+C)H2*[:?W7C%_J2:]T[J=#?5"PJP'2A\'9U& BUK,=N4"3G,
MY4,H_P Q!7K!OB$J. C3*%WI+%I(H8:C$5;7]2YDV B:*NBT1FLGC'EA8K[=
M7S0)HBYW8HLD18S"4>2,DFLV08??23.LT]?=PQYVD4GZCD4D+V3D)VC"0+JO
M-S(U*QDZ:[BWFL$:+$Z8W5<X;,-HFF^H:Q4PWT 9'DYC%!-VU%*EBGVQ'DBH
ME<]0''K9T([ER"^UQC<A:W5K<$N@; ;QV2O7 6PFJ&=0)U)VAM8VH58:F,I4
M.QT:P74:<W>*(J';8BM'7U;<$UZ>AXZ9==EU^MU^Z%S6F+#4;[ %MMG*:S4+
M/T(-2_&6DH1H:U%=TJ2<AXQ4:,;5J=6TN&303:#:.AXGWNG]Z*L\K]3_  #M
M29 ^YKU6J6%?:W%F0U76<J>O,K0RIYDP-BUK22SCIG3\-?+!O+JT4KS%9H&T
M+1>86M('+EAI_E\_$(KR'[%R,N'4D7J?.21]@VC'6<>[UF:'9>CRQPZ.UEC9
M[:9#494-L-"<;?!7Y5L<%[PY")^$16.Z]3_$TUGK%.@M3.W/K<D4VA7!S&C7
M_K8(=3?N2J^CN%G=\OJ]N24NGMW(#,!;:K@Q1U\R1.[D'8R0(V\P1%?9G7N3
MKQF9A_3^> B)'DU8<E&76M##*+*/I\0BO,YYF>D0#R"/.-YE)6T1\6F?>W'U
MU_?\(I,+LW,2IS!2;BF0EB6"Y5K4.U%QU4QDQY_KM+<)D@M@V73O%*,778XQ
MTIC,5:+]=COF_E==I<$7NF]?Y_?[19ZC47XKQG5:_2+:80NE@-3LJIT76QZ5
M&RH' <Q"]RE:FT^UJXS0Y]]-65>9C[8]D6DDI%DSPB>$3PB>$3PBU\SZI>'Q
MV+:L%W0=:SAO'1>>F2-A#%:Q98N4TN;H%ZV:MCX1URQ,DJD$S.1^<3 GFUBD
MA@,WETVTP17.!Z@.#-2JJ"K[;R-D;>E[-O2 P.DTTPJXJDF[2-RSJHX[J26P
MKU$B1S&S-4:&# ;J&FI<L6P!>(FA][HZ?B16K2O59Z?K]6>HWNO]5H^_..0W
M@/G]NZ>5;:Q!S3ZX=3>>W8>=5>L.)*T>JV!Z;6%&6'U"'3%FV/1XTR4+CXS3
MH^/H_N17-'ZA>!3'[JHNX\?E:15.6^R+8^ETO<^.C0(@+3/=-P]7>2-*G#66
MJNQRV/:/">-$R ;[F87F#D2$5LU3U6>GVV\\<=;'ZM1DW+D]UL]#ST.S6ZKH
MJ0T<50TP(\I';"W.$#5.9@$HU0R%8[1L5T,AL6N(M),ZD5W$]ZX8'.T%,[1R
M<4I'3X.ANAB>BT^"=10"AP2A;RTAE<:2+Z>2*S6DP68O6%+,.P!FC-VC+@VD
M(J9S7U#\BZW8;=6*+=$;IM47>B?$0SA,1I:A-N=<GZCO:J/L$R*WM5+@K':^
M>?,6=;'NMA9.X ]Y<:D S&/\T6:_")X1/")X1/")X1/")X1/")X18 ZUU6Q4
M1ZO6)PTQ Y:F,^3=B.;--K-L88/G7389@)IB/W!],XUVCVV][.V??]F<:XR[
M9_ 4\K4FGL2V6/CL.A A?$UI:(XGZD/AD.]J\\00- .&NI.!;5[49#!W:]:I
M%4DCEJB=QL1S/>'F:6/1ICGB ;NL!T+2==>.G 8K_=&7?_JRK?ZBU_;?E][C
M<7\/?\[7^JK%_="S?5\9YBU]<3]T9=_^K*M_J+7]M^.XW%_#W_.U_JJ>Z%F^
MKXSS%KZXG[HR[_\ 5E6_U%K^V_'<;B_A[_G:_P!53W0LWU?&>8M?7$_=&7?_
M *LJW^HM?VWX[C<7\/?\[7^JI[H6;ZOC/,6OKB?NC+O_ -65;_46O[;\=QN+
M^'O^=K_54]T+-]7QGF+7UQ/W1EW_ .K*M_J+7]M^.XW%_#W_ #M?ZJGNA9OJ
M^,\Q:^N)^Z,N_P#U95O]1:_MOQW&XOX>_P"=K_54]T+-]7QGF+7UQ/W1EW_Z
MLJW^HM?VWX[C<7\/?\[7^JI[H6;ZOC/,6OKB?NC+O_U95O\ 46O[;\=QN+^'
MO^=K_54]T+-]7QGF+7UQ/W1EW_ZLJW^HM?VWX[C<7\/?\[7^JI[H6;ZOC/,6
MOKB?NC+O_P!65;_46O[;\=QN+^'O^=K_ %5/="S?5\9YBU]<3]T9=_\ JRK?
MZBU_;?CN-Q?P]_SM?ZJGNA9OJ^,\Q:^N)^Z,N_\ U95O]1:_MOQW&XOX>_YV
MO]53W0LWU?&>8M?7$_=&7?\ ZLJW^HM?VWX[C<7\/?\ .U_JJ>Z%F^KXSS%K
MZXJDH]1MAPQ%^NJ4VZG,F-3?I8YT!^D6V,ZYE'V*9DP;[Q9SB3X.\>N)L:YB
MQ+#G?$NOC8V,I\C)VK8LBQNZQ<N^)T1<..Z\1P,> [HWFN.Z3O;KM-TU-/LA
MWQ9B[>JTW5"[2;M:.9D[6GAOQF2S(PEGX6XYHWP"T.82'#;)6T = "M%941@
M!D6)AR(<^W3?3/MQG&<9QC;233;&T<L4FNLL4NN\<FFDFFVN, G@FK3203QN
MBEB<6O8X<0? ?>+2""UP):YI#FD@@K:M:S!<@BLUI6S03-#XY&'4.!^<.!!:
MYK@',<"UP#@0)_SQ7NGA$\(GA$\(GA$\(GA$\(GA$\(GA%3VW\F,/]#(_P!E
MMX18?\(GA$\(GA$\(GA$\(OR$@FDKC0V <GPBP"AS19?<TW^$2++I/!)[DFN
M\>_N2QZ[>Y)KMIM[/9MKMKG.,_326)DT4D,@WHY8WQ2-U(WF2-+'C5I#AJTD
M:@@CI!!7QLAFDKS16(7;DL$L<T3] =V2)X>QVA!!W7-!T((.FA!"S9T/M@UW
M0N$RKF]1HT]OM@%YOC1"?;&!%FLJP>PPARP#V2P.1*^KCEM;\S*Q3%'C<DV/
M78G(@8HL>-8C9E^,MU[-C,Y#*-Q]"7%XJ"W%CX64:4[J;I6N?2J5I+D[FT*D
M8GL.<0R)Q#.4E>\YEG]LH\U2N5*NSV)PC\ME(,UG+-&?*SR9+(UF7VPN9'D;
M]R*A6:_*7IC6J,8'23-!DY***)O1+\'W^?\ V;^I]:_OHWS3OW1/Y)V;_:-W
M^6B6_P#[DS\N[8?LG&_SDRWH:^@&F.NC=4N[.RKS%W6>T\G[<_3D<WI\[O=U
MR>W<KM2RK&W:73=RZH[#;E\(<E<90R"@R6!FQ%S\UI'C?E)=Q+"Q?X2O-RZV
MPIF>KV^&K,:,_K6PT%9J.CH-\X].O1?3"*X6V/Y/+(&KJ^<=);&Q\\@SJD*M
MX0;J4O4.=DH.B"0=?L>.O']Z*_*Q^&I2$+T&SG](?-W.M\K]_<1#U*H5VNLF
M5<[+RGK0:\*KHPA5")21'R&O5H\-?#G0K#!V^SC4\[X,<$5$IWX92ZBXYK#7
M.[VL 'F=1YY65H,="H6\+,WCZKN5=YA86FI !$<IRBO]U>QV8;2+4.Y/$JIT
M?&'$0U5G1U^?_3Z$4DN_"ZKJU74$VG:[,,FKU'I-2L"];2ZF#%<CN<G=\+K%
MM:ED?/L17I6/45>CKJ4.=M/<;+$MLAY(Q$C@9JU^W'XOH^W#0JK%^%[SA+HR
M)H_0']!?&:$1B/ZM6Z\H8 CS\8]/O'LKM2E6JUCHKEBX"'9R(UC)4SB<76S$
M)VR9GHN<C0][XOI)_P T4?E'X9=+Y7T'F-X%ZI:'L7-F%<=95,JW6=V3MS3Y
M.W35J:2Y3PF6Q8NTW[O:,OE8[*;6Q:JT>A9,.F&^K:.OV\G[O!]N&A2]X_#?
M ZKM>X;;TAW4MMK_ .H&T\HLW/9=(K95].^=.]/G=B[&28T7Z:*[;3^D\=<(
M%0JZ9HI;41WKAD3I.<6F :Z?;XB/[CQ\**&U_"YY\8?6!%75>@5KGU7NCVX@
M<Z0? 6I19&UN8V0->OE#*&CUT4KFDU;#,=@6$@(,)8:B^A&_6]WL$5<'_#<I
MT]3G1V#H$K=\-Q[F?'JU:@N;4!#)7E7).B1]$JC#Z, OW7,]FIJ](JOZPGX8
M%T4@$@DZ@A&#AKB*B1_ABU@"4(E%V6X)2G-G07+J61*O4M1;=9*WWGI_J"4M
M::/"*/+RF8*Q]GZ34(!J\2>LDYV_B1'KSV8.KZ:.I^WZ /\ +Z$5+6_A0<E#
M1LJ\PN[]^%/-=H%YM@6_<#B)):>7=RYDG7M"+&Z=K2C*;%WFSV!,<A458*1H
M&-).GP06>;/#W_C^D'_)%=L'X;=0!9V\\7HAC,/H5/Z91[PCN=$JEO5.$/03
MG+?0<#)GRK.NR@LWQ^CHM,Q&,M*? BV8E82 $T@(LS>G/TRV'B5^M5G?WX_H
M T_%^+<8K;EZ<P8VUBOYG:NUWIN]MI9\4DTII[OLQ"11H2YLS/6OU=><\L+-
MZT:$R1/Z/"?_ ,?N1;B^01/")X1/")X1<[.C?AD>G/ICB^65S"Y5V_HUE[!8
M;+>*\!3%MX)A[%SR;G;&N[6K>J$MBZW5A9=7U53M)V(,#R+79K U723KY8@D
M:?%_DBHCS\,;F=I@J:ZQ=<[*37J\#9=6=45M*LCK%FL-N.ZJ38;H>G J^!Q+
M>Y&ZZ^ <6(/W'#6-%4IS3Y25S65Y!%?BST=53FW#^H<]-]0G4$6O3.G<]Z39
M^M2->?T.Q".JDAXQSU)7!):M4ZK5 ZO8D_(*I5W"C*G!UA'>NP)V4Y;?275[
MWQ?23_FBQGI^%1PC6@C\\VNW3]P1DX:B%OL93?KV1UGIG_<P 2RD?9_R1&1:
MQ\.UY%G7RJY[=K[2@)J_-.BECKQ/Q_2#P\B+/U?]&]-54RNU%U=;G<)4OJ(:
M^IHY^Z%I09]@Z&[9OG+.!@MK]335T5!*SL)I X2I,"4-\(7&I^\D<DLT$6N"
M/\*?AU7715]7TOID.^E/Y*HK9#"3G[-TAM/#JIPRHUN_))F=+)QL86#P#FY=
MLK\PI-8=$ZLQ"UVB,X)0OCK^_P#3]OC\'Z>GBBV2Y#Z/*IR#N'0/4$NOU\L?
M0>L*UBSIDKW2GCI[?LAI'+*77F$R>NU5&$E-1:\V/= XKD:@*4_H5O&8!FJQ
MJD%6FOS?ZG_-%M[Y!$\(H4\FT,$TVD4D^\44DFL$7N_%FVTTVVUBB]_;33XD
MF<8TT]_?77WML>]MKCVYP1<Y.5>L:Y6K:G 3#5&]7'I2SE#=95T^ J76J1OT
M=7<FC90UN UOZ9:2RZ$33F]2L2VT<QI%CGLJ-J:$KT#-A3J"+T1^(<C$H,_0
MS.?:K5>Y QR5>SL=E'<OJYLJ>N&H@P0W,C?I_1*X*DQ"\KSB1?SL=BU6K!>O
MF'9.@"(KDK'K,L1=KK-%?\W2%6*P]9ZQ1Y]JA;VYX:NLT'U#3<,#<>^QI0HI
M5@ UV@L]P2,6=?@&K^%[-,:>XM*BFCD5RG>HFYN^8>FNYZ1T;C'[HEN!/E];
MV$UZ1TFKM^6VOIU=%-FS+SD"6Z6*%&L39"E/V2*RRFN@3&R3BK=&1%9R+U67
M>!UM6K"!678SOIPR.D=!J9^FZVP5I?Z@/3QQZQ[3566(J),$3#WE4?5V8UTM
MQ!P@;68S(NX:N=V^WV\B*F1?B!!B5"M66S\\5UYE9HN>V(&KZWEX[8E4'H=7
MI5G#< &*N7RK?N=+'= ECFOOB:Y5XV. H ^@E[-1]8WV^WVXHNC/A%IIZC_Y
MW)?ZN0_WFR\V3L9^3K/ZZ_\ @0+3_9$_*M+]GM_F;"UZ\R]:_3PB>$3PB>$3
MPB>$3PB>$3PB>$3PB>$3PB>$69^,W&Q)+$*B7"DN%;<C74Q5'G'M'S[,:R-!
M=Y-M8AI!H\>\3F3:,<B#3$<^VF^D$\.-[2XVG:IR6II&5IZS"8[#A^'TD02
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M/2M8VX=Q-Y_Z?HMK/8RMLJY[+SM3>T7J%*:<\&*G -S=J] EK,24-1M3B*P
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MC^$9\IOTIR$_P,OFW_0GRA?^;$?^#)_N^.4C^$9\IOTIR$_P,OFW_0GRA?\
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M?QT#<C>699"GA$\(GA$\(GA$\(GA$\(GA$\(GA%3VW\F,/\ 0R/]EMX18?\
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M"HEC$":UGXP^=5U;$GZL;/7WN!]2H]G+0VRK]II1Y<(==()(2'(3_ R^;?\
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M^R9P/!C+P2*%I[((<?-?Q6GND7LWB?&60MH!8\CYBP"N[B&Q70,VA54H6WV
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M/P.KC^V96QNVQ;.1+\EN>5G)!699<YW\(I>/A_%HE@Z6+D'+XTXEK^^Q5,=
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MD#:RN=M*T$Z,-X3T%!]U'LNMW.J=1AFM:UH%6.>0<JYFJKM]JSUAC==UF1S
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MXOSQ\_T+Z;UQ\.%8R!>;,3RE+W"U&!';J:/):D^9B(\V,2<EK&,K%Q%%#/\
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MV]DD*^H::U63RCKLDB8_E'![IV0;G) M#GG4.W^5UT#-2?O>N]WNFG?B :"
M=X[Q<&@;O#CX==[WOBZ>'QJP4/K?)>4CH'6L\R5K.4T>=;31F[+I@XEPL_8G
M"FDRJ*,MJI-/@1@UUK:KRMI8-X;W@*?#&&5P=4P:WMAMK.ZGNOCBY0F60%Y
MCU8V$%^KRX/+B\-87F,1G@= \N[U1,>A:-27.&NFG -XZDG774 :D ='AU"V
M?X'U@7NO%>7=B#60I(>DTE!;LI!V\3^-(0X!B)+39<PAKM&,JDO:=?.3]/ W
MWG&D^(&+)C>#2GGB,,TL1.O)O<S>(W=X-) =IJ=-1Q U/ ])4CANN<W770D:
M^_H>G]_2LN>>2@GA$\(GA$\(GA%6ZW_+ZC_3Q_\ :8\JJ/XY6_WT?^(*>/\
MI(__ )V_X@MC?,V5U3PBM&_WBN\RHETZ/;C<+JI0*G8KI93]O=S@)!5U!CMN
M5[-MM-=LP+P2),:YVU][.N-?;CV^WPBXBI/Q0>]*JASEQTNCUBLV.H]2;S^J
M6M-N9]3IKFO< S1Z1TTBXTVMW,A-:@B.>T^Z6/1J^:I6:N\'\<MA-=6BKW2Z
M6&.G'0>'HX^'73CI[_@_2.*+,_IF_$$Z-?.LT^J=^VY1RJO7PCU'EI@F6TU3
M=KX:K7O0]>^-4DUC8[80";?!ZQZG+<KO(P(V,/'5?$)1KDXJXR UIPU_1_G]
M"+)?J\]=+WTU]'XE84P%;O/IP>\IZ!U#JKBO L++;"4/USF5$Y6YYNU1MI%)
MH#GH'5*: 9C90ZA:)'FS!>8+\I'N0 U'[Q_<2?[D6I2?\1;U1+%\.G0V/IV2
M=%J -L'>\E@JUD^K]KO-8]:?6?349S?D1TO4]&:ZPRUZAKITY,:&^XFLI63V
M*F-+/L,*/#R ^4:_;[:%G2E^L[KG18+MR6&U4F#O#;U*<]Y-33>;)JM9Z-7^
M>6]M<;TTN=9N@M^Z6COY2CT[<SO=G) M=<HUCKUV70+[13 U%@KDLC3^[7[?
MI/DU1==_((GA$\(M5_4-Z<W':+#2KC6.AR\UN?.JI>5-(M(:"-VRKMEN-PX\
M^VL8>L[(&#,/VYS:Q4ENLWUSEJDOK'74P/Y7:,PBU\.] #"#2J)*ETFO5FF4
MO'6(JTKCYL&38D@/2FG:)=5 =TP[@LDBH1'U)$H+7S,,JR-J.09HLU*MY,R0
MBOV+T61AN K JN:M:\WM$]ELK:"GZY-M<@?J!XGVNH0.YL.XY&.*:NY8_J"/
M+"0N,'6]LF $04.&"UN16'4?0 <J!$S:>A5-\Z4M+)8JZ6IY:LJRFJ6M[^Y?
MDBL]3KJEO$FJS<4[T_6-IK/7 U.82^GM-0LC:AL-WY%?-,]%NR&G^H*G-[C7
M=].Y\B5<E+L57HFR.PD;JINP;S=(O\YME<C7[H=AQU..>SLIH$XK<E'[A$&P
MIV(12*[K1Z:K1TJWTSHG2;3S\R\48VB35]I5N>-%4:<6I=BY]TQSHHE>W>S-
M%QMP34]S3F1@C ?6)/:-PB(&889T3TBQ8O\ 0D<DK\6B?H%:Q>=:VBJ!MR<<
MT66"1U4TW >2<=GJ3<!ZT9#GUMB_YB3?<*66K)6 T?Z386&-%>6; BV;]/G.
M;KR2FC<WL+6OO*W4PX@JHW5KC%+ [8]S8GC36=3NP8KTE>3!MD-7JJ0*:20(
M= PGDFP :J! (M?_ %8W6XUJ\U\.NVJQ(1)ZI 3,,G<L%H\I&S=O%F>2$,B&
M/>;,44<>9-M<[YTCTU]ONZXQC1W9/S&6QV9H18_)WZ43\8R1\=2W/78^0VK3
M2]S(I&-+RUK6EQ&NC0-= %B.T%JS!:A;#8FB::X<6QR/8"[E)!J0T@$Z #7I
MT 6K7YL=1_I&O'ZU._\ &^:U[J-I/'^9_M.Y[96'G"_UVUY^7UD_-CJ/](UX
M_6IW_C?'=1M)X_S/]IW/;)SA?Z[:\_+ZR?FQU'^D:\?K4[_QOCNHVD\?YG^T
M[GMDYPO]=M>?E]9/S8ZC_2->/UJ=_P"-\=U&TGC_ #/]IW/;)SA?Z[:\_+ZR
M?FQU'^D:\?K4[_QOCNHVD\?YG^T[GMDYPO\ 7;7GY?63\V.H_P!(UX_6IW_C
M?'=1M)X_S/\ :=SVR<X7^NVO/R^LGYL=1_I&O'ZU._\ &^.ZC:3Q_F?[3N>V
M3G"_UVUY^7UD_-CJ/](UX_6IW_C?'=1M)X_S/]IW/;)SA?Z[:\_+ZR?FQU'^
MD:\?K4[_ ,;X[J-I/'^9_M.Y[9.<+_7;7GY?63\V.H_TC7C]:G?^-\=U&TGC
M_,_VG<]LG.%_KMKS\OK)^;'4?Z1KQ^M3O_&^.ZC:3Q_F?[3N>V3G"_UVUY^7
MUD_-CJ/](UX_6IW_ (WQW4;2>/\ ,_VG<]LG.%_KMKS\OK)^;'4?Z1KQ^M3O
M_&^.ZC:3Q_F?[3N>V3G"_P!=M>?E]9/S8ZC_ $C7C]:G?^-\=U&TGC_,_P!I
MW/;)SA?Z[:\_+ZRK5=[EU*ON06_WG8G&H<V-Y5;QRR:*SH<_P91RA"B9-,ZR
M1YVUUECQH1!MG$L$L<NFNV*RAMGM+0MP6N=[]L1/#G5KMNQ9K3,/!\<L4DCF
MD.:2 YNCV'1['-< 1ZPY6_#*R3MF:4-.ICED?)&\=!:YKG$<1X1H6GBT@@%=
M0>9],KW4:]$[22_")B^'"X3S2:[&J#=M<YS#-C&-?BCR^[ON&9IIK$5%KG.,
M1SQSCP](;.[14-I*#;E-V[(W=9;J/<#-5F(U+'@:;S':$PS !LK0>#7M?&S.
MZ-Z&_")8CH1H)(R>_B?^:[WP>):X#1P]XAS1D7R_JL3PB>$3PB>$3PB>$3PB
M>$3PB>$3PBI[;^3&'^AD?[+;PBP_X1/")X1/")X1/")X1?E7\^1ZY73PBZH_
MA=?SC[?_ %$5?^O8>=._<S_E';/]B5?X\ZV1V.?QC+_J<7^.197LW/\ TALN
ME6I8_2P1=&>VB"P.R@R>C*9)NA*J%&^TE0OTI0:<'IFG,-<L"%U38C7<VAS%
M[%"$5XLS6;IULEH1M(.L;6[H!$9^]N?IHYK@28N5X O!C$@ !W@%LO5X X\-
M-!KH>&OA!U[W>]\:;VFG$!?(U7H_M%V,H^M:7-;@=BZ:,Q9:M?/@^X<)RBQ]
M D9O9UL:470?:G<BTM)!C.'"=^M05]E($_(F6D-;+6!^\0T;FZ=]FO RMC &
MN]_7EW0!Q:7.&K>*=^!KKH-!X1T=\!\?A=I\1)'#BKJT]*?I=%!3A[<ZK&RZ
MOMV]E5#&NG)8@L]J9UYN]AWC-=S1%5NQ/$59<M:P9B>JM7:Y4U*43LHH"?)>
MV;)+CRCM7 ,)#6ZG=#FCH;P>UKG-#QH\-) =IP4 ]VI(=Q(&IX<=-=#^D G0
M](!.AXJQ0O1SZ1*+5F*JS5Q(SA:6J(YO9KG8Y!GI;NXV*^*E";+9>8DT7 -3
M>N7FG!UQ7"O76(>XOE34)R:_<RL/0W+4CP6N((;H&L:"T!C6%SMTAVI A8\N
M.I:6-<"T,;I'?<3KKX.@#@ -#T<>C0'7IX Z\%D8[C_IE-JYDS>GU(6K+2;R
M],W>8/2ABYE@TK]V?28:$ RZJRP*O!K(YQC*DU4O&;+2IET\!T_D); < 'O+
MR&-&Z=XG^LQO#7CJ[\'I!)!&H(4-YVHXG70 <=?C ^W'I!\*J6> ^G0T?>;>
MATHL.014TFS-)\P)NO%M=TORDR?24S>#=?\ =E^N[Z&277(I!+YEKO\ %'QI
M#%#EYP?Z1X(U;[QXL9&1T?F,8W_]H\*AO'WS]@!_<!Y%A4OBWH<4UBEOBJ&D
M.2YLCV6DZ:A]!M+MXY&CJ0%CP B@W;6BVJM5W&J=*UBF7-J]O7*0L9D:;(8,
M%R^PFN.<\"1P.Z-\ZL8UK27[NKN]:PZS/ XM<'/('?'13[TFI&I!TX]  ''3
MW@W\(Z=&A/#B5DVPD>F/L;6[+;/(D<,8J'<*C;2F_P!R5:$WG-2MPFG0 @GY
M.$8+JLU:Y!!@71A7V)H:%MF%2^,$W,P)/YM[8B#"W> WV/:!NNTD>TF,EHWB
M'.826!P!<.+0>E2C>&FFO2"-./$]'#CH2.@'I'@(5KUM+Z/C;K5GU<IJ21WV
MU"I)JYNE$N<='O0$-/C:J"X=#$FG-Y;##1J9!+$45'!:8J\@%%DDU#&'@\F)
MM!CVE[MV%QWQOMWV'?W7:Z.Y3=WW\=-6;SB>GBHG?T(UX-)UXC4<>/AWM-3^
MC4K9*FURB<VJ2>CTD!'5J?3%\"12A6R0C+D0(<.V\0>--I=MH<Z1:R3R;$;Y
MGES\4B;???:23-.]SGN+WDN<\EQ<>)<2>)\OT*0DDZGB2I)]U7GU;C=RM+,'
M[*T7,!8HUL)STA"?"G!?_(N148K$E8:0J:*B01#8H"&.[92(!&28T '(BV-[
MM-&GOAJW4AN\-2W5I<0" 002#H-UQ.@:2&A\HU'0-1KIKQT&FO2>@>'H*O>,
MX*78?2(P63<N#8H76,B+?8D77X>=B1]==\YF@UQ-%G::/&T>/BQ^W;^'K[9$
M5%2V^M6,FP")&XS":K.!$#SX.)=8A&QR1)8A!8R98XQSM9U%B43Z$KY2Q/CD
MR+\SX8A'"#3%KFAI(TWAO-Z.(WG-UTZ1WS2-#H>&O002TZ/CXCRD?W@JY/)4
M3PB>$5;K?\OJ/]/'_P!ICRJH_CE;_?1_X@IX_P"DC_\ G;_B"V-\S975/"*"
M0..7!,*7!"4,1'O"0.1%I-!/#)KG62*:&37:.6/?7.==]-]=M=M<YQMC.,^S
MPBL"WV_DE4;* +[:.=5IY<<[*$(5O=UE,VM6=Y(%>ZQ0,Y)&,>9WE<#+M@@]
M"L[2-( \Q9V.CCE(JU8J+3;:L8IK)6$CA<V%8A'P%KQ]MIH&P,:UC[I&FFA(
M\Q0$4(LA0TT)6(AQ\:3:Y'ASH1?3XZ77 4@;$:NIUOQ5-/KPDXH H>FY9 @Z
M6N*H,Q:PQ:3$A 1 +1M-(OBB"8ABQL/#[A%5M4:70N%AJG5ZGC;%;CFZKQ-2
MX-SIIB3=X2<0XFBV,((((*VTWUR1-/-+-G?>7?;8BH,G/:/)845LS54FEBK4
MUC)1-8088"%IEN'#$LI\&L&L<.6+D0 80UC)'(=(+K*/@C6$DG28BO+PB>$3
MPB>$6I?J22]\;N$>>)O]J]'%Q_OH[D@M0[?JBK*:)SW6AACK$E\H4H=QE(@?
M;5*RSG,M$7N.<:K9,L-I-"+#X=C]8\C.&O""6)=_E540NRV50KK%-5JY/TGA
MJ$*WU.RG[R%7&UM>9..R6>\ANB'P5>>5^#25:@U7+!KZ14GD/>>WMO4PCY!T
M^PBIX4BIDG8(=5=?C;7AN'5#K N?,DJVN,&R&$]1KK8R[>-9JS0]F, E(7U[
M5T;'J<14NK3>K2G 6K%JQUD@QUUQUM!;4 0?0B*[PO8;LY]$55:BV ALOBNT
M/31*HIO#0Y0\).YK=JH6(X2H$<(W(WV_N^P][^\I3HG8_6+S.FF7F\CK4L;*
M%*F9K!!*<IKU(=E]+],E7CVKUR=#/Q_F'B6_=ZF"=W :S5V+:FU<CZ)I].:X
MMA%NEZ<NDR=-Y756IS<RRV("L4B&W6K:NEUM-8[0\H=7N#-E612U:7,Z.36R
M#_*RPK!HH-L[@[XV*$)]C]"+._A%S=]9G_.#6OZFC_WVZ\Y][+GY=QW[)9_.
M6UA6TWXY!^K#^+*M0?-4K'$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA%L1
MZ:T?0&-_$8TLG9: NVBQ9V1,<DJG95)OC:5:6/KO%@XDW$><!":21SQS:8,T
MF&U&V)BS[L>4L[8SD5C$2&O7KEO.5B1KG535<=75I8P6B>28-/(Q-<U[7@3!
M\0C,C;S@XKC[C7UG;C&:=L/<"8S&3QC<-1ON?IWC0001O@M#2X=6/.FEGZ>$
M3PB>$3PB>$3PB>$3PB>$3PB>$5/;?R8P_P!#(_V6WA%A_P (GA$\(GA$\(GA
M$\(ORK^?(]<KIX1=4?PNOYQ]O_J(J_\ 7L/.G?N9_P H[9_L2K_'G6R.QS^,
M9?\ 4XO\<BRQ?/2VWO?YEQ/>@#EHKE8KK=5Z-33\K&\=BM7)=^)C:/;";;V
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MVEQT:&M#F]\'][ OU!&AUX $G70  '])=H-3H.@CB'<-V/*12)X1/"*MUO\
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M:'.A%(A<H4 @UT".V=0GCK3_ .XA2#>GW<TYD3\4>7Z=8CB7,A5A0>T?73Z
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M!U!T(56EYPMF.:'YLG0M)&M2VITP\70;9$"(%M"-!EPK!T:ZC*[;C473?6V
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M?G\/0BGEU>_$^$KBFRV>VV5W>A^E^GI>RYU3H_34NH;OGX7ISYMKV]S/:WH
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MJ[)6.GKBR XUS-$'1B<-<8B[E "6Z+EN%T;9HG31F6)LC'2Q!YC,D8<"^,2
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MKF,W^3W)2R1E#D(+=BOR-.PRLY[P)I'-D+S!H[?CB?&]CH9'G=;RS27L9O\
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M30@KVCECE!=%(R1H.A=&]KP#TZ$M)&NA!TZ>*GP%'5(I*AEG>Z4;$OPQ^^=
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MB_A2?SXZY_52N_WN9YMO[E[\M;5_LO'_ ,W,LJ[&OXYE/U:#^*]93[EVSO\
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M1P_#C^%H5F76/X>GN8U]S7V$3%;KN)=)\(4N)HUF$NDV%8.)=$V-,Q84Z2?
M]_59B/.8\ 8S@7W,YT^%[N<X\(OD-9K8^5FP]?20;)?CX3[0J@(LJ<$[;;DX
M69T'UR!\QOMMO/\ *_"^+MMMM)[V<YSX10M*G5HX(!8ZU7]!AC_JHP^B9=K
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M/MS1+S1AT@7-OG8GIEGH^IO 6 I 95CS#('8.IU*/J;?.V_U J.>'24V1V'
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MIWM=0+9>RU:A(R*9LSG/9R@,;6.&Z7.;Q+I&'75I\!&FG%8Z_=B\N_ZIN_\
MY4E__:+RP>ZQLUU;,>BU/KZHNZ2A\':\W%[9/W8O+O\ JF[_ /E27_\ :+Q[
MK&S75LQZ+4^OIW24/@[7FXO;)^[%Y=_U3=__ "I+_P#M%X]UC9KJV8]%J?7T
M[I*'P=KS<7MD_=B\N_ZIN_\ Y4E__:+Q[K&S75LQZ+4^OIW24/@[7FXO;+*W
M->T4GJ>3H*[.<*P7XQ),I<PCB,=Q=O=Q@X>(<LV$@363;$,N\4^T@\ON8(BB
MUG'VFR?9[:[#[2\NS'OFCGKZ.?5MLCBL&(Z 31M9+*U\6\=QSFO+F.T$C6A\
M9?<*.3JW]\0ES7LXF.4-:_=X=^ US@6ZG0D'4'I U;KEGS)U<$\(GA$\(GA$
M\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA%3VW\F,/]#(_V6WA
M%A_PB>$3PB>$3PB>$3PB_*OY\CURNGA%UA_"D_GQUS^JE=_O<SSJ3[E[\M;5
M_LO'_P W,ME]C7\<RGZM!_%>MSK!;_5##T>P$TJJR#TB'I]9R4 \KMB='V:I
M&= Y)R\Z.N',[2*DJ0JZIUOMO2&!2M7"NE$<<^=SA?,'.#K/V9P\/V^QT6W5
M8P/4O49N9R/H[>M="8B:5?3\RJVJX]T%%"B8]"L?/CVE96T0V3Z_:65#AYM>
MJ@EN)PD@ZP;IRFR'SZ5WYQX616BSNOK#Z"YIB-Q4[=59U2I!+:@*Y4+S5JY*
MTO/+N94%D<9T9395DK.!'=N[],M?V_53IBJ@OX(#8CVU?LZ6$EH^VJ*3Z7ZG
M/5/R^AR6:VJE"4VRUU98*N+ORYR0T NAU O]Q"XU$@Q:_F&A4SO/(Z,ZN)Y
M"\2Q3] 6ZR)3V]0C1OM]OG1;']DM_=Q;/O0JDD9V!0WY0,K/=UZJ7E5HKZ#9
MK #4"7YMQ!PG$&1+@+ )9UT//KI'>JOI6[,:Y!T6D*[%72*W9+;ZG+WQ3L'S
M-1:UFZ,^EUWGG,%PP3NA.ORNN%KJ$(_36EA!DLCBO.0N>W<D^W%J5F2^>/*8
M]&B52.U1<&Q%C:"L>H)+>1Z?H_[&]MM><<<FIS6%QU#;D:ZM,.W7SHO91K3=
MW^FU2Z2L0\4L%7XFL+O4;WISQA3@'Z9+7';8UNK?;[?;1%F1YT;I2M[Z@I[3
M6NFK3E/&Z4-2ZQS"K=)Z%7V%I7;W=BY:<]NL?,!43*PV J]4JKFP3)Q'*_[/
M*:&+(42(EU$169T9KW^M<7X"F2XNC&0.3E<=EZ(C0](OO576]5Y58[,W)O/-
M/MBM-4TMLZ16ZE539[#9C!)2K;.5?EBU.,Z!E(K/8=M]:(X]CF*H,@+I/57$
M+&L*^.7]LKTN:.\\[5JP:#>%^MB%MA'0Z%!UNT)VQ"2>AT]LWY>FN#L+*2\9
M/(KA9=B]6@["X%%U&577 >AMZ0,%7^.]&NMU35E-M>YZW?UP.%J:J6S/1XZ8
MC6[:5JUW&NT\SJU996@^K 4U]%9"*#.7ZFJL?Z1DR[:W,[(LY'7 ^PRGU2XV
MJJ6N\W2[\5AO,S^R0LXT52*I51K_ &%^(=93S2QH6J])5@V35B(J8Q]_]/Q?
M']O>]_P(MM.$&=*/Y_73NE5L*N-6]=K]FF%S9[,[L(KZVA;62VU^P*+,KQ/6
M,U)XSFKRE:):K0+]/"TA'CK@88B6&'V^WV"+-'A$\(GA$\(GA$\(GA%K[U7U
M$UWE#&S!G5"[VD6@<_%ZMTYQ58:KLOYSSHTVS!BV=Y%8[97&KC2:.D7AEHHI
M2VTOLKJ@XS],^?)KZ]X13FWJ7XG@JQ 1W3);&KOI:PP5KJW;F;4Y^,_L]6/5
MU96O0$GW8E58*5<%3K%,'?:)"JP^PVW"T5&[PD5/=^J#D*HK8(:QPL9Q+8NJ
M[67:(M.L TGLI-1?/1G;P5>E?)*580C4MT-KQ[2"KNA9DCR5>VU^4\(H^/5%
MP[,"N;6XE[2N'L-;#5Z4R][OXVQ4]'&!C9UO6L9L"4-E-TWF^BILY6 *6N.@
M4K=<<5':4>QQ%DZF=!I?0P96=(L2ZS+H8$),ARO>2<36&SUE-<T.WS&8]8MM
MF=5L2%_!%KMF7"QPN)ETCT+A]\BO'PB>$3PB>$3PBQMV6FNNB<CZ?0:XYTKU
M@NM MU52O)9#(H531\A/6 FD2KMXV,(T!),>Y,RV6%C%!B20":$O6&70BT9T
M].?J!^?8/:ZJYQS(<5D[^WJ?2WZBM%@U%OMQ+2QTI==N=\HH92_1ZEHUZI]/
MNA*QA=:@G95AO,UPS#P*I(O*[T]^J57?AKLOL 66<]37IX#W7<NEF"K4M?Z%
MZH[0@YW=E0B32;IFD%-ZSRZCZ="=,BK4F85RP6Y29]: #,M)%F#TX\B[;3[9
M-:NON5C;?%;M2!5'#;+5;V*U>YM:2R*U<C:XE.WY0X7P&VOL:6BP2KOBC+ V
M1BT<7>%^A%NCX1/"+F[ZS/\ G!K7]31_[[=><^]ES\NX[]DL_G+:PK:;\<@_
M5A_%E6H/FJ5CB>$3PB>$570OF]8;@O41TZUJMGU($+'VQC?3?'MQMIOKG&=)
M89=,[1$#RZ[PD0[[PS:;Q[[:YJZ-ZWC;<-VE,^O9KO#XI6'B#T%K@=6O8]I+
M9&.!8]A+7 M)"]89I*\K)H7EDC#JUP^<$=!!' @Z@@D$:%=6>)]H5]83;:2Z
M1+[8J@CR[4ZYV^%)IG.(]6BW.^=MI%\\F<:[Q;;;3 3[X'GVDTW&)*Z;V/VN
MJ[3U""&P9.LQO;E4$[I&H:+-?4DN@>[0%I)?"\B-Y(,<DF?XS)QY"+P,L1@<
MK%X/>Y1FO$L)_26$[KM>]<[.'F9*Z)X1/")X1/")X1/")X1/")X1/")X1/")
MX1/")X1/")X1/")X1/")X14]M_)C#_0R/]EMX18?\(GA$\(GA$\(GA$\(ORK
M^?(]<KIX1=8?PI/Y\=<_JI7?[W,\ZD^Y>_+6U?[+Q_\ -S+9?8U_',I^K0?Q
M7KH3>?5Q4*+8[?4RJ#TEP\J-@!02!+8^?KI7,9G+[QUK>SJX[9T"LS#T<6M<
MZMX/WB^B2HVMF2,Z_7BG)JQG@/LQ;=5)3^M"DV=IHKJ?,^TV3#)S)5JHU&J2
M1.ANET VF^XJ:A=VFU(%T-@J<"JX&6&%^0D%'%H%RD#+.V#4Z.2+&=C]:SE7
M=Q!(J:<KYTE:,(.B6AJDKAY=8BBZW<^3Q D#!=B"/TPI(XSVNS.[$A0W4:1"
MD2$+T6T6&I&A%L56NY++?=Z?17G*.A4QY9*O/T"NS7P?G< >JT3,L&9 )U-]
M?S&V$322'+9(@@9/JN,W5%V<-,N;AESD4'H'4;G4NNHJP/O21^=1<KO75KRZ
M;"NYWZ!1S][3%Y@L.PC(99IM8U]J9F)BBH-M ]Z>XP1$=H1IJ(16BJ]05RN<
M/'J94:TB4]=Z#SYS?;F'<HK2)4Z!!2E/-\W=<'G5< QN9T%LZI3ZVIU6E@KL
M@$N; 2VDG0QU]T^WV\B+$R7UT9O5YM--YPGI%CBR\HE.HCH*TG6')#YE5>\7
MJ_N;57JRK/L8JY-4>'L6W/JLJ7$6;H/UFMQD35;2PDS5DBA#>N[0>PBJ9T:"
MS)G'$];I3;2DWM-4BN_5";"DA4\\&KMT2"O*R,RHUTI-^9G.(R)JC7Y[0Y;X
M(K=9(?3$67AO54.EI?#&%UH5F(NW4Z5Q^Q6I#2MJ[.LYXTZ]8:31$8K<NXV>
MJ&$!&7^Y82*XE(S=T0&C>,9U<.B_.LQ%CUWZ_J='0;-:ZUROJC1RLYTRZBBK
MAT7.@)W-$%I 5U'NLI6_2,  H?EWU/"(3%'CW[<JYUF,"H%ZM-)8B+.-HZ!T
MY)U3E=#@SSN!58^=V^_7]FS%L&)U G-VU 66[=%)"VC$U@82=$41H]&>)=P]
M0V)ALQT46!_"*[N(=2CZYSFH6\A:0C>NJA3[)8$$H#D>% ?;:X!8]$T#!H %
M"WW70GZB%%KMR(-289-9,Q;YQ%@BR[X1/")X1/")X1/")X1/"+"71N T/I[@
M]O89K,)]Q506@WM8AL)BA1T:@@L&[,*F74*#WOJ",8NQ676/Y"58RW LUB3S
M,94SMDO)(J$R]+_,C6(;T.2TH+,JL%EM**SH;#.(Y0/;A<.A7.QG*Y)X2P],
MM#.J7Q3/ 6$6-BOOYUL<.F8!)X"*DF>D#BS7ZM"^7V*PJV9M@*'1NK.T,5HQ
MKC;BK[=E*33$D1@ZNXW N1T]B*,-)VS"O5KBER-4K6!D6.+1Z(4K.]<SOM?O
MS,1[0["98V+J[I-.B65ZQ((XR**:"R,<I4J1FJJ?%*Y5%IAE8L0T.LTMFD7R
MVW)KID1;#<0XVBX?46E41D9-U<7B\74PS:"8;&N;78SF"5"*.0>RD'2T2I?;
MG.JL)@O>(&IU%$#!$/ -&/$19A\(GA$\(GA%ICZC>N7WE/1:$?72'5O0S5]Y
M\?B=$UKN.AW>R9VEW3,( G]$LQ]CIH>!MQK3O3K32'5#'DTLC*&WK3X@%1%C
M33U6=P9!R;U*E\\N4"S6TM)+@N@O8E.N*Q!%Z;]_I55]D#$T%H,T[?;JFS9%
M3N8(6_)WDVR<=AN[K%6(KOH/J8ZQ8^RUCE=@YRE4B[%W)18+!,:,BTLN]0N_
M<*27:>?K']GB?F+89.45AT76P$-QG#3]*%,:6I0(G2E7HBL2_>I;MX=LNLE0
M0I&,/'Y^[-7E=#7L7""UUFA5\MQ54,=I0-'&^W1K!&AV&)3&+ZFVHC>QZZL:
M;;D0M6=] (KR0^J#IUQZY8N8U6EJ-@%W5DE*@M[Y.X !5)I0_4F59-&:Y98G
M19#E5C@B7=<0XVHTC&+I]<(GK *:9 ]M1%@NR^L_NU@X[8FB^E(N:V1[0.B-
M$+,N3Z^[K5W54A"P6<3DKM8=VV9?VP5O8V$ZG-MC32M!Z*]E;<PK_O3#@O#]
MO\]/GT1=9_"+F[ZS/^<&M?U-'_OMUYS[V7/R[COV2S^<MK"MIOQR#]6'\65:
M@^:I6.)X1/")X17=2*18.@V 2N5P3))A.??FFW][41>'IMKB<\^?&NV(!8,;
M8][;V;22R;1CP:2D2Q1;W7#8:_GK\6/Q\7*2R=\][M1%7B! ?/.\ [D;-1J=
M"YSBUC&ND<UIJ*M6:Y,V"!N\YW$D\&L:.E[SQT:->/222&M!<0#UFY;RVO\
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MR=6]81, 2-"W*U2$&K :3XD.#7"C@CSQC0QQ:D4KIR#DT8P@4?+^>1AKXIH
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M10-FL_Q!X?MROEP120.7WQ2Q8OHZZ0EA\0D?3Y?WIH\;?+SN V[_ /!6UO\
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MTK#>:,=3FVZ$,H]JWAH1-% NRYP%\[-+'$-\7??77)%[VZQRS0R==OTOG^K
M6H[7\D':Y5W4P>AZC:F;7:<;++$\51U#WT*VLDFFJ; V^L^3?A;8WR1%_6>5
MMB:H$JZ7S]F9?!SC*,(ON5<-)N8BSYC#(JJ0#,I);$.OR*5@Z=1H9$)\L1\Q
MM'\&3W2*2$[7QH\%&T ZWS(U99[!]IUMB)?:J2#8;5[\&GVTC+A:[CMK![Y(
MVGT8"0AC[Y$&ORWMECQL1#>U\:7!V)BPZUS(!?3WFM8MIQM\JHH=7LFTQ ^M
M>L1,[6.%(\VG$*@U4L]Q3\S#$1X'SO#)KJ13Q_6.6*C;0N:=*H"UA1UX;:Z
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M9CDEQ4C#MW&!A;-F*&67"&>71K\.*3?Y3W=-LX(IH^[<_59MVK3I'.%NW/\
M9;K?,'WRJAYI.SF?051K;L$-8\UO9J5)&,MPY^2R=/OI"+B63;77)%$WN-$C
M,,7[]#YYHP7U';H!X.]YJ^I@-#T'C,WNQ@V6F)AJCH)-"5M9)M-$VH\L<^3<
M1;Z[9(B^XT1N955ZKHG/&9][$,84@%?>:N:9<@%V"=F!M5&&:2S6$0#4(S8P
ME1H9"+@0G,^^F()?<(H"Z]<[;J!+ IZ9S5HA8$FA@.UU_J9J@TM9\O\ 411&
;0S:4,DE?\X)\[!#-O*)\T/\ 'UC^/%[Q%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g273774g83j43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273774g83j43.jpg
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M 0<(  D2$1,4%18A%R(C"C%A,C="47>V_\0 '@$  00# 0$!
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ME=69[Z/F*.-IB_'V+5%E(+2S<^NP.:Y]Q:>)A*1LGN$#,$B8WF-]J0[@G?\
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M?7<=@E'*K*]B ()*E#LP8;'&8DA))[S^(9OIEZBW=:-RM++5*=*_176M5UU
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MFHH)*?'#YQ])M^Z4##/+2EQ[#",9RAQW*)1RB_K-[5NERD>=O$T,A2@I^V+
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MU'ZY>N6&L+TXC&Z&T%C9?D59C.4DY;5F;8TK=NN>.QS2]K5&S)O!#; NJ\)
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M>D+*/,O$<CBJ[DD+,<J)U#2OF6/C+LYUD1=@VV_J LXDGW ]D*DC)2ZQW5'
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&U.CHZ__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
